EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria

Innsbruck
PROGRAMME BOOK

www.eas2016.kenes.com

EAS

EAS 2016 AT YOUR FINGERTIPS

Download the App for the Full Congress Experience Search "EAS 2016"

Your all-in-one guide for the duration of the Congress:

- Access the programme and venue maps
- Bookmark your preferred sessions and read about your favorite speakers
- Receive important notifications from the organisers
- Learn about exhibitors and sponsors, accreditation, and much more

Get it on Google play

Available on the App Store

View on Mobile Website

EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Innsbruck PROGRAMME BOOK

Organised by

kenes international
a Kenes Group company

Rue François-Versonnex 7
1207 Geneva, Switzerland
Tel: +41 22 501 7420
Fax: +41 22 906 9140
Email: eas@kenes.com

CONTENTS

DEAR FRIENDS AND COLLEAGUES,

On behalf of the European Atherosclerosis Society (EAS) and the Austrian Atherosclerosis Society (AAS) we are delighted to welcome you to Innsbruck for the 84th EAS Congress.

The congress committees have been working hard on preparing a programme of scientific excellence that will excite and inform the European and Global Atherosclerosis communities. We are particularly proud to announce the certainly inspiring Keynote Lecture by Nobel laureate Michael S. Brown entitled "How genes control cholesterol" and invaluable contributions by outstanding plenary speakers. The comfortable atmosphere of the congress venue and its impressive setting will provide a unique meeting place for high-level interdisciplinary exchange of newest research highlights and effective networking among participants from more than 70 countries from across the world.

The congress will be held at Congress Innsbruck, located next to the scenic river Inn and in walking distance to the city centre and all major hotels. Innsbruck is one of the most beautiful cities in the Alps, surrounded by impressive mountain peaks. Another attraction, of course, are the superb Tyrolean culinary highlights that will be offered during the unique Social Programme and throughout the meeting. Finally, for those with a few days to spare, there are many interesting opportunities to visit Innsbruck's cultural highlights before and after the congress.

The 84th EAS congress is accompanied by an International Satellite Symposium on Lp(a) two days ahead of the main congress, again bringing together world experts in this small but exciting and emerging field of an extraordinary atherogenic lipoprotein.

On behalf of the organising committee, we welcome you to Innsbruck for a memorable and inspiring congress.

Alberico L. Catapano
EAS President

Geesje Dallinga-Thie
Chair, Programme Scientific Committee

Seppo Ylä-Herttuala
Co-Chair, Programme Scientific Committee

Hans Dieplinger
Congress Chair

Florian Kronenberg
Congress Chair

COMMITTEES

CONGRESS CHAIRS

Hans Dieplinger, Austria
Florian Kronenberg, Austria

EAS EXECUTIVE COMMITTEE

Alberico L. Catapano, Italy, **President**
Olov Wiklund, Sweden, **Vice President**
M. John Chapman, France, **Past President**
Petri Kovanen, Finland, **Secretary & Award Committee Chair**
Jan Borén, Sweden, **Treasurer**
Lale Tokgözoglu, Turkey, **President Elect**
Christoph J. Binder, Austria
Geesje Dallinga-Thie, The Netherlands
Børge Nordestgaard, Denmark
Arnold von Eckardstein, Switzerland
Michal Vrablík, Czech Republic

LOCAL ORGANISING COMMITTEE

Hans Dieplinger, Innsbruck, **Congress Chair**
Florian Kronenberg, Innsbruck, **Congress Co-Chair**
Christoph Binder, Vienna
Benjamin Dieplinger, Linz
Christoph Ebenbichler, Innsbruck
Bernhard Föger, Bregenz
Gerhard Kostner, Graz
Dagmar Kratky, Graz
Bernhard Paulweber, Salzburg
Ruth Prassl, Graz
Andreas Ritsch, Innsbruck
Wolfgang Schneider, Vienna
Herbert Stangl, Vienna
Ernst Steyrer, Graz
Gerd Utermann, Innsbruck
Rudolf Zechner, Graz

SCIENTIFIC PROGRAMME COMMITTEE

Geesje Dallinga-Thie, The Netherlands, **Chair**
Seppo Ylä-Herttuala, Finland, **Co-Chair**
Eric Bruckert, France
Alberico L. Catapano, Italy
Hans Dieplinger, Austria
Jörg Heeren, Germany
Dimitris Kardassis, Greece
Florian Kronenberg, Austria
Chris Packard, UK
Erik Stroes, The Netherlands
Arnold von Eckardstein, Switzerland

COUNSELLING MEMBERS

Gerhard Kostner, Austria
Wolfgang Schneider, Austria

CONGRESS COMMITTEE

Marja-Ritta Taskinen, Finland, **Chair**
Jan Borén, Sweden
Hans Dieplinger, Austria
Danilo Norata, Italy
Chris Packard, UK

APPRECIATION AND THANKS

We would like to thank the reviewers of the submitted abstracts for their valuable help and assistance.

FACULTY LIST

Afonyuskin Taras, Austria
Alitalo Kari, Finland
Armitage Jane, UK
Assmann Gerd, Germany
Averna Maurizio, Italy
Banach Maciej, UK
Besseling Joost, The Netherlands
Binder Christoph J. , Austria
Borén Jan, Sweden
Bossano Prescott Eva, Denmark
Boulanger Chantal M., France
Brouwer Ingeborg A., The Netherlands
Brown Mark J., USA
Brown Michael, USA
Bruckert Eric, France
Bujo Hideaki, Japan
Caligiuri Giuseppina, France
Carmeliet Peter, Belgium
Catapano Alberico, Italy
Chapman M. John, France
Colhoun Helen, UK
Dallinga-Thie Geesje, The Netherlands
de Meyer Guido R.C., Belgium
Després Jean-Pierre, Canada
Dieplinger Benjamin, Austria
Dieplinger Hans, Austria
Ebenbichler Christoph J., Austria
El-Osta Assam, Australia
Farinaro Eduardo, Italy
Ferri Nicola, Italy
Föger Bernhard, Austria
Fu Jingyuan, The Netherlands
Gaetano Carlo, Germany
Gaudet Daniel, Canada
Gordts Philip, USA
Graham Ian, Ireland
Herz Joachim, USA
Heeren Jörg, Germany
Hersberger Martin, Switzerland
Hobbs Helen, USA
Hoefer Imo, The Netherlands
Hoffmann Michael, Germany
Humphries Steve, UK
Hunt Steve, Qatar
Jauhainien Matti, Finland
Karagigas Georgios, Germany
Kardassis Dimitris, Greece
Karpe Fredrik, UK
Koenig Wolfgang, Germany
Kollerits Barbara, Austria
Kostner Gerhard, Austria
Kotseva Kornelia, UK
Kovanen Petri, Finland
Kratky Dagmar, Austria
Kronenberg Florian, Austria
Kuivenhoven Jan Albert, The Netherlands
Lambert Gilles, France
Lamina Claudia, Austria
Laufs Ulrich, Germany
Letourneur Didier, France
Luetjohann Dieter, Germany
Ley Klaus, USA
Lichtenstein Alice H., USA
Lutgens Esther, The Netherlands
Mach Francois, Switzerland
Maegdefessel Lars, Sweden
März Winfried, Germany
Malik Vasanti, USA
Mangelsdorf David, USA
Manolio Teri, USA
Marsche Gunther, Austria
Martinez Laurent O., France
Matsuzawa Yuji, Japan
McCormick Sally, New Zealand
Moschetta Antonio, Italy
Moulin Philippe, France
Müller Thomas, Austria
Nicholls Stephen, Australia
Norata Giuseppe Danilo, Italy
Nordestgaard Børge, Denmark
Öörni Katariina, Finland
Packard Chris, UK
Parini Paolo, Sweden
Pasterkamp Gerard, The Netherlands
Paulweber Bernhard, Austria
Pechlaner Raimund, Austria
Piepoli Massimo, Italy
Poirier Steve, Canada
Prassl Ruth, Austria
Ray Kausik K., UK
Reaven Peter D., USA
Ripatti Samuli, Finland
Ritsch Andreas, Austria
Rudling Mats, Sweden
Ryan Robert O., USA
Sanjana Neville, USA
Schmid Johannes, Austria
Schneider Markus, Germany
Schneider Wolfgang, Austria
Scharbagl Hubert, Austria
Scheja Ludger, Germany
Schunkert Heribert, Germany
Seed Mary, UK
Stangl Herbert, Austria
Steinhagen-Thiessen Elisabeth, Germany
Steyrer Ernst, Austria
Stojakovic Tatjana, Austria
Stroes Erik, The Netherlands
Suhre Karsten, Qatar
Stuling Thomas, Austria
Taskinen Marja-Riitta, Finland
Tawakol Ahmed, USA
Titze Jens M., Germany
Tokgözoglu Lale, Turkey
Tschöp Matthias, Germany
Ulmer Hanno, Austria
Utermann Gerd, Austria
van Gaal Luc, Belgium
von Eckardstein Arnold, Switzerland
Vrablik Michal, Czech Republic
Watts Gerald, Australia
Wiklund Olov, Sweden
Willeit Peter, UK
Ylä-Herttuala Seppo, Finland
Yvant-Charvet Laurent, France
Zambon Alberto, Italy
Zechner Rudolf, Austria
Zelcer Noam, The Netherlands
Zimmermann Robert, Austria

THE EUROPEAN ATHEROSCLEROSIS SOCIETY

The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of "advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease".
For more than 50 years the Society's expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis. By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS contributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders.
In recent years the Society has made a particular effort to recruit young scientists and clinicians also from other related disciplines.
The European Atherosclerosis Society's goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis.

WHAT WE DO – AT A GLANCE

- EAS is active in the publication of **Guidelines** and **Consensus Position Papers**, and its official **Journal** is Atherosclerosis. Through a regular series of **Featured Commentaries** EAS puts into perspective topical issues of relevance to our members.
- The Society organizes an annual **Congress** for approximately 2000 delegates, and runs a programme of **Advanced Courses** for both basic scientists and clinicians.
- **EAS Academy** is the Society's online e-Learning resource, containing a range of educational material and self-teaching programmes.
- EAS is co-organiser of the **European Lipoprotein Club** (ELC) annual Scientific meeting.
- EAS coordinates the **FH Studies Collaboration**, working to establish an international registry of observational studies on FH.

WHY SHOULD I BECOME AN EAS MEMBER?

CONTINUE YOUR PROFESSIONAL DEVELOPMENT WITH EAS EDUCATIONAL ACTIVITIES - ADVANCED COURSES & EAS ACADEMY

EAS membership offers opportunities to deepen your theoretical skills and/or practical knowledge, which you can then apply in your own research or clinical practice. The Society organises educational activities such as Advanced Courses (many CME accredited by EBAC), and offers a wealth of online learning material, such as webcasts, videos and quizzes, on the Society's educational platform, EAS Academy. As an EAS member, you have access to the very latest uploaded material, EAS Academy's Premium content.

STAY WELL INFORMED WITH EAS PUBLICATIONS

EAS membership makes it easier for those working in the field to stay abreast of the latest developments in the field. In addition to access to the Society's own publications of Consensus position papers and Guidelines, EAS membership includes complimentary access to Atherosclerosis Journal (worth ca. 300 €), and members receive by email newsletters and featured commentaries on topical issues.

INTERACT WITH LEADING EXPERTS IN THE FIELD AT EAS CONGRESS

The participants at EAS annual Congress are world leaders in atherosclerosis research and clinical practice, and the size and format of the Congress lends itself to networking and interaction. EAS members are encouraged to submit their findings as an abstract to Congress, where they can participate at significantly reduced registration fee (savings of up to 100 € compared to non-member fees).

APPLY FOR GRANTS AND PRIZES AS AN EAS MEMBER

EAS members may apply for the Society's travel grants to attend Congress, and, where eligible, may apply for the Society's Prizes.

GREAT VALUE MEMBERSHIP BENEFITS AT AFFORDABLE ANNUAL SUBSCRIPTION RATES

EAS' aim is to provide access to learning that will help our members to manage lipid disorders and to prevent and treat atherosclerosis. We keep our annual membership subscription rates low – 40 € (persons over 35) or 20 € (persons 35 or younger) – so that as many as possible can afford to become members.

HOW TO BECOME AN EAS MEMBER

If you're not an EAS member and would like to become one, you should complete the application form and pay the annual subscription fee. Once your application is approved, and the subscription payment processed, you become eligible for membership benefits for one year at www.eas-society.org.

EAS

ABOUT INNSBRUCK

Innsbruck is the capital city of the federal state of Tyrol in western Austria. It is located in the Inn Valley at the junction with the Wipptal (Sill River), which provides access to the Brenner Pass, some 30 kilometers (19 mi) south of Innsbruck. Located in a broad valley between high mountains, it is an internationally renowned winter sports centre.

Innsbruck serves as an ideal place for skiing in winter, and mountaineering in summer. There are several ski resorts around Innsbruck as well as nearby, which include the Axamer Lizum, Patscherkofel, Igls, Seefeld, Tulfes and Stubai Valley.

The city of Innsbruck is suffused with the spirit of the Habsburg dynasty.

The Habsburgs' legacy in Innsbruck is sumptuous and palatial majestic and has left many architectural landmarks in the city.



EAS KEYNOTE LECTURE

The Keynote Lecture at EAS Congress 2016 is given by Michael S. Brown, Paul J. Thomas Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at University of Texas Southwestern, Dallas, USA.

Dr. Brown and his long-time colleague, Dr. Joseph L. Goldstein, are recognised as the discoverers of the low density lipoprotein (LDL) receptor, which controls the level of cholesterol in blood and in cells. Drs. Brown and Goldstein have received many awards for this work, including the U.S. National Medal of Science and the Nobel Prize for Medicine or Physiology in 1985.

Working together, Drs. Brown and Goldstein showed that familial hypercholesterolaemia is caused by genetic defects in the LDL receptor, which disrupt the normal regulation of cholesterol metabolism. Their studies led to the elucidation of the mechanism by which this receptor carries LDL particles into cells through coated pits and coated vesicles. These LDL receptor studies provided clear evidence for selective uptake of macromolecules into cells, giving rise to the concept of receptor-mediated endocytosis.

More recently, study of another genetic disease called Niemann-Pick C (NPC), has provided insights into how cholesterol is transported from one organelle to another, which underlie the consistency in cholesterol concentration in the plasma membrane. Extensive studies showed that both the NPC1 and NPC2 proteins have the capacity for binding LDL cholesterol. Whereas binding of cholesterol to NPC2 is rapid, occurring within minutes, binding to NPC1 is extremely slow, requiring several hours to reach equilibrium. However, this process can be accelerated when cholesterol is delivered by NPC2. Based on these findings, it was proposed that NPC2 extracts cholesterol from LDL in the lysosome and then transfers it to the N-terminal domain of membrane-bound NPC1 for insertion into the lysosomal membrane, currently being tested in the laboratory of Professor Brown.

The work of Drs. Brown and Goldstein has not only been the stimulus for new thinking about cholesterol homeostasis, but also has led to the development of new concepts in biology. Specifically, these include selective sorting of proteins within the plasma membrane, a prerequisite for receptor-mediated endocytosis; receptor-mediated endocytosis and receptor recycling; and, finally, the concept of feedback regulation of receptors.

Michael Brown graduated in 1962 from the College of Arts and Sciences of the University of Pennsylvania, with chemistry as his major subject, and subsequently obtained his M.D. degree in 1966 at the same university. He was an intern and resident at the Massachusetts General Hospital, where he met Joseph L. Goldstein, a fellow intern; the two established the friendship and mutual respect that led to their long-term scientific collaboration. Dr. Brown subsequently completed a postdoctoral fellowship at the National Institutes of Health, before moving to UT Southwestern, becoming Professor in 1976. The remainder of this story has been instrumental in changing how hypercholesterolaemia is managed, and paving the way for innovative new therapeutic agents targeting LDL cholesterol.

THE ANITSCHKOW PRIZE

THE ANITSCHKOW PRIZE RECIPIENT 2016 IS PROFESSOR PETER CARMELIET, PROFESSOR AT THE KATHOLIEKE UNIVERSITEIT LEUVEN (LEUVEN, BELGIUM).

The Anitschkov lecture entitled *Endothelial Cell Metabolism: A Novel Player in Atherosclerosis? Basic Principles and Therapeutic Opportunities* will be part of the Congress Opening Ceremony.

PROFESSOR PETER CARMELIET

Peter Carmeliet is a physician and professor at the Katholieke Universiteit Leuven (Leuven, Belgium). He is former director (2008-2015) of the Vesalius Research Center, VIB - KU Leuven and is heading the Laboratory of Angiogenesis and Vascular Metabolism at the VRC. His research interests are vasculogenesis, angiogenesis, and vascular endothelial growth factors. His research group has sought to elucidate the molecular basis of angiogenesis with the aim of translating their findings to therapeutic concepts and ultimately novel treatments. Latest findings indicate that the efficacy of current anti-angiogenic therapy in cancer is limited by intrinsic refractoriness and acquired drug resistance. To overcome this problem, his research team pioneered the study of endothelial cell metabolism during vessel sprouting. Professor Carmeliet is the recipient of numerous awards, including InBev-Baillet Latour health prize (2010), Ernst Jung-Priz für Medizin (2010), the Blaise Pascal Medal in Medicine and Life Sciences by the European Academy of Sciences (2011), the Münster Heart Center Award (2015), and award of the Noble title of Baron, granted by King Filip of Belgium (2015).

YOUNG INVESTIGATOR AWARDS

THESE ANNUAL AWARDS ARE PRESENTED BY EAS FOR OUTSTANDING PUBLICATIONS BY YOUNG SCIENTISTS IN THE FIELD OF ATHEROSCLEROSIS

STEVE POIRIER

In 2003, Steve joined the team of Dr. Nabil Seidah at the Clinical Research Institute of Montreal the same year the laboratory published the identification of PCSK9 and its link to familial hypercholesterolemia. Over the years, he actively designed and performed key experiments as well as collaborated with international researchers to accomplish important studies in the highly competitive field of PCSK9 biology in cardiovascular diseases. Cited by more than 850 publications, those manuscripts have questioned and revisited published papers that supported the fact that PCSK9 had only one target and that it was acting exclusively via an extracellular route. He was the first to show that PCSK9 has other important targets towards LDLR family members and revealed the existence of an intracellular route for PCSK9-induced LDLR degradation. In addition, he also made many other significant contributions in the field of PCSK9 such as the identification of the two known natural inhibitors of PCSK9 namely AnxA2 (extra-hepatic) and GRP94 (hepatic) now used as precursors for the design of lipid-lowering agents with high therapeutic potentials. He also showed that the cytosolic adaptor AP-1A is directly implicated in the intracellular trafficking of Niemann-Pick type C proteins and revealed the first evidence and mechanism by which the cancer drug 5-Azacytidine favorably perturbs lipid and cholesterol metabolism. Together with his great scientific partner Dr. Gaétan Mayer (CSO), he is the co-founder and CEO of Monogenic Pharmaceuticals a Montreal Heart Institute-based biotech primarily developing 4 distinct unprecedented and highly innovative therapeutic pipelines to lower circulating LDL-Cholesterol and cardiovascular diseases by specifically targeting PCSK9.

YOUNG INVESTIGATOR AWARDS

JOOST BESSELING

Dr. Besseling started Med School at the University of Amsterdam (the Academic Medical Center) in 2004 and obtained his medical degree in 2012. Subsequently, he started his PhD research under the guidance of Prof. Kastelein, Dr. Hovingh and Dr. Hutten.
He worked on studies focused on different aspects of familial hypercholesterolemia and published in highly cited peer reviewed journals, such as Lancet and JAMA. He specifically focused on the diagnosis, consequence and treatement of FH and as such showed that FH patients are relatively protected from diabetes mellitus.
Moreover, he developed a new prediction model for carriership of an FH mutation, and investigated the consequence of CETP inhibition in these patients. In January 2016, he started his residency to become a board certified specialist in internal medicine, and in October 2016, he will defend his PhD thesis on familial hypercholesterolemia.

GENERAL INFORMATION

VENUE
Congress und Messe Innsbruck GmbH
Rennweg 3
6020 Innsbruck, Austria
www.cmi.at

OFFICIAL LANGUAGE
The official language of the Congress is English. All presentations will be made in English.

CLOTHING
Clothing is informal for all occasions.

REGISTRATION DESK HOURS
The Registration Desk will be situated at the North Entrance, ground level of the convention center, as follows:

Sunday, May 29	10:00 – 21:00
Monday, May 30	07:30 – 19:40
Tuesday, May 31	08:00 – 18:30
Wednesday, June 1	08:00 – 12:30

EXHIBITION OPENING HOURS

Sunday, May 29	17:30 – end of Welcome Reception
Monday, May 30	10:00 – 17:30
Tuesday, May 31	10:00 – 17:30
Wednesday, June 1	10:00 – 12:30

CONGRESS NAME BADGE
Upon registration you will receive your name badge. You are kindly requested to wear your badge during all sessions and events.

EAS 2016 APP
Install the EAS 2016 interactive mobile App to your smartphone and portable devices to access all the Congress information you could need during the Congress:

- See the overview of sessions, speakers and exhibitors
- Create your own programme for the event, including bookmarking the sessions you wish to attend
- Receive real-time updates

Download the EAS App now to enhance your congress experience!
(available on the App Store or Google Play).

EAS 2016 E-BOOK

EAS 2015 Final Programme E-Book is available online and can be viewed and downloaded at:
www.eas2016.kenes.com
This e-book offers a 'green alternative' to the printed programme book, provides delegates a convenient and enjoyable way to access congress content on the move and is designed to provide a user friendly interface on any mobile device. EAS is dedicated to implementing innovative and environmentally-friendly technology. The programme book can be downloaded as a PDF file from the congress website.

REFRESHMENTS

Coffee and refreshments will be served to Congress participants in the Exhibition Area from May 29-June 1, as indicated in the Programme.
Cash Bars will be available next to the Exhibition Area.

INTERNET ACCESS

WiFi is available for congress participants throughout the public areas. In order to log in please use the following user name and password:
User name: **eas-2016**
Password: **eas-2016**
Free internet and email facilities will be available in the exhibition area during the exhibition opening hours only. Congress abstracts will also be available for viewing from these stations. Please be considerate of fellow participants when using these facilities.

CONGRESS ABSTRACTS

The congress abstracts will be published online in the Atherosclerosis Journal following the congress.

MOBILE PHONES AND PHOTOGRAPHY

Participants are kindly requested to keep their mobile phones switched off in session halls and refrain from taking pictures during sessions.

SMOKING POLICY

The 84th EAS Congress is a Non-Smoking event and participants are requested to refrain from smoking in the venue.

CLOAK ROOM

A cloak room will be available for participants on Wednesday, June 1st at the Innfoyer.

LIABILITY AND INSURANCE

The Congress Secretariat and Organisers cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised to take out their own personal travel and health insurance for their trip.

SAFETY AND SECURITY

Please do not leave bags or suitcases unattended at any time, whether inside or outside the session halls. Hotels strongly recommend that you use their safety deposit boxes for your valuables.

WEBCASTING

A selection of sessions will be webcast and will be available on the Society website after the Congress.

CONGRESS ORGANISERS

kenes international
a Kenes Group® company

84th EAS Congress
Rue François-Versonnex 7,
1207 Geneva,
Switzerland
Tel: +41 22 501 7420
Fax: +41 22 906 9140
E-mail: **eas@kenes.com**

CME ACCREDITATION

EDUCATIONAL OBJECTIVES

After participating in this educational event, learners should be able to:

- Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
- Exchange ideas and knowledge in the field of Atherosclerosis and related cardiovascular conditions across continents, institutions, and individuals.
- Discuss the innovative new therapeutic agents targeting LDL cholesterol.
- Identify possible programmatic collaborations to more effectively address regional, national and local responses to Atherosclerosis around the world and overcome barriers that limit access to prevention, care and services.
- Discuss the latest scientific advantages in the field of Atherosclerosis and related cardiovascular conditions.
- Summarise the latest research outcomes in the field of Atherosclerosis and related cardiovascular conditions.

TARGET AUDIENCE

Specialists in the field of atherosclerosis, clinical chemistry, diabetes, endocrinology, primary care and more.

ACCREDITATION STATEMENT AND CREDIT DESIGNATION

EUROPEAN BOARD FOR ACCREDITATION IN CARDIOLOGY (EBAC)

An application was made to the European Board for Accreditation in Cardiology (EBAC) for CME accreditation of this event. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

AMERICAN MEDICAL ASSOCIATION (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at **www.ama-assn.org/go/internationalcme.**

ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: **www.royalcollege.ca.**

CREDIT BREAKDOWN

Day	Monday, May 30	Tuesday, May 31	Wednesday, June 1	**Total Credits:**
Maximum Credits	6	6	3	**15**

EBAC ACCREDITED EDUCATIONAL PROGRAMME

EBAC Accredited Educational Programmes will be taking place during the Congress as follows:

- EBAC Accredited Educational Programme: Diet and prevention of cardiovascular disease.
  Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:30
  This session is supported by an unrestricted educational grant from BASF, Raisio and Unilever.
- EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase deficiency.
  Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:00
  This session is supported by an unrestricted educational grant from Chiesi.
- EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase deficiency.
  Symposium at EAS 2016 Innsbruck Monday, May 30, 2016, 13:00-14:00
  This session is supported by an unrestricted educational grant from Meda (Rottapharm).
- EBAC Accredited Educational Programme: Low HDL high triglyceride, diabetic dyslipidaemia.
  Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00
  This session is supported by an unrestricted educational grant from Mylan.
- EBAC Accredited Educational Programme: Lysosomal Acid Lipase Deficiency.
  Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00
  This session is supported by an unrestricted educational grant from Alexion.

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

CREDIT BREAKDOWN

Day	Sunday, May 29	Monday, May 30	Tuesday, May 31	**Total Credits:**
Maximum Credits	2	1	2	**5**

TO RECEIVE YOUR CME/CPD CERTIFICATE

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

Before June 29, 2016:

1. Access the online system via any of the following
   Please note that web browsers Mozilla Firefox 2.X or higher, or Google Chrome are recommended
   - Visit the CME/CPD Accreditation page on the event website
   - Follow the link in the email sent at the end of the event
2. Complete the anonymous online evaluation
3. Complete the credit claim form and submit
4. The CME/CPD certificate will be available for download; fill-in and retain for your personal records

DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

INDUSTRY SUPPORT DISCLOSURE

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organizations is made in the Programme guide, on the event website, and with signage during the event. Disclosure is made to participants prior to the activity.

Aegerion Pharmaceuticals	Akcea Therapeutics	Alexion	Amgen	BASF
Chiesi	Denka Seiken	European FH Network	FH Score	Fuji Film/ Sonosite
IBL	Kaneka Pharma	Kowa	Meda Pharma	Merck MSD
Mercodia	Mylan	Numares	Pfizer	Raisio
Randox	Regeneron	Sanofi	Unilever	Wisepress

INFORMATION FOR PRESENTERS

ORAL PRESENTATIONS

DATA PRESENTATION:

A speakers' ready room will be available throughout the entire Congress for speakers. The room is located on the 1st Level (Maximilian).

If using a PowerPoint presentation (or any other PC based application, such as PDF), please note you need to bring it on USB Memory stick and load it on one of the Congress computers in the Speakers' Ready Room at least 1 hour before the start of the session.

The recommended format for PPT presentations is 16:9.

Please make sure to prepare your presentation accordingly.

Please note that the Congress computers in the session halls are being supplied with Office 2010 (at least).

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session - **even after checking it in the Speakers' Ready Room.**

Alternatively you may supply your own laptop computer. In such a case please confirm that it has a VGA socket for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session.

Important note for Apple Mac users:

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions below, before bringing it to the Speakers' Ready Room:

1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).

Alternatively you may use your own Macintosh laptop computer. In such a case please confirm you provide it with a **VGA adaptor** for external signal, advise the operators in the Speakers' Ready Room about it as soon as you arrive and later on test it in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session

SCIENCE AT A GLANCE PRESENTATIONS

EAS is proud to have Science at a Glance E-Poster sessions that will be located in the Exhibition area, providing the unique opportunity for convivial scientific discussions and exchange. For further details please refer to the Overview of these Sessions.

OVERVIEW OF SCIENCE AT A GLANCE E-POSTER SESSIONS

SESSION I, MONDAY, MAY 30, 2016 — 13:00-14:00

Session Topic	Session Chair	E-Poster Station	Poster #
Lipids and Lipoproteins	Jörg Heeren, Germany	Station A	SaG001-SaG008
Vascular Biology I	Guido de Meyer, Belgium	Station B	SaG009-SaG016
Genetic, Omics and in silico Approaches	Neville Sanjana, USA	Station C	SaG017-SaG024
CV Risk Factors and Atherosclerosis I	Yuji Matsuzawa, Japan	Station D	SaG25-SaG032

SESSION II, MONDAY, MAY 30, 2016 — 14:00-15:00

Session Topic	Session Chair	E-Poster Station	Poster #
Experimental Cadiovascular Medicine I	Paolo Parini, Sweden	Station A	SaG033-SaG040
Nutrition, Nutraceuticals and Cardiovascular Disease	Alice H. Lichtenstein, USA	Station B	SaG041-SaG048
Pharmacology of Dyslipidemia	Maurizio Averna, Italy	Station C	SaG049-SaG056
Imaging in Vascular Dysfunction and Myocardial Infarction	Wolfgang Koenig, Germany	Station D	SaG057-SaG064

SESSION III, TUESDAY, MAY 31, 2016 — 13:00-14:00

Session Topic	Session Chair	E-Poster Station	Poster #
CV risk factors and Atherosclerosis II	Winfried März, Germany	Station A	SaG065-SaG072
Vascular Biology II	Herbert Stangl, Austria	Station B	SaG073-SaG080
Insulin Resistance, Diabetes, Metabolic Syndrome and Obesity	Gerald Watts, Australia	Station C	SaG081-SaG088
Hypertension, Liver and Chronic Renal Disease	TBA	Station D	SaG089-SaG096

SESSION IV, TUESDAY, MAY 31, 2016 — 14:00-15:00

Session Topic	Session Chair	E-Poster Station	Poster #
Experimental Cadiovascular Medicine II	Matti Jauhiainen, Finland	Station A	SaG097-SaG104
Immunity and Atherosclerosis	Giuseppina Caligiuri, France	Station B	SaG105-SaG112
Emerging Aspects in Pharmacological Treatment of Primary and Secondary Dyslipidemia	Benjamin Dieplinger, Austria	Station C	SaG113-SaG120
Vascular Biology III	Joachim Herz, USA	Station D	SaG121-SaG128

POSTER PRESENTATIONS

Posters will be on display in 2 shifts. Please check the Scientific Programme to see the exact poster board number, date, and time of the poster discussion groups.

The organisers are not responsible for any posters that have not been removed by the end of sessions on Wednesday, June 1.

POSTER SHIFT I

Posters may be mounted from 17:30 on Sunday, May 29, 2016 and should remain on display until Monday, May 30, 2016 at 18:30.

POSTER SHIFT II

Posters may be mounted from 08:30 on Tuesday, May 31, 2016 and should remain on display until Wednesday, June 1, 2016 at 12:30.

Authors are asked to actively participate in both the poster sessions on the day in which their poster was allocated to.

Poster sessions will take place on Monday, May 30 from 13:00-14:00, 17:00-18:00 and Tuesday, May 31 from 13:00-14:00, 17:00-18:00.

POSTER AREA MAP



POSTER OVERVIEW

Please note that posters of Abstract presenters that were not registered to the congress by the deadline were not allocated poster boards. Such abstract presenters are requested to approach the poster help desk to be allocated an available poster board on-site.

POSTER SHIFT I – MONDAY, MAY 30, 2016

Session Time	Topic	Poster Board
13:00-14:00	Vascular Biology: Endothelium and Smooth Muscle Cells	001 – 044
	Vascular Biology: Macrophages, Inflammation, Immunity	045 - 088
	Vascular Biology: Myocardial Infarction, Stroke, Peripheral Vascular Disease	089 - 134
	Vascular Biology: Immune Disease and Cardiovascular Pathologies	135 - 142
	Lipoproteins and Lipid Metabolism: ApoB Containing Lipoproteins	143 - 163
	Lipoproteins and Lipid Metabolism: Lipoprotein Metabolism	164 - 187
17:00-18:00	Lipoproteins and Lipid Metabolism: Lp(a)	188 - 210
	Lipoproteins and Lipid Metabolism: HDL	211 - 245
	CVD Risk Factors	246 - 320

POSTER SHIFT II – TUESDAY, MAY 31, 2016

Session Time	Topic	Poster Board
13:00-14:00	Metabolic Abnormalities and Atherosclerosis: Diabetes	001 - 056
	Metabolic Abnormalities and Atherosclerosis: Adipose Tissue	057 - 066
	Metabolic Abnormalities and Atherosclerosis: Kidney	067 - 081
	Metabolic Abnormalities and Atherosclerosis: NASH and Liver Abnormalities	082 - 090
	Dyslipidemias: Dyslipidemias, Screening and Treatment	091 - 167
17:00-18:00	Dyslipidemias: Treatment	168 - 199
	Dyslipidemias: Coagulation	200 - 210
	Dyslipidemias: Endothelial Dysfunction	211 – 220
	Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation	221 - 259
	Genetics, Nutrition, Biomarkers: Nutrition	260 - 298
	Genetics, Nutrition, Biomarkers: Biomarkers	299 - 333
	Genetics, Nutrition, Biomarkers: Guidelines and Miscellaneous	334 - 344

Please note that posters of abstract presenters that were not registered to the Congress by the deadline were not allocated poster boards. Such abstract presenters are requested to approach the poster help desk to be allocated an available poster board on-site.

PROGRAMME AT A GLANCE

Plenary Session	Workshop	Science at a Glance Session	Young Investigators Session	Oral Communication Session
Company Sponsored Session	EBAC Accredited Session	Poster Walk Session	Other	Social Event

SUNDAY, MAY 29, 2016

	Exhibition & Posters Area	Nikolai N. Anitschkow (Tirol)	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Brussel)	Wilhelm Auerswald (Strassburg)
12:00-13:30				12:30-13:30 Meet the Expert Supported Session Not included in the CME/CPD programme	
13:30-14:00	Break				
14:00-15:30				EBAC Accredited Educational Programme Diet and Prevention of Cardiovascular Disease	14:00-15:00 EBAC Accredited Educational Programme Gene Therapy and Lipoprotein Lipase Deficiency
15:30-16:00	Break				
16:00-17:30		Educational Symposium Supported Session Not included in the CME/CPD programme			
17:30-18:00	Break				
18:00-19:45		Opening Ceremony, including the Anitschkow Lecture			
19:45– 20:45	Welcome Reception				

MONDAY, MAY 30, 2016

	Exhibition & Posters Area	Nikolai N. Anitschkow (Tirol)	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Brussel)	Wilhelm Auerswald (Strassburg)
08:30-10:30		Plenary Session: Integrative Approach in Atherosclerosis			
10:30-11:00	Coffee Break, Exhibition and Poster Viewing				
11.00-12.30		Workshop 1.1 Novel Aspects of Pathogenesis in Atherosclerosis	Workshop 2.1 Lipoproteins and Extracellular Matrix	11:00-11:45 Advanced Clinical Seminar Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians? 11:45-12:30 Advanced Clinical Seminar Role of Nutrition in Disease Pathology	Workshop 3.1 Novel Therapies
12:30-15:00	Break, Exhibition and Poster Viewing				
	13:00-14:00 Science at a Glance Session I 13:00-14:00 Poster Walk Session I 14:00-15:00 Science at a Glance Session II	13:00 – 14:30 Educational Symposium Supported Session Not included in the CME/CPD programme	13:00 – 14:30 Educational Symposium Supported Session Not included in the CME/CPD programme	13:00-14:00 EBAC Accredited Educational Programme Nutraceuticals with Lipid Lowering: Who Can Benefit?	
15.00-16:30		EAS- ESC Joint Workshop Sex differences in Cardiovascular Diseases	Workshop 1.2 Therapeutic and Diagnostic Targeting of the Arterial Wall	Workshop 2.2 Adipose Tissue – Liver Axis	15:00-15:45 Late Breaking: Basic Science 15:45-16:30 Young Investigator Award Session
16:30-17:00	Coffee break, Exhibition and Poster Viewing				
17:00-18:30	17:00-18:00 Poster Walk Session II	Young Investigator Session Vascular Biology and Inflammation	Young Investigator Session Lipids and Lipoproteins Metabolism	Young Investigator Session Clinical Epidemiology and Pharmacology	Oral Communication Session Vascular Biology
18:40-19:40		Keynote Lecture			

TUESDAY, MAY 31, 2016

	Exhibition & Posters Area	Nikolai N. Anitschkow (Tirol)	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Brussel)	Wilhelm Auerswald (Strassburg)
08:30-10:30		Plenary Lecture: Lipid Biology, New Insights			
10:30-11:00	Coffee Break, Exhibition and Poster Viewing				
11:00-12:30		Workshop 1.3 Cellular Stress Response in Atherosclerosis	Workshop 2.3 Gut- Liver Axis	ICCR-EAS Joint Session Management of Cardiometabolic Risk; Where Do We Stand?	Workshop 3.2 Vascular Aging and Athero-thrombosis
12:30-15:00	Break, Exhibition and Poster Viewing				
	13:00–14:00 Science at a Glance Session III		13:00-14:30 Educational Symposium Supported Session Not included in the CME/CPD programme	13:00-14:00 EBAC Accredited Educational Programme Low HDL High Triglyceride, Diabetic Dyslipidaemia	13:00-14:00 EBAC Accredited Educational Programme Lysosomal Acid Lipase Deficiency
	13:00-14:00 Poster Walk Session III	14:00-14:45 Supported Session Special Lecture Not included in the CME/CPD programme		14:10-14:55 Supported Session Not included in the CME/CPD programme	14:10-14:55 Supported Session Meet the Expert Not included in the CME/CPD programme
	14:00–15:00 Science at a Glance Session IV				
15.00-16:30		Workshop 3.3 Genetics in Risk Factor Prevention and Treatment	Late Breaking: Clinical Science	15:00-16:30 EAS Initiatives Update Session (open to all)	Advanced Clinical Seminar Economics and Guidelines/ Technology of the Future
				16:30-16:50 EAS General Assembly	
16:30-17:00	Coffee Break, Exhibition and Poster Viewing				
17:00-18:30	17:00-18:00 Poster Walk Session IV	Workshop 3.5 Epigenetics and Gene Regulation	Oral Communication Session Imaging, Biomarkers	Oral Communication Session Intracellular Lipid	Young Investigator Session Novel pathways in

WEDNESDAY, JUNE 1, 2016

	Exhibition & Posters Area	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Brussel)	Wilhelm Auerswald (Strassburg)	Fritz Pregl (Freiburg)
08:30-10:30		Plenary Session: Future Therapeutic Challenges			
10:30-11.00	Coffee Break, Exhibition and Poster Viewing				
11:00-12:30		Workshop 1.4 Inflammation Immunity and Atherosclerosis	Workshop 3.4 Biology of CVD Risk	Workshop 4.4 New Guidelines on Prevention of Cardiovascular Disease in Clinical Practice	Workshop 2.4 Novel Role of Lipoprotein Receptors

CONGRESS FLOOR PLAN

LEVEL 0

LEVEL 1

LEVEL 2

LEVEL 3

HALL NAME EULOGY OF DISTINGUISHED SCIENTISTS

NIKOLAI N. ANITSCHKOW (1885-1964)

Professor of the Department of Pathological Physiology of the Military Medical Academy St. Petersburg, Russia
In 1913, experimental pathologist Dr. Nikolai N. Anitschkow showed that simply feeding to rabbits purified cholesterol dissolved in sunflower oil induced vascular lesions closely resembling those of human atherosclerosis, both grossly and microscopically. Controls fed with only the sunflower oil showed no lesions. It is fair to say that this paper marked the beginning of the modern era of atherosclerosis research. Dr. Anitschkow was not only a keen-eyed structural pathologist and a careful experimentalist; he thought in terms of function and time-related pathogenesis.
However, the landmark studies by Dr. Anitschkow were largely rejected at the time. An important reason for this was that the findings were inconsistent with the prevailing view of atherosclerosis. It was generally accepted to be an inevitable accompaniment of aging (the "senescence hypothesis"). If the full significance of his findings had been appreciated at the time, we might have saved more than 30 years in the long struggle to settle the cholesterol controversy.
In honor of Dr. Nikolai N. Anitschkow, the "Anitschkow Prize in Atherosclerosis Research" awarded annually by the EAS recognizes outstanding research in the field of atherosclerosis and linked metabolic disturbances.

KARL LANDSTEINER (1868-1943)

Karl Landsteiner, Austrian pathologist, studied medicine at the University of Vienna. In 1896 he became an assistant in the Hygiene Institute at Vienna where he was interested in the mechanisms of immunity and in the nature of antibodies. From 1898 till 1908 he held the post of assistant in the University Department of Pathological Anatomy in Vienna, in 1911 he became Professor of Pathological Anatomy in the University of Vienna.
He showed that the cause of poliomyelitis could be transmitted to monkeys by injecting into them material prepared by grinding up the spinal cords of children who had died from this disease. His work laid the foundations of our knowledge of the cause and immunology of poliomyelitis.
Landsteiner made numerous contributions to both pathological anatomy, histology and immunology, all of which showed, not only his meticulous care in observation and description, but also his biological understanding. But his name will no doubt always be honoured for his discovery in 1901 of the blood groups, for which he was given the Nobel Prize for Physiology or Medicine in 1930. In 1875 Landois had reported that, when man is given transfusions of the blood of other animals, these foreign blood corpuscles are clumped and broken up in the blood vessels of man with the liberation of haemoglobin. In 1901-1903 Landsteiner pointed out that a similar reaction may occur when the blood of one human individual is transfused, not with the blood of another animal, but with that of another human being, and that this might be the cause of shock, jaundice, and haemoglobinuria that had followed some earlier attempts at blood transfusions.
His suggestions, however, received little attention until, in 1909, he classified human blood into the now well-known A, B, AB, and O groups and showed that transfusions between individuals of groups A or B do not result in the destruction of new blood cells and that this catastrophe occurs only when a person is transfused with the blood of a person belonging to a different group. Earlier, in 1901-1903, Landsteiner had suggested that, because the characteristics which determine the blood groups are inherited, the blood groups may be used to decide instances of doubtful paternity. In 1922, he accepted a post in the Rockefeller Institute for Medical Research in New York. It was here that he did further work on the blood groups which greatly extended the number of these groups, and studied bleeding in the new-born, leading to the discovery of the Rh-factor in blood, which relates the human blood to the blood of the rhesus monkey.

KARL BARON VON ROKITANSKY (1804-1878)

Austrian pathologist whose endeavours to establish a systematic picture of the sick organism from nearly 100,000 autopsies—30,000 of which he himself performed—helped make the study of pathological anatomy a cornerstone of modern medical practice and established the New Vienna School as a world medical centre during the latter half of the 19th century.

A professor of pathological anatomy at the Vienna General Hospital, he inspired the Bohemian student Ignaz Semmelweis, later a martyr to the cause of antiseptic medical practice, to take up the study of medicine and afterward supported him in his struggle to eliminate childbed fever by cleaning up Europe's maternity wards.

First to detect bacteria in lesions of malignant endocarditis, an often rapidly fatal inflammation of the membrane lining the inner walls of the heart, Rokitansky created the basis for a differentiation of lobar pneumonia (originating in the lower lobe of the lung) and lobular pneumonia, or bronchopneumonia (originating in the finer subdivisions of the branched bronchial tree). He made a fundamental study of acute yellow atrophy of the liver (now known as Rokitansky's disease), established the micropathology of pulmonary emphysema (a condition of the lung characterized by enlarged air spaces separated from the terminals of the bronchial tree), and first described spondylolisthesis, the forward displacement of one vertebra over another.

WILHELM AUERSWALD (1917-1981)

Wilhelm Auerswald, Austrian physiologist, graduated from medical school at the University of Vienna in 1940. Auerswald became assistant at the Physiological Institute of the University of Vienna in 1944. Under the later-appointed Director Carl Schwarz-Wendl Auerswald could finish his habilitation in Physiology in 1950 and was established in 1968 as the successor to Gustav Schubert.

His scientific work includes 370 publications in the fields of physiology and pathology of blood proteins, nutrition, thrombosis, atherosclerosis, aerospace- and work physiology. It was Auerswald's concern to make his research results available for practical medicine; he provided valuable pioneering work in the fields of plasma replacement, productions of vaccines (first Poliomyelitis vaccine in Austria) and immunoglobulins (first intravenous application). His blood coagulation studies gained high international reputation.

In his teaching Auerswald was anxious to consider physiology as medical basic science with strong and immediate reference to the bedside; he also succeded in renaming his workplace into the Department of Medical Physiology. Its translation and adaptation of the "Textbook of Physiology"

FRITZ PREGL (1869-1930)

Fritz Pregl, Austrian physiologist and chemist, studied medicine at the University of Graz and received his M.D. In 1894, he became assistant lecturer for physiology and histology under Alexander Rollett, taking over the chair when Rollett died in 1903. During this time Pregl also acquired a thorough knowledge of all branches of chemistry under the guidance of Professor Skraup. He started investigating the components of albuminous bodies and the analysis of bile acids. His work, however, was handicapped by the lack of sufficient starting materials and this fact impelled him to look for methods requiring smaller amounts when making quantitative analyses of elements in compounds.

The years 1910-1913, whilst professor at the University of Innsbruck, were almost entirely devoted to developing the method of quantitative organic micro-analysis. Pregl continued this work when he was recalled to Graz in 1913.

Initially Pregl's scientific work had been mainly in the fields of physiology and physiological chemistry; later he turned to the study of the constitution of chemical compounds, in particular the investigation of bile acids. By 1912 he was able, by using his own methods of quantitative micro-analysis, to make measurements of carbon, hydrogen, nitrogen, sulphur, and halogen, using only 5-13 mg of starting materials with results as accurate as those obtained by macro-analysis. Later he perfected his techniques so that as little as 3-5 mg were adequate. Pregl also contributed a number of micromethods for measuring atomic groups and developed a series of apparatus, including a sensitive microbalance, necessary for his work.

The greatest honour was the award of the Nobel Prize for Chemistry by the Swedish Academy of Sciences in 1923. The Nobel Committee pointed out that it was not for a discovery, but for modifying and improving existing methods that Pregl was awarded the prize. Following the Nobel Prize for Chemistry in 1923, chemists from all over the world came to the Medico-Chemical Institute in Graz to study Pregl's techniques of quantitative organic micro-analysis under his guidance.

EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme

SUNDAY, MAY 29, 2016

www.eas2016.kenes.com

SUNDAY, MAY 29, 2016

12:30 - 13:30 C. von Rokitansky Hall

Industry Symposium: Meet the Expert

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:30 - 14:00 Exhibition & Poster Area

Break

14:00 - 15:30 C. von Rokitansky Hall

EBAC Accredited Session: Diet and Prevention of Cardiovascular Disease

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from BASF, Raisio and Unilever in support of the Programme.

14:00 - 15:00 W. Auerswald Hall

EBAC Accredited Session: Gene Therapy and Lipoprotein Lipase Deficiency

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Chiesi in support of the Programme.

15:30 - 16:00 Exhibition & Poster Area

Break

16:00 - 17:30 N. Anitschkow Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

17:30 - 18:00 Exhibition & Poster Area

Break

18:00 - 19:45 N. Anitschkow Hall

Plenary: Opening Ceremony, including the Anitschkow Lecture

19:45 - 20:45 Exhibition Area

Welcome Reception

EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme
MONDAY, MAY 30, 2016

www.eas2016.kenes.com

MONDAY, MAY 30, 2016

8:30 - 10:30 N. Anitschkow Hall

Plenary: Integrative Approach in Atherosclerosis

10:30 - 11:00 Exhibition & Poster Area

Coffee Break, Exhibition & Poster Viewing

11:00 - 12:30 N. Anitschkow Hall

Workshop 1.1: Novel Aspects of Pathogenesis in Atherosclerosis

Chair: **C.J. Binder** (Austria) 36

Chair: **S. Ylä-Herttuala** (Finland) 37

11:00 BEYOND VASCULAR INFLAMMATION: RECENT ADVANCES IN UNDERSTANDING ATHEROSCLEROSIS 38

K. Ley (USA)

11:25 B-CELLS AND ATHEROSCLEROSIS 39

C.J. Binder (Austria)

11:50 REGULATORY T CELLS FROM PATIENTS WITH ATHEROSCLEROSIS HAVE ENHANCED SUPPRESSION FUNCTION DUE TO INCREASED EFFECTOR/RESTING RATIO AND PRO-INFLAMMATORY SKEWING 40

I.E. Dumitriu, P. Baruah, J.C. Kaski (United Kingdom)

12:03 CONTROL OF ATHEROSCLEROSIS BY AN APOE RECEPTOR-DEPENDENT NEUROMODULATOR 41

J. Herz (USA)

12:16 DYNAMIN-RELATED PROTEIN 1 INHIBITION REDUCES OSTEOGENIC DIFFERENTIATION INDUCED TYPE 1 COLLAGEN SECRETION AND PREVENTS HUMAN VASCULAR CELL CALCIFICATION 42

M. Rogers, N. Maldonado, J. Hutcheson, C. Goettsch, M. Aikawa, E. Aikawa (USA)

11:00 - 12:30 K. Landsteiner Hall

Workshop 2.1: Lipoproteins and Extracellular Matrix

Chair: **J. Borén** (Sweden) 43

Chair: **P. Gordts** (USA) 44

11:00 POSTPRANDIAL HYPERLIPIDEMIA, ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR RISK: FOCUS ON INCRETINS 45

P.D. Reaven (USA)

11:30 THE ROLE OF PROTEOGLYCANS IN HEPATIC TRIGLYCERIDE-RICH LIPOPROTEIN METABOLISM: ROLE OF ACOCIII AND APOAV 46

P. Gordts (USA)

12:00 INCREASED LIPOPROTEIN BINDING TO ARTERIAL PROTEOGLYCANS AND NORMAL MACROPHAGE CHOLESTEROL EFFLUX CAPACITY DEFINE THE PRO-ATHEROGENIC FEATURE OF CKD DYSLIPIDEMIA 47

M. Pedrelli, P. Stenvinkel, M.E. Minniti, K. Emma, A. Dikkers, S. Ebtehaj, M. Gomaraschi, P. Barany, A.R. Qureshi, G. Camejo, B. Lindholm, K. Oörni, U. Tietge, L. Calabresi, E. Hurt-Camejo, P. Parini (Sweden)

12:15 BROWN AND BEIGE ADIPOCYTE ACTIVITY CONTROLS METABOLIC FLUX THROUGH THE HDL COMPARTMENT 48

N. Schaltenberg, A. Bartelt, J. Clara, A. Worthmann, C. Lisa M., R. Franz, H. Markus, N. Stefan K., S. Ludger, J. Heeren (Germany)

11:00 - 11:45 C. von Rokitansky Hall

Advanced Clinical Seminar 4.1: Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians?

Chair: **C. Packard** (United Kingdom) 49

11:00 LESSONS FROM CLINICAL EXPERIENCE 50

U. Laufs (Germany)

11:20 LESSONS FROM CLINICAL TRIALS 51

J.M. Armitage (United Kingdom)

11:40 DISCUSSION 52

11:45 - 12:30 C. von Rokitansky Hall

Workshop 4.2: Role of Nutrition in Disease Pathology

Chair: **E. Bruckert** (France) 53
Chair: **J.M. Titze** (Germany) 54

11:45 ROLE OF SODIUM IN ATHEROSCLEROSIS 55
J.M. Titze (Germany)

12:05 SATURATED FAT IN THE DIET: GOOD OR BAD? 56
I. Brouwer (Netherlands)

12:25 DISCUSSION 57

11:00 - 12:30 W. Auerswald Hall

Workshop 3.1: Novel Therapies

Chair: **F. Mach** (Switzerland) 58
Chair: **D. Gaudet** (Canada) 59

11:00 ANTI-INFLAMMATORY INTERVENTIONS VERSUS INTENSIVE LDL LOWERING 60
F. Mach (Switzerland)

11:25 COMPARATIVE EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION, STATIN AND EZETIMIBE THERAPY ON ATHEROGENIC AND PROTECTIVE LIPID FACTORS: THE ACCENTUATE TRIAL 61
S. Nicholls, K. Ray, C. Ballantyne, L. Beacham, D. Miller, G. Ruotolo, J. Riesmeyer (Australia)

11:50 A NOVEL COMBINATORIAL NON-VIRAL VECTOR TO TREAT FAMILIAL HYPERCHOLESTEROLAEMIA (FH) 62
A. Kerr, L. Tam, M. Cioroch, A. Hale, G. Douglas, K. Channon, R. Wade-Martins (United Kingdom)

12:03 CURRENT STATUS-PHASE I TRIAL OF CELL-TRANSPLANTATION THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE PROGENITOR CELLS IN SEVERE FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS UNDERGOING LDL-APHERESIS 63
M. Koseki, S. Ayami, T. Okada, T. Kobayashi, M. Asaji, R. Kawase, M. Nishida, Y. Sakata, S. Yamashita (Japan)

12:16 NOVEL INTRANASAL ANTI-CETP VACCINE AGAINST THE DEVELOPMENT OF ATHEROSCLEROSIS AND FATTY LIVER DISEASE 64
J. Mas-Oliva, B. Delgado-Coello, K. Méndez-Acevedo (Mexico)

12:30 - 15:00 Exhibition & Poster Area

Break, Exhibition & Poster Viewing

13:00 - 14:00 Exhibition Area

Science at a Glance Session I

13:00 - 14:00 Kristall Foyer

Poster Walk Session I

13:00 - 14:30 N. Anitschkow Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:00 - 14:30 K. Landsteiner Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:00 - 14:00 C. von Rokitansky Hall

EBAC Accredited Session: Nutraceuticals with Lipid Lowering Activity: Who Can Benefit?

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Meda (Rottapharm) in support of the Programme.

14:00 - 15:00 Exhibition Area

Science at a Glance Session II

15:00 - 16:30 N. Anitschkow Hall

EAS-ESC Joint Workshop: Sex Differences in Cardiovascular Diseases

15:00 - 16:30 K. Landsteiner Hall

Workshop 1.2: Therapeutic and Diagnostic Targeting of the Arterial Wall

15:00 - 16:30 C. von Rokitansky Hall

Workshop 2.2: Adipose Tissue – Liver Axis

15:00 - 15:45 W. Auerswald Hall

Late Breaking: Basic Science

Chair: **J. Herz** (USA) 91

Chair: **R. Zechner** (Austria) 92

15:00 FLOW PERTURBATION MEDIATES NEUTROPHIL RECRUITMENT AND POTENTIATES ENDOTHELIAL INJURY VIA TLR2 IN MICE. A NOVEL IN VIVO APPROACH FOR PROBING THE PATHOPHYSIOLOGY OF SUPERFICIAL EROSION 93

G. Franck, G. Sausen, T. Mawson, M. Salinas, G. Masson, A. Cole, M. Beltrami-Moreira, Y. Chatzizisis, Y. Tesmenitsky, E. Swartz, G. Sukhova, F. Swirski, M. Nahrendorf, E. Aikawa, K. Croce, P. Libby (USA)

15:15 THE ATYPICAL CADHERIN FAT1 SUPPRESSES MITOCHONDRIAL RESPIRATION TO LIMIT SMOOTH MUSCLE CELL RESPONSE TO VASCULAR INJURY 94

N. Sibinga, L.L. Cao, D. Riascos-Bernal, P. Chinnasamy, C. Dunaway, M. Pujato, A. Fiser (USA)

15:30 THE CORONARY ARTERY DISEASE RISK ASSOCIATED GENE PLPP3/PPAP2B SUPPRESSES ATHEROSCLEROSIS IN MICE 95

A. Morris, P. Mueller, J. Brandon, L. Yang, S. Smyth (USA)

15:45 - 16:30 W. Auerswald Hall

Young Investigator Award Session

Chair: **P. Kovanen** (Finland) 96

Chair: **G. Dallinga-Thie** (Netherlands) 97

15:45 GRP94 REGULATES CIRCULATING CHOLESTEROL LEVELS THROUGH BLOCKADE OF PCSK9-INDUCED LDLR DEGRADATION 98

S. Poirier (Canada)

16:05 ASSOCIATION BETWEEN FAMILIAL HYPERCHOLESTEROLEMIA AND PREVALENCE OF TYPE 2 DIABETES MELLITUS 99

J. Besseling (Netherlands)

16:30 - 17:00 Exhibition & Poster Area

Coffee Break, Exhibition & Poster Viewing

17:00 - 18:00 Kristall Foyer

Poster Walk Session II

17:00 - 18:30 N. Anitschkow Hall

Young Investigator Session: Vascular Biology and Inflammation

Chair: **K. Öörni** (Finland) 100

Chair: **L.O. Martinez** (France) 101

17:00 IRON ACCELERATES CARDIOVASCULAR DISEASE: THE IMPORTANCE OF MAINTAINING IRON BALANCE 102

F. Vinchi, A. Simmelbauer, S. Altamura, B. Galy, M.W. Hentze, M. Muckenthaler (Germany)

17:15 INCREASED APOA-I TRANSCRIPTION BY BET INHIBITOR JQ1(+) ACTS INDEPENDENTLY FROM PPAR-ALPHA ACTIVATION AND IS LINKED TO ER-STRESS INHIBITION 103

S.E. Van der Krieken, H.E. Popeijus, R.P. Mensink, J. Plat (Netherlands)

17:30 PHOSPHATIDYLSERINE IMPROVES ANTI-INFLAMMATORY FUNCTION OF RECONSTITUTED HDL IN MACROPHAGES VIA SR-BI-, AKT- AND P38 MAPK-DEPENDENT PATHWAYS 104

M. Darabi, E. Tubeuf, M. Lhomme, I. Guillas-Baudouin, C. Dauteuille, M. Patel, T. Huby, E.L. Gautier, K.A. Rye, P. Lesnik, W. Le Goff, A. Kontush (France)

17:45 CCAAT/ENHANCER BINDING PROTEIN DELTA CONTRIBUTES TO LIPID ACCUMULATION IN M1 MACROPHAGES OF BLOOD VESSEL LESIONS 105

H.Y. Lai, L.W. Hsu, P.Y. Liu, J.M. Wang (Taiwan)

18:00 INHIBITION OF THE CHOLESTEROL SYNTHESIS PATHWAY PREVENTS TRAINED INNATE IMMUNITY 106

S. Bekkering, S. Bernelot Moens, S. Verweij, J. Roeters van Lennep, J. Van Tuijl, L. Joosten, E. Stroes, M. Netea, N. Riksen (Netherlands)

18:15 SELECTIVE DONOR ENDOTHELIAL HEPARAN SULFATE MODIFYING ENZYME NDST1 DELETION SIGNIFICANTLY BLOCKS REJECTION AFTER RENAL TRANSPLANT 107

S. Ambadapadi, H. Chen, D. Wakefield, S. Morshed, W. Clapp, A. Lucas (USA)

17:00 - 18:30 K. Landsteiner Hall

Young Investigator Session: Lipids and Lipoprotein Metabolism

Chair: **L. Scheja** (Germany) 108

Chair: **A. Ritsch** (Austria) 109

17:00 PARAOXONASE 1 (PON1) MAINTAINS CELLULAR CHOLESTEROL HOMEOSTASIS VIA THE REGULATION OF CHOLESTEROL EFFLUX 110

S. Ikhlef, H. Berrougui, **A. Khalil** (Canada)

17:15 A UBIQUITOUS TRANSCRIPTION FACTOR INFLUENCES DIET-INDUCED THERMOGENESIS AND SENSITIZES BAT TO NORADRENERGIC STIMULI IMPROVING CARDIOMETABOLIC HEALTH 111

P.P. Laurila, J. Soronen, S. Kooijman, M. Boon, M.R. Taskinen, V. Olkkonen, S. Ripatti, P. Kovanen, P. Rensen, M. Jauhiainen (Finland)

17:30 CALCIUM DEPENDENT ENDOCYTOSIS AND RECYCLING OF LIPOPROTEIN(A) IN HEPG2 CELLS 112

M. SHARMA, G. Redpath, S. McCormick (New Zealand)

17:45 PLASMA CETP IS DERIVED FROM HEPATIC KUPFFER CELLS RATHER THAN ADIPOSE TISSUE 113

L. Blauw, R. De Mutsert, Y. Wang, H. Lamb, A. De Roos, F. Rosendaal, W. Jukema, S. Van der Tuin, S. Rensen, R. Shiri-Sverdlov, B. Atanasovska, J. Fu, W. Buurman, J.W. Greve, M. Hofker, K. Willems van Dijk, P. Rensen (Netherlands)

18:00 IN VIVO INHIBITION OF NUCLEAR FACTOR OF ACTIVATED T CELLS (NFAT) RESTORES MICROVASCULAR ENDOTHELIAL FUNCTION IN DIABETIC MICE 114

E. Garcia-Vaz, A. Mc Neilly, J. Gallagher, R. Mc Crimmon, F. Khan, M.F. Gomez (Sweden)

18:15 OXYSTEROLS, 24S-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL, IN SUBJECTS WITH GENETIC HYPERCHOLESTEROLEMIA NEGATIVE FOR LDLR/APOB/PCSK9/APOE MUTATIONS. ASSOCIATION WITH LIPIDS AND CAROTID ATHEROSCLEROSIS 115

L. Baila-Rueda, A. Cenarro, I. Lamiquiz-Moneo, R. Mateo-Gallego, A.M. Bea-Sanz, S. Perez-Calahorra, V. Marco-Benedi, F. Civeira (Spain)

17:00 - 18:30 C. von Rokitansky Hall

Young Investigator Session: Clinical Epidemiology and Pharmacology

Chair: **K. Kotseva** (United Kingdom) 116

Chair: **P.D. Reaven** (USA) 117

17:00 APABETALONE (RVX-208) DECREASES ATHEROGENIC, THROMBOTIC AND INFLAMMATORY MEDIATORS IN VITRO AND IN PLASMA OF PATIENTS WITH CARDIOVASCULAR DISEASE (CVD). 118

N. Wong, E. Kulikowski, S. Wasiak, D. Gilham, C. Calosing, T. Laura, C. Halliday, J. Johansson, M. Sweeney (Canada)

17:15 IMPACT OF DIABETES, INSULIN RESISTANCE AND CETP INHIBITION ON CIRCULATING PCSK9 LEVELS IN PATIENTS AT HIGH CARDIOVASCULAR RISK: THE ILLUMINATE STUDY 119

B. Arsenault, F. Tabet, W. Bao, F. Petrides, G.K. Hovingh, S.M. Boekholdt, D. DeMicco, K.A. Rye, D. Waters, J. Kastelein, P. Barter, G. Lambert (Canada)

17:30 CLINICAL CHARACTERISTICS AND LONG-TERM CLINICAL OUTCOMES OF PATIENTS WITH TYPICAL RESTING CHEST PAIN ACCORDING TO THE TYPES OF VASOMOTOR RESPONSE TO AN ACETYLCHOLINE PROVOCATION TEST 120

E.M. Lee, H.S. Seo, M.H. Choi, H.K. Kim, S.Y. Lee, N.H. Kim, D.O. Kang, C.U. Choi, J.W. Kim, E.J. Kim, S.W. Rha, C.G. Park, D.J. Oh (Republic of Korea)

17:45 RESPONSE TO TREATMENT AND OCCURRENCE OF CARDIOVASCULAR (CV) COMPLICATIONS IN PATIENTS WITH AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA (ARH): A RETROSPECTIVE ANALYSIS 121

L. D'Erasmo, I. Minicocci, L. Masana, J. Roeters van Lennep, M. Harada-Shiba, S. Muntoni, P. Pintus, S. Bertolini, C. Sirtori, L. Calabresi, C. Pavanello, M. Averna, A.B. Cefalù, D. Noto, A. Pacifico, G. Pes, R. Fellin, E. Manzato, S. Zambon, M. Arca (Italy)

18:00 ASSOCIATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS ADENYLATE CYCLASE-ASSOCIATED PROTEIN 1 MRNA WITH CORONARY ARTERY DISEASE 122

M. Sopic, J. Joksić, V. Spasojević Kalimanovska, D. Kalminaovska Oštrić, K. Anđelković, Z. Jelić Ivanović (Serbia)

18:15 FILAGGRIN MUTATIONS AS RISK FACTORS FOR ISCHEMIC STROKE IN THE GENERAL POPULATION 123

A. Varbo, B.G. Nordestgaard, **M. Benn** (Denmark)

17:00 - 18:30 W. Auerswald Hall

Oral Communication Session: Vascular Biology

Chair: **L. Yvant-Charvet** (France) 124

Chair: **K. Ley** (USA) 125

17:00 SELECTIVE HDL-RAISING GENE TRANSFER COUNTERACTS THE DEVELOPMENT OF PRESSURE OVERLOAD-INDUCED CARDIOMYOPATHY IN MICE 126

R. Amin, I. Muthuramu, F. Jacobs, **B. De Geest** (Belgium)

17:15 BONE MARROW-SPECIFIC SIRT6 DELETION INCREASES ATHEROGENESIS BY INCREASING MACROPHAGE SCAVENGER RECEPTOR 1 127

T. Arsiwala, L. J. van Tits, M. Miranda, K. Nussbaum, J. Weber, S. Stivala, J. H. Beer, M. Greter, B. Becher, M. O. Hottiger, R. Mostoslavsky, J. Auwerx, T. F. Lüscher, C. M. Matter (Switzerland)

17:30 T CELL-SPECIFIC CD40L CONTRIBUTES TO ATHEROSCLEROSIS 128

C. Bürger, H. Winkels, C. Spitz, S. Meiler, S. Reim, C. Weber, E. Lutgens, N. Gerdes (Germany)

17:45 STRUCTURAL REMODELING AND GLUCOSE METABOLISM IMPAIRMENT AT EARLY ATHEROSCLEROSIS: IN-SITU AORTA ALTERATIONS AND PLASMA TRANSLATION. 129

M. Martin-Lorenzo, L. Gonzalez-Calero, A.S. Maroto, P.J. Martinez, A. Heredero, G. Aldamiz-Echevarria, F. Vivanco, G. Alvarez-Llamas (Spain)

18:00 LIVER-SPECIFIC ABLATION OF HNF-4α IN MICE IS ASSOCIATED WITH CHANGES IN PLASMA LIPOPROTEIN PROFILES AND THE EXPRESSION OF GENES INVOLVED IN LIPOPROTEIN METABOLISM 130

E. Thymiakou, D. Kardassis (Greece)

18:15 HEPATOCYTE-SPECIFIC PPAP2B ABLATION INCREASES PLASMA LEVELS OF SEVERAL MINOR PRO-ATHEROGENIC LIPID SPECIES AND WORSENS ATHEROSCLEROSIS IN APOE-/- MICE 131

M. Busnelli, S. Manzini, M. Hilvo, C. Parolini, G.S. Ganzetti, F. Dellera, K. Ekroos, M. Jänis, C.R. Sirtori, R. Laaksonen, G. Chiesa (Italy)

18:40 - 19:40 N. Anitschkow Hall

Plenary: Keynote Lecture

Chair: **A. Catapano** (Italy) 132

Chair: **W.J. Schneider** (Austria) 133

18:40 HOW GENES CONTROL CHOLESTEROL 134

M.S. Brown (USA)

EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme
TUESDAY, MAY 31, 2016

www.eas2016.kenes.com

TUESDAY, MAY 31, 2016

8:30 - 10:30 N. Anitschkow Hall

Plenary: Lipid Biology, New Insights

10:30 - 11:00 Exhibition & Poster Areater Area

Coffee Break, Exhibition & Poster Viewing

11:00 - 12:30 N. Anitschkow Hall

Workshop 1.3: Cellular Stress Response in Atherosclerosis

Chair: **G.R.Y. De Meyer** (Belgium) 198

Chair: **R. Prassl** (Austria) 199

11:00 MICTOPARTICLES IN ATHEROSCLEROSIS 200
C.M. Boulanger (France)

11:25 ROLE OF AUTOPHAGY IN VASCULAR DISORDERS 201
G.R.Y. De Meyer (Belgium)

11:50 HYPERCHOLESTEROLEMIA ALTERS THE MICRORNA PROFILE OF VASCULAR SMOOTH MUSCLE CELL-DERIVED MICROPARTICLES 202
D. De Gonzalo Calvo, A. Cenarro, F. Civeira, V. Llorente-Cortés (Spain)

12:03 A FUNCTIONAL GENETIC VARIANT IN THE LIPID DROPLET-ASSOCIATED PROTEIN PERILIPIN 2 (PLIN2) AFFECTS CHOLESTEROL CONTENT AND AUTOPHAGY IN HUMAN PRIMARY MACROPHAGES TREATED WITH OXLDL 203
E. Ehrenborg, P. Gustafsson, O. Werngren, M. Pedrelli, P. Parini, J. Magné (Sweden)

12:16 EXTRACELLULAR LIPID PARTICLES ACCUMULATING IN HUMAN CAROTID ARTERY INTIMA INDUCE STERILE INFLAMMATION IN MACROPHAGES 204
S. Lehti, I. Belevich, S.D. Nguyen, P. Lindsberg, E. Jokitalo, P.T. Kovanen, **K. Oörni** (Finland)

11:00 - 12:30 K. Landsteiner Hall

Workshop 2.3: Gut - Liver Axis

Chair: **A. Moschetta** (Italy) 205

Chair: **D. Kardassis** (Greece) 206

11:00 THE GUT MICROBIOME ENDOCRINE ORGAN: BACTERIALLY SIGNALS DRIVING CARDIO-METABOLIC DISEASES 207
M.J. Brown (USA)

11:25 INTESTINAL NUCLEAR RECEPTORS IN LIPID REGULATION 208
A. Moschetta (Italy)

11:50 A MARCH6 AND IDOL E3 UBIQUITIN LIGASE CIRCUIT UNCOUPLES CHOLESTEROL SYNTHESIS FROM LIPOPROTEIN UPTAKE IN HEPATOCYTES 209
A. Loregger, E. Cook, J. Nelson, M. Moeton, L. Sharpe, S. Engberg, M. Karimova, G. Lambert, N. Zelcer (Netherlands)

12:03 BUTYRATE VIA THE GUT-BRAIN CIRCUIT REDUCES APPETITE AND ACTIVATES BROWN ADIPOSE TISSUE 210
Y. Wang, L. Zhuang, C. Yi, C.K. Chuang, S. Kooijman, K. Willems van Dijk, A.K. Groen, P.C.N. Rensen

12:16 NON-ALCOHOLIC FATTY LIVER DISEASE AS A CAUSE OF ISCHEMIC HEART DISEASE: A MENDELIAN RANDOMIZATION STUDY AND META-ANALYSIS OF 170,998 INDIVIDUALS 211
B. Lauridsen, S. Stender, T. Kristensen, K. Kofoed, B. Nordestgaard, A. Tybjærg-Hansen (Denmark)

11:00 - 12:30 C. von Rokitansky Hall

Workshop: ICCR-EAS Joint Session: Management of Cardiometabolic Risk; Where Do We Stand?

Chair: **J.P. Després** (Canada) 212
Chair: **J. Chapman** (France) 213

11:00 MANAGEMENT OF SUBJECTS AT HIGH CARDIOMETABOLIC RISK - WHERE DO WE FALL? 214
J.P. Després (Canada)

11:22 DOES THE HEALTHY METABOLICALLY OBESE PHENOTYPE EXIST? 215
L. Van Gaal (Belgium)

11:45 TRANSLATING NUTRITIONAL SCIENCE INTO CLINICAL PRACTICE 216
V. Malik (USA)

12:07 NAFLD - THE NOVEL TREAT FOR VASCULAR DISEASE 217
M. Taskinen (Finland)

11:00 - 12:30 W. Auerswald Hall

Workshop 3.2: Vascular Aging and Atherothrombosis

Chair: **C. Gaetano** (Germany) 218
Chair: **B. Föger** (Austria) 219

11:00 VASCULAR PROGENITOR CELLS, LYMPHATICS, ANGIOGENESIS AND ATHEROSCLEROSIS 220
A. Kari (Finland)

11:25 SIRTUINS IN CARDIOVASCULAR DISEASE 221
C. Gaetano (Germany)

11:50 PENTRAXIN 3 DEFICIENCY IS ASSOCIATED WITH INCREASED ARTERIAL THROMBOSIS IN ANIMAL MODELS 222
F. Bonacina, S. Barbieri, L. Cutuli, P. Amadio, A. Doni, M. Sironi, S. Tartari, B. Bottazzi, C. Garlanda, E. Tremoli, A. Mantovani, A.L. Catapano, G.D. Norata (Italy)

12:03 HDL MODULATES CARDIAC GLUCOSE METABOLISM AND INFLAMMATION AND IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL ISCHEMIA-REPERFUSION INJURY 223
B. Kingwell, S. Heywood, A. Richart, D. Henstridge, K. Alt, H. Kiriazis, A. Carey, H. Kammoun, H. Begum, L. Delbridge, P. Meikle, C. Hagemeyer, M. Febbraio, X.J. Du, A. Siebel (Australia)

12:16 DIET-INDUCED OBESITY REQUIRES SIGNALLING THROUGH TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR 1 (TRAF-1) IN ADIPOCYTES 224
D. Wolf, N. Anto Michel, I. Hilgendorf, Bode, A. Zirlik (Germany)

12:30 - 15:00 Exhibition & Poster Area

Break, Exhibition & Poster Viewing

13:00 - 14:00 Exhibition Area

Science at a Glance Session III

13:00 - 14:00 Kristall Foyer

Poster Walk Session III

13:00 - 14:30 K. Landsteiner Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:00 - 14:00 C. von Rokitansky Hall

EBAC Accredited Session: Low HDL High Triglyceride, Diabetic Dyslipidaemia

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Mylan in support of the Programme.

Chair: **O. Wiklund** (Sweden) 225

13:00 DIABETIC DYSLIPIDEMIA 226
A. Zambon (Italy)

13:20 TRIGLYCERIDE, REMNANTS AND ATHEROSCLEROSIS 227
B. Nordestgaard (Denmark)

13:40 CONCLUSION AND DISCUSSION 228

13:00 - 14:00 W. Auerswald Hall

EBAC Accredited Session: Lysosomal Acid Lipase Deficiency

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Alexion in support of the Programme.

Chair: **E. Bruckert** (France) 229

Chair: **P. Kovanen** (Finland) 230

13:00 LIPID METABOLISM ABNORMALITIES IN GENERAL WITH DIFFERENTIAL DIAGNOSIS INCLUDING ALSO LAL-D 231
T. Stulnig (Austria)

13:20 LIPID METABOLISM ABNORNALITIES IN LAL-D AS A LYSOSOMAL STORAGE DISEASE WITH A FOCUS ON SPECIFIC SIGNS AND SYMPTOMS 232
M. Averna (Italy)

13:40 CONCLUSION AND DISCUSSION 233

14:00 - 15:00 Exhibition Area

Science at a Glance Session IV

14:00 - 14:45 N. Anitschkow Hall

Industry Symposium: Special Lecture

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

14:10 - 14:55 C. von Rokitansky Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

14:05 - 14:50 W. Auerswald Hall

Industry Symposium: Meet the Expert

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

15:00 - 16:30 N. Anitschkow Hall

Workshop 3.3: Genetics in Risk Factor Prevention and Treatment

Chair: **G. Utermann** (Austria) 234

Chair: **S. Ripatti** (Finland) 235

15:00 GENETIC DISCOVERIES FOR LIPID GENETIC TRAITS. LESSON LEARNED FROM FAMILIES AND THE GENERAL POPULATION 236

S. Ripatti (Finland)

15:20 LOSS-OF-FUNCTION MUTATIONS IN *APOC3*, REMNANT CHOLESTEROL, LDL CHOLESTEROL, AND RISK OF ISCHEMIC VASCULAR DISEASE 237

A.B. Jørgensen, R. Frikke-Schmidt, B. Nordestgaard, **A. Tybjaerg-Hansen** (Denmark)

15:34 LEUKOCYTE TELOMERE LENGTH, GENETICALLY DETERMINED, IS CAUSALLY ASSOCIATED WITH THE PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS AND INCIDENCE OF CARDIOVASCULAR EVENTS 238

A. Baragetti, J. Palmen, K. Garlaschelli, L. Grigore, S. Humphries, A.L. Catapano, P.J. Talmud, N. Giuseppe Danilo (Italy)

15:48 DEEP SEQUENCING IDENTIFIES DNA METHYLATION DEPENDENT GENES IMPLICATED IN DIABETIC COMPLICATIONS 239

I. Khurana, A. El-Osta (Australia)

16:02 PLEIOTROPIC MOLECULAR TARGETS OF COXIBS REVEALS NOVEL GENOMIC LOCI CONFERRING CORONARY ARTERY DISEASE RISK 240

I. Brænne, C. Willenborg, B. Reiz, L. Zeng, V. Tragante do Ó, T. Meitinger, N.J. Samani, T. Kessler, F.W. Asselbergs, J. Erdmann, H. Schunkert (Germany)

16:16 INVESTIGATION OF MULTIPLE DYSLIPIDEMIAS IN A LARGE AUSTRIAN PEDIGREE BY GENETIC RISK SCORES AND EXOME SEQUENCING 241

E. Nikkola, A. Ko, R.M. Cantor, R. Muxel, N. Matikainen, S. Söderlund, M.M. Motazacker, J.A. Kuivenhoven, J. Boren, F. Kronenberg, W. Schneider, A. Palotie, M. Laakso, M.R. Taskinen, P. Pajukanta (USA)

15:00 - 16:30 K. Landsteiner Hall

Late Breaking: Clinical Science

Chair: **P. Moulin** (France) 242

Chair: **M. Vrablik** (Czech Republic) 243

15:00 A PILOT STUDY OF MBX-8025 IN THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) 244

D. Gaudet, S. Saheb, E. Bruckert, J. De Graaf, G. Langslet, J.C. Tardif, S. Bergheanu, A. Steinberg, Y.J. Choi, R. Martin, C. McWherter, J. Kastelein, **P. Boudes** (USA)

15:15 AFFITOPE-BASED ANTI-PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) VACCINE (AT04A) REDUCES ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP MICE 245

G. Galabova, C. Juno, J.W.A. Van der Hoorn, E.J. Pieterman, M. Pouwer, C. Landlinger, J.W. Jukema, H.M.G. Princen, **G. Staffler** (Austria)

15:30 TREATMENT ADHERENCE TO THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR ALIROCUMAB IN SIX ODYSSEY PHASE 3 CLINICAL STUDIES WITH TREATMENT DURATION OF 52 - 104 WEEKS 246

M. Farnier, H.M. Colhoun, W.J. Sasiela, J. Edelberg, G. Asset, J.G. Robinson (France)

15:45 SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY 247

D. Gaudet, D.A. Gipe, E. Khoury, R. Pordy, W. Sasiela, K.C. Chan

16:00 DYNAMIC CHANGES IN MR SIGNALS OF INTRAPLAGUE HEMORRHAGE ARE STRONGLY CORRELATED WITH PLAQUE PROGRESSION: A SERIAL IMAGING STUDY ON CAROTID ATHEROSCLEROSIS 248

J. Sun, J. Liu, N. Balu, D. Hippe, K. William, A. Wang, G. Canton, T. Hatsukami, **C. Yuan** (USA)

16:15 MORTALITY IN RELATION TO GLYCAEMIC STATUS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 249

I.D. Hjellestad, E. Søfteland, R.M. Nilsen, E.S. Husebye, T. Jonung (Norway)

15:00 - 16:30 C. von Rokitansky Hall

EAS Initiatives Update Session (open to all)

Chair: **A. Catapano** (Italy) 250
Chair: **O. Wiklund** (Sweden) 251

15:00 WELCOME AND OVERVIEW OF EAS ACTIVITIES 252
A. Catapano (Italy)

15:15 FHSC UPDATE 253
K.K. Ray (United Kingdom)

15:30 CONSENSUS ACTIVITIES HIGHLIGHT- CONSENSUS ON FASTING/ NONFASTING LIPID ANALYSES (WITH EFLM) 254
B. Nordestgaard (Denmark)

15:45 EDUCATIONAL ACTIVITIES HIGHLIGHT- ADVANCED COURSES & EAS ACADEMY ACCREDITED PROGRAMMES 255
L. Tokgözoglu (Turkey)

15:55 OTHER ACTIVITIES: GUIDELINES & CONSENSUS UPDATE 256
A. Catapano (Italy)

16:05 OTHER ACTIVITIES: JOURNAL 257
A. von Eckardstein (Switzerland)

16:15 Q&A 258
A. Catapano (Italy)

15:00 - 16:30 W. Auerswald Hall

Advanced Clinical Seminar: Economics and Guidelines/ Technology of the Future

Chair: **M. Banach** (Poland) 259
Chair: **G. Dallinga-Thie** (Netherlands) 260

15:00 PHARMACO-ECONOMICS - HOW TO EXPLORE IT 261
G. Corrao (Italy)

15:30 CRISPRCAS9 TECHNOLOGY AS A NEW STRATEGY FOR TARGET DISCOVERY 262
N. Sanjana (USA)

16:00 WHAT DID WE LEARN FROM Lp(a)? SUMMARY OF THE SATELLITE MEETING 263
G. Kostner (Austria)

16:30 - 16:50 C. von Rokitansky Hall

EAS General Assembly (Members Only)

16:30 - 17:00 Exhibition & Poster Area

Coffee Break, Exhibition & Poster Viewing

17:00 - 18:00 Kristall Foyer

Poster Walk Session IV

17:00 - 18:30 N. Anitschkow Hall

Workshop 3.5: Epigenetics and Gene Regulation

Chair: **L. Maegdefessel** (Sweden) 264
Chair: **A. El-Osta** (Australia) 265

17:00 THE EMERGING ROLE OF MICRORNAS IN CARDIOVASCULAR DISEASE 266
L. Maegdefessel (Sweden)

17:25 IDENTIFICATION OF HISTONE DEACETYLASE 3 AS A MOLECULAR BRAKE OF WHITE ADIPOSE TISSUE BROWNING 267
M. Crestani, A. Ferrari, E. Fiorino, R. Long, N. Mitro, G. Cermenati, A. Mai, D. Caruso, E. De Fabiani, S.W. Hiebert (Italy)

17:38 HYPERCHOLESTEROLEMIA TRANSFORMS HIGH-DENSITY LIPOPROTEINS-MEDIATED TRNA-DERIVED SMALL RNA INTERCELLULAR COMMUNICATION 268
R. Allen, D. Michell, W. Zhu, S. Zhao, Q. Sheng, L. MacRae, **K. Vickers** (USA)

17:51 QUAKING POST-TRANSCRIPTIONALLY PROMOTES DIFFERENTIATION OF MONOCYTES INTO PRO-ATHEROGENIC MACROPHAGES BY CONTROLING PRE-MRNA SPLICING AND GENE EXPRESSION 269
R.G. De Bruin, L. Shiue, J. Prins, A. Djaramshi, H. De Boer, W.S. Fagg, J. Van Gils, J. Duijs, C. Van Kooten, J.W. Jukema, H. Van Esch, T.J. Rabelink, H. Kazan, E.A.L. Biessen, M. Ares Jr., **A.J. Van Zonneveld**, E. Van der Veer (Netherlands)

18:09 INNATE IMMUNE CELL ACTIVATION IN SYMPTOMATIC AND ASYMPTOMATIC ATHEROSCLEROSIS IN HUMANS IN VIVO 270
S. Bekkering, I. Van den Munckhof, T. Nielen, J. Rutten, J. De Graaf, L. Joosten, M. Netea, M. Gomes, N. Riksen (Netherlands)

17:00 - 18:30 K. Landsteiner Hall

Oral Communication Session: Imaging, Biomarkers and Clinical Epidemiology

17:00 - 18:30 C. von Rokitansky Hall

Oral Communication Session: Intracellular Lipid Metabolism

17:00 - 18:30 W. Auerswald Hall

Young Investigator Session: Novel Pathways in Atherosclerosis

Chair: **J.A. Kuivenhoven** (Netherlands) 287

Chair: **R.O. Ryan** (USA) 288

17:00 REDUCING AMYLOID PROCESSING PREVENTS DIABETES INDUCED VASCULAR DYSFUNCTION. 289

P. Meakin, F. Khan, M. Ashford (United Kingdom)

17:15 A LIPID METABOLITE PROFILE IN ATHEROSCLEROTIC PLAQUES ASSOCIATED WITH INCREASED INFLAMMATION AND CARDIOVASCULAR RISK 290

L. Tomas, H. Björkbacka, A. Edsfeldt, A. Danielsson, M. Wigren, H. Grufman, A. Persson, C. Prehn, J. Adamski, J. Nilsson, I. Gonçalves (Sweden)

17:30 A COMPLEX ATHEROSCLEROTIC PHENOTYPE OF MIF GENE-DEFICIENT MICE IN AN ATHEROGENIC APOE-/- BACKGROUND UNCOVERS A NOVEL CONNECTION BETWEEN MIF AND B CELLS 291

C. Schmitz, E. Straußfeld, O. El Bounkari, H. Noels, J. Bernhagen (Germany)

17:45 MARKERS OF VULNERABLE PLAQUES IN NON-HUMAN PRIMATES UNDER ATHEROGENIC DIET 292

V. Di Cataldo, J. Piraquive Agudelo, A. Geloen, M. Verset, A. Paturet, A. Serusclat, F. Lamberton, D. Ibarolla, F. Lavenne, D. Le Bars, H. Contamin, E. Canet-Soulas (France)

18:00 THE ROLE OF INFLAMMATION IN THE ASSOCIATION BETWEEN ADIPOSITY AND SUBCLINICAL ATHEROSCLEROSIS 293

T. Christen, S. Trompet, K.B. Gast, P.C.N. Rensen, J.A.P. Willems van Dijk, H.J. Lamb, A. De Roos, J.W. Jukema, F.R. Rosendaal, S. Le Cessie, R. De Mutsert (Netherlands)

18:15 THE RELATIONSHIP OF NETRIN- 1 EXPRESSION WITH MACROPHAGE INFILTRATION AND POLARIZATION IN HUMAN EPICARDIAL ADIPOSE TISSUE AND SEVERITY OF CORONARY ARTERY DISEASE 294

K.M. Gurses, F. Ozmen, D. Kocyigit, N. Yersal, E. Bilgic, E. Kaya, C. Kopru, T. Soyal, S. Doganci, L. Tokgozoglu, P. Korkusuz (Turkey)

EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme
WEDNESDAY, JUNE 1, 2016

www.eas2016.kenes.com

WEDNESDAY, JUNE 1, 2016

8:30 - 10:30 K. Landsteiner Hall

Plenary: Future Therapeutic Challenges

10:30 - 11:00 Exhibition & Poster Area

Coffee Break, Exhibition & Poster Viewing

11:00 - 12:30 K. Landsteiner Hall

Workshop 1.4: Inflammation, Immunity and Atherosclerosis

Chair: **G.D. Norata** (Italy) 301

Chair: **E. Lutgens** (Netherlands) 302

11:00 TARGETING THE ADAPTIVE IMMUNE SYSTEM: A NEW STRATEGY IN ATHEROSCLEROSIS 303

E. Lutgens (Netherlands)

11:25 CHOLESTEROL, INFLAMMATION AND IMMUNITY 304

L. Yvant-Charvet (France)

11:50 CD27 CO-STIMULATION FOSTERS REGULATORY T CELL SURVIVAL AND AMELIORATED PROGRESSION OF ATHEROSCLEROSIS. 305

H. Winkels, S. Meiler, C. Spitz, C. Buerger, A. Faussner, J. Borst, C. Weber, E. Lutgens, N. Gerdes

12:03 EARLY ATHEROPROTECTION BY SYK INHIBITION FAILS IN ESTABLISHED DISEASE WHEN LOCAL MACROPHAGE PROLIFERATION DOMINATES LESION PROGRESSION 306

A. Lindau, C. Haerdtner, F.K. Swirski, P. Libby, L. Hein, C. Bode, A. Zirlik, **I. Hilgendorf** (Germany)

12:16 DEFICIENCY OF SECRETED IGM ANTIBODIES CAUSES INCREASED PLASMA IGE LEVELS THAT PROMOTE ATHEROSCLEROSIS 307

D. Tsiantoulas, I. Bot, M. Kiss, B. Bartolini-Gritti, L. Göderle, M. Ozsvar-Kozma, T. Perkmann, K. Hartvigsen, A. Bergthaler, D.H. Conrad, J. Kuiper, Z. Mallat, H. Jumaa, C.J. Binder (Austria)

11:00 - 12:30 C. von Rokitansky Hall

Workshop 3.4: Biology of CVD Risk

Chair: **H. Colhoun** (United Kingdom) 308

Chair: **F. Kronenberg** (Austria) 309

11:00 NOVEL BIOMARKERS FOR CVD IN METABOLIC DISORDERS 310

H. Colhoun (United Kingdom)

11:25 CIRCULATING CELLS AND CVD RISK 311

G. Pasterkamp (Netherlands)

11:50 CIRCULATING MICRORNA-122 IS ASSOCIATED WITH INCIDENT METABOLIC SYNDROME AND TYPE-2 DIABETES 312

P. Willeit, X. Yin, D. Kaudewitz, P. Skroblin, A. Zampetaki, A.R. Moschen, C.M. Ramirez, L. Goedeke, N. Rotllan, E. Bonora, A.D. Hughes, P. Santer, C. Fernandez-Hernando, H. Tilg, J. Willeit, S. Kiechl, M. Mayr (United Kingdom)

12:03 ASSOCIATIONS BETWEEN LIPOPROTEIN SUBFRACTIONS AND GENOME-WIDE DNA METHYLATION IN KORA F4 313

L. Pfeiffer, R. Wilson, H. Grallert, E. Reischl, A. Peters, C. Gieger, S. Wahl, M. Waldenberger (Germany)

12:16 PLASMA LIPIDOMIC PROFILES IMPROVE UPON CONVENTIONAL RISK FACTORS TO PREDICT CARDIOVASCULAR EVENTS 314

P. Mundra, C. Barlow, N. Mellett, K. Huynh, Z. Alshehry, G. Wong, B. Kingwell, P. Nestel, P. Thompson, D. Sullivan, E. Barnes, J. Simes, A. Tonkin, **P. Meikle** (Australia)

11:00 - 12:30 W. Auerswald Hall

Workshop: New Guidelines on Prevention of Cardiovascular Disease in Clinical Practice

11:00 - 12:30 F. Pregl Hall

Workshop 2.4: Novel Role of Lipoprotein Receptors

EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



SCIENCE AT A GLANCE
E-POSTER PRESENTATIONS

www.eas2016.kenes.com

Poster #

MONDAY, MAY 30, 2016

13:00 - 14:00 Exhibition Area

Lipids and Lipoproteins

Chair: **J. Heeren** (Germany) 334

SAG001 CONSEQUENCES OF DEFECTIVE LIPOLYSIS IN THE SMALL INTESTINE ON LIPID METABOLISM 335
M. Korbelius, S. Obrowsky, S. Rainer, N. Vujic, D. Kratky (Austria)

SAG002 POSTTRANSCRIPTIONAL REGULATION OF THE LDLR BY ACTH TREATMENT - IMPORTANCE OF PCSK9 IN LIVER WHILE IDOL TAKES THE SCENE IN THE ADRENALS 336
M. Ghosh Laskar, B. Angelin, **M. Rudling** (Sweden)

SAG003 TNF-ALPHA INDUCES PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) EXPRESSION IN HEPATIC HEPG2 CELL LINE IN A SOCS-3-DEPENDENT MANNER 337
M. Ruscica, Ricci, C. Macchi, P. Magni, L. Jingwen, A. Corsini, N. Ferri (Italy)

SAG004 A POTENTIAL ROLE OF CHOLESTEROL UPTAKE CAPACITY, A NEW MEASURE FOR HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, IN CORONARY RISK STRATIFICATION 338
A. Harada, R. Toh, K. Murakami, M. Kiriyama, K. Yoshikawa, T. Kubo, K. Miwa, Y. Irino, K. Mori, N. Tanaka, T. Ishida, K. Hirata (Japan)

SAG005 LOW-DENSITY LIPOPROTEIN UPREGULATE SR-BI THROUGH SP1 SER702 PHOSPHORYLATION IN HEPATIC CELLS 339
L. Wang, F. Yang, Y. Du, J. Zhang, B. Hong (China)

SAG006 SNPS LOCATED IN ABCA1, CETP AND APOA5/A4/C3/A1 ARE ASSOCIATED WITH PLASMA CHOLESTEROL EFFLUX 340
C. Talbot, J. Plat, H. Popeijus, A. Ritsch, R. Mensink

SAG007 IDENTIFICATION OF A NOVEL APOLIPOPROTEIN THAT FACILITATES MTP-MEDIATED LIPID TRANSPORT 341
H. Peng, C.S. Liu, T.Y. Chiu, H.T. Chen, J.J.Y. Yen, H.F. Yang-Yen (Taiwan)

SAG008 BETA CELL-SPECIFIC DELETION OF ABCA1 AND ABCG1 REGULATES THE INCREASE OF SMALL NUCLEOLAR RNAS IN ADIPOCYTES 342
F. Tabet, L. Hou, B. Cochran, L.F. Cuesta Torres, P.J. Barter, K.A. Rye (Australia)

Poster #

13:00 - 14:00 Exhibition Area

Vascular Biology I

Chair: **G.R.Y. De Meyer** (Belgium) 343

SAG009 HIGH-DENSUTY LIPOPROTEIN PHOSPHOLIPID CONTENT AND APOLIPOPROTEIN A-I LEVEL ARE DETERMINANTS OF CHOLESTEROL EFFLUX CAPACITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 344
M. Ogura, M. Harada-Shiba (Japan)

SAG010 A HIGH-THROUGHPUT SCREENING OF KINASE INHIBITORS IDENTIFIES A REGULATORY ROLE OF VEGF SIGNALING FOR TRANSENDOTHELIAL TRANSPORT OF HIGH-DENSITY LIPOPROTEINS 345
S. Velagapudi, L. Rohrer, A. Von Eckardstein (Switzerland)

SAG011 MITOPHAGY ACTS AS A SAFEGUARD MECHANISM AGAINST HUMAN VASCULAR SMOOTH MUSCLE CELL APOPTOSIS INDUCED BY ATHEROGENIC LIPIDS 346
H. Nahapetyan, A. Swiader, J. Faccini, R. D'Angelo, E. Mucher, M. Elbaz, P. Boya, C. Vindis (France)

SAG012 SMOOTH MUSCLE CELLS PCSK9 KNOCK-OUT EXHIBIT AN IMPAIRED RESPONSE TO PDGF STIMULATION 347
S. Marchianò, G. Tibolla, A. Corsini, A.L. Catapano, N. Ferri (Italy)

SAG013 5-METHOXYTRYPTOPHAN REDUCES NEOINTIMA FORMATION FOLLOWING ARTERIAL INJURY 348
C.H. Chen, Y.C. Ho, H.H. Ho, C.H. Su, S.F. Yet (Taiwan)

SAG014 IMPACT OF FIBRE ORIENTATION IN FIBROUS CAP ON THE MECHANICAL LOADING IN HUMAN CORONARY ATHEROSCLEROTIC PLAQUES 349
Z. Teng, G. Douglas, A. Brown, M. Sutcliffe, J. Gillard (United Kingdom)

SAG015 MDM2 E3 LIGASE-MEDIATED UBIQUITINATION AND DEGRADATION OF HDAC1 IN VASCULAR CALCIFICATION 350
H. Kook, D.H. Kwon, G.H. Eom, S. Shin, E.M. Kim, Y.U. Lee, N. Choe (Republic of Korea)

SAG016 IN VITRO MIGRATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) INTO HUMAN HEALTHY AND DISEASED ARTERIES 351
B. Jakic, C. Krapf, M. Buszko, G. Cappellano, M. Grimm, G. Wick (Austria)

Poster #

13:00 - 14:00 Exhibition Area

Genetic, Omics and in silico Approaches

Chair: **N. Sanjana** (USA) 352

SAG017 GENE EXPRESSION PROFILES OF RECURRENT ACUTE PANCREATITIS RISK IN SEVERE HYPERTRIGLYCERIDEMIA 353
K. Tremblay, D. Gaudet (Canada)

SAG018 EVIDENCE FOR ENHANCED DE NOVO LIPOGENESIS AND UNCOUPLING OF OBESITY FROM TYPE 2 DIABETES RISK IN THE LOW-EXPRESSION VARIANT CARRIERS OF FATTY ACID-BINDING PROTEIN 4 354
J. Saksi, P. Ijäs, A. Jula, H. Heikkilä, J. Tuimala, O. Dwivedi, T.M. Tuomi, L. Groop, M. Jauhiainen, P. Kovanen, P. Lindsberg (Finland)

SAG019 THE PREVALENCE OF FAMILIAL HYPERLIPIDAEMIA AND HYPER-LIPOPROTEIN(A) IN MUTATION-NEGATIVE FAMILIAL HYPERCHOLESTEROLAEMIA AND ASSOCIATIONS WITH CARDIOVASCULAR EVENTS 355
K. Ellis, J. Pang, D. Chan, A. Hooper, D. Bell, J. Burnett, G. Watts (Australia)

SAG020 THE RS16900627 POLYMORPHISM OF THE RECEPTOR-INTERACTING PROTEIN 2 (*RIP2*) GENE IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS. THE GENETICS OF ATHEROSCLEROTIC DISEASE (GEA) MEXICAN STUDY 356
G. Vargas-Alarcon, R. Posadas-Sánchez, J. Angeles-Martínez, E. Alvarez-León, N. Pérez-Hernánez, J.M. Rodríguez-Pérez, J.M. Fragoso, G. Cardoso, T. Villarreal-Molina, C. Posadas-Romero (Mexico)

SAG021 RARE VARIANTS IN ABCG2 IDENTIFIED BY SEQUENCING MAY INFLUENCE THE LIPID RESPONSE TO ROSUVASTATIN TREATMENT 357
M. Hu, J. Chan, B. Tomlinson (Hong Kong- China)

SAG022 CHARACTERISTICS OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN SPAIN 358
R.M. Sánchez-Hernández, M. Stef, S. Perez-Calahorra, F. Almagro, P. Sáenz-Aranzubía, N. Plana, J.T. Real, F. Blanco-Vaca, J.F. Ascaso, F. Civeira, M. Pocovi (Spain)

SAG023 CLINICAL CHARACTERISTICS AND PREVALENCE OF CARDIOVASCULAR DISEASE RISK FACTORS IN SUBJECTS SCREENED FOR FAMILIAL HYPERCHOLESTEROLEMIA - A CROSS SECTIONAL STUDY IN THE NETHERLANDS 359
M.L. Hartgers, J. Besseling, B. Lucius, L. Kutikova, G.K. Hovingh (Netherlands)

SAG024 LOOKS LIKE FH BUT IT'S NOT FH - EXTENDED LIPID PROFILE OF PAEDIATRIC CLINICAL FH PATIENTS REVEALS A DIFFERENT LIPID PROFILE IN FH NEGATIVE PATIENTS 360
A.M. Medeiros, **M. Bourbon**, P. Aguiar (Portugal)

Poster #

13:00 - 14:00 Exhibition Area

CV Risk Factors and Atherosclerosis I

Chair: **Y. Matsuzawa** (Japan) 361

SAG025 SERUM PHOSPHATIDYLCHOLINE PLASMALOGEN AND ALKYL-PHOSPHATIDYLCHOLINE CONCENTRATIONS ARE INVERSELY ASSOCIATED WITH MYOCARDIAL INFARCTION INCIDENCE IN PATIENTS WITH PERIPHERAL ARTERY DISEASE 362
J. Moxon, R. Jones, G. Wong, D. Liu, J. Weir, R. Behl-Gilhotra, B. Kingwell, P. Meikle, J. Golledge (Australia)

SAG026 SERUM ACYLCARNITINES AND RISK OF INCIDENT TYPE 2 DIABETES IN PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS - A PROSPECTIVE COHORT STUDY 363
E.W. Rebnord, E. Strand, G.F.T. Svingen, P.R. Njølstad, G. Mellgren, G.S. Tell, R.K. Berge, A. Svardal, O.K. Nygård, E.R. Pedersen (Norway)

SAG027 ANTI-APOLIPOPROTEIN A-1 ANTIBODIES AS A NOVEL CARDIOVASCULAR RISK FACTOR: RESULTS FROM THE COLAUS STUDY 364
N. Vuilleumier (Switzerland)

SAG028 REDUCTION IN PLASMA CHOLESTEROL EFFLUX CAPACITY FROM HUMAN MACROPHAGES IS ASSOCIATED WITH THE APPEARANCE OF CLINICAL FEATURES OF METABOLIC SYNDROME 365
J. Gall, E. Frisdal, R. Bittar, W. Le Goff, E. Bruckert, P. Lesnik, M. Guerin, P. Giral (France)

SAG029 REMNANT CHOLESTEROL PREDICTS CARDIOVASCULAR EVENT RISK IN PATIENTS WITH TYPE 2 DIABETES INDEPENDENTLY FROM THE BASELINE CORONARY ARTERY DISEASE STATE 366
C. Saely, D. Zanolin, P. Rein, A. Vonbank, **A. Leiherer**, A. Muendlein, H. Drexel (Austria)

SAG030 THE PROSPECTIVE RELATIONSHIPS OF CIRCULATING AND URINARY CHOLINE METABOLITES WITH INCIDENT TYPE 2 DIABETES AMONG PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS 367
G.F.T. Svingen, H. Schartum-Hansen, E.R. Pedersen, P.M. Ueland, G.S. Tell, G. Mellgren, P.R. Njølstad, R. Seifert, E. Strand, T. Karlsson, O.K. Nygård (Norway)

SAG031 ASSOCIATIONS OF TRIGLYCERIDES WITH PERCENT BODY FAT IN ADOLESCENTS: THE PEP FAMILY HEART STUDY 368
T. Bertsch, G.M. Haas, E. Liepold, P. Schwandt (Germany)

SAG032 HEPATITIS C VIRUS (HCV) AND ATHEROSCLEROSIS RISK: A ROLE FOR LOW-DENSITY IMMUNE COMPLEXES? 369
M. Bassendine, S. Nielsen, D. Neely (United Kingdom)

Poster #

14:00 - 15:00 Exhibition Area

Experimental Cadiovascular Medicine I

Chair: **P. Parini** (Sweden) 370

SAG033 THE ROLE OF MICRO RNAS AND THEIR TARGETS IN A CAROTID ARTERY INTIMAL HYPERPLASIA 371
Y.U. Lee, N. Choe, E.M. Kim, S. Shin, D.H. Kwon, T. Kook, H. Kook (Republic of Korea)

SAG034 HEPATIC MIRNA EXPRESSION PROFILING IN GENETICALLY MODIFIED MOUSE MODELS OF DIFFERENT ATHEROSCLEROSIS SUSCEPTIBILITY 372
S. Manzini, M. Busnelli, M. Chiara, C. Parolini, F. Dellera, G.S. Ganzetti, D.S. Horner, G. Chiesa (Italy)

SAG035 ESTRADIOL PROTECTS OVARIECTOMIZED FEMALE RATS AGAINST FRUCTOSE RICH DIET INDUCED CARDIAC INFLAMMATION 373
M. Bundalo, M. Zivkovic, G. Koricanac, A. Stankovic (Serbia)

SAG036 IMPACT OF ENDOTHELIAL LIPASE OVEREXPRESSION ON CHOLESTEROL EFFLUX CAPACITY OF SERUM, APOLIPOPROTEIN B-DEPLETED SERUM AND HDL 374
I. Schilcher, A. Hrzenjak, T. Eichmann, T. Stojakovic, H. Scharnagl, G. Marsche, S. Frank (Austria)

SAG037 SR-BI INVOLVED ON PLASMA HDL2-APOA-I RECIRCULATION TO PREβ-HDL IN MICE 375
M. Tsujita, T. Yokota, N. Akita, F.J. Gonzalez, S. Yokoyama (Japan)

SAG038 MICE ABUNDANT IN MURICHOLIC BILE ACIDS SHOW RESISTANCE TO DIETARY INDUCED STEATOSIS, WEIGHT GAIN, AND TO IMPAIRED GLUCOSE METABOLISM 376
Y. Bonde, G. Eggertsen, M. Rudling (Sweden)

SAG039 IMPACT OF *LITOMOSOIDES SIGMODONTIS* ANTIGEN ON T CELL DIFFERENTIATION AND ON THE DEVELOPMENT OF INITIAL ATHEROSCLEROTIC LESIONS IN APOE-KNOCKOUT MICE 377
C. Kühn, M. Tauchi-Brück, J. Ajendra, A. Hörauf, C. Stumpf, S. Achenbach, M. Hübner, B. Dietel (Germany)

SAG040 UNSTABLE LDL - NOVEL MECHANISM OF ATHEROGENESIS AND LINK TO CARDIOVASCULAR DEATHS 378
M. Ruuth, S.D. Nguyen, T. Vihervaara, T.D. Laajala, M. Uusitupa, U. Schwab, M. Savolainen, J. Sinisalo, T. Aittokallio, R. Käkelä, M. Jauhiainen, P. Kovanen, K. Oörni (Finland)

Poster #

14:00 - 15:00 Exhibition Area

Nutrition, Nutraceuticals and Cardiovascular Disease

Chair: **A.H. Lichtenstein** (USA) 379

SAG041 MIDDLE-TERM DIETARY SUPPLEMENTATION WITH RED YEAST RICE PLUS COENZYME Q10 IMPROVES LIPID PATTERN, ENDOTHELIAL REACTIVITY AND ARTERIAL STIFFNESS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS 380
A. Cicero, M. Morbini, M. Rosticci, S. D'Addato, E. Grandi, C. Borghi (Italy)

SAG042 INCREASED OXIDATIVE STRESS AND IMPAIRED MITOCHONDRIAL BIOGENESIS AND DYNAMICS ARE IMPROVED BY RICE BRAN ENZYMATIC EXTRACT DIET SUPPLEMENTATION 381
C. Perez Ternero, C. Werner, M. Alvarez de Sotomayor, M.D. Herrera, U. Laufs (Spain)

SAG043 INVESTIGATION OF THE IMPACT OF CROCUS SATIVUS ON THE METABOLIC PROFILE OF DIABETIC RATS 382
P. Konstantopoulos, L.M. Korou, I. Vlachos, I. Doulamis, A. Tzani, S. Fragouli, G. Mastorakos, **N**. Katsilambros, D. Perrea (Greece)

SAG044 LONG-CHAIN METABOLITES OF A-TOCOPHEROL EMERGE FROM THE SHADOW OF THEIR PRECURSORS: A-13'-OH AND A-13'-COOH AS A NEW CLASS OF REGULATORY METABOLITES 383
L. Schmölz, M. Wallert, S. Ciffolilli, S. Kluge, G. Cruciani, M. Glei, O. Werz, F. Galli, M. Birringer, S. Lorkowski (Germany)

SAG045 CONSUMPTION OF POLYUNSATURATED FAT IMPROVES THE SATURATED FATTY ACID-MEDIATED IMPAIRMENT OF HDL ANTIOXIDANT POTENTIAL 384
A. García León, L. Cedó, J. Metso, D. Santos, J.L. Sánchez-Quesada, J. Julve, J. Mora-Brugués, M. Jauhiainen, F. Blanco-Vaca, J.C. Escolà-Gil (Spain)

SAG046 PLASMA LEVELS OF THE PRO-ATHEROGENIC NUTRIENT BIOMARKER TMAO IS INCREASED BY EXPOSURE TO DIOXIN-LIKE POLLUTANTS THROUGH UPREGULATION OF FMO3 385
M. Petriello, J. Hoffman, M. Sunkara, A. Morris, B. Hennig (USA)

SAG047 SOYA-ENRICHED MIXED DIET SIGNIFICANTLY IMPROVES CARDIOVASCULAR AND METABOLIC RISK FACTORS: A RANDOMIZED CONTROLLED TRIAL 386
M. Ruscica, C. Pavanello, B. Morlotti, M. Gomaraschi, C. Vitali, R. Bosisio, C.R. Sirtori, A. Arnoldi, P. Magni (Italy)

SAG048 PREVALENCE AND 2010-15 SECULAR TRENDS IN SUGAR-SWEETENED BEVERAGES SALES IN EUROPE AND THE MIDDLE EAST 387
B. Arsenault, M.R. Taskinen, J.P. Després (Canada)

Poster #

14:00 - 15:00 Exhibition Area

Pharmacology of Dyslipidemia

Chair: **M. Averna** (Italy) 388

SAG049 ATTAINMENT OF ACC/AHA RECOMMENDED LDL-C LOWERING WITH STATIN AND EZETIMIBE STATIN THERAPIES 389
P. Toth, H. Bays, M. Farnier, E. Jensen, J. Tomassini, A. Polis, J. Foody, A. Tershakovec (USA)

SAG050 EFFICACY AND SAFETY OF PITAVASTATIN IN PAEDIATRIC FH COMPARED WITH OTHER STATINS FROM COCHRANE DATABASE 390
M. Harada-Shiba, T. Ohta, A. Ohtake, T. Okada, O. Arisaka, J. Kastelein, I. Luirink (Japan)

SAG051 HOW TO IMPROVE THE CHOLESTEROL-LOWERING EFFICACY OF EZETIMIBE IN STATIN-INTOLERANT PATIENTS IN CLINICAL PRACTICE: A RETROSPECTIVE STUDY 391
A. Cicero, M. Morbini, S. D'Addato, F. Fogacci, M. Rosticci, C. Borghi (Italy)

SAG052 IDENTIFICATION AND MANAGEMENT OF CANADIAN PATIENTS WITH SYMPTOMS OF STATIN INTOLERANCE: RESULTS FROM A REAL-WORLD CLINICAL PRACTICE SURVEY 392
P. Oh, G.K. Hovingh, S.R. Gandra, J. McKendrick, **R. Dent**, H.M. Wieffer, A.L. Catapano, R.S. Rosenson, E.S.G. Stroes (Switzerland)

SAG053 PCSK9 CIRCULATING LEVELS AND CETP PLASMA ACTIVITY ARE ASSOCIATED INDEPENDENTLY OF LIPID LOWERING THERAPIES 393
J. Girona, D. Ibarretxe, N. Plana, S. Guaita, N. Amigó, M. Heras, **L. Masana** (Spain)

SAG054 UNDERSTANDING LIPOPROTEIN(A) METABOLISM: REBOUND ANALYSES OF LIPOPROTEIN(A) AND PCSK9 CONCENTRATIONS FOLLOWING REGULAR LIPOPROTEIN APHERESIS TREATMENT (THE LIPARE-STUDY) 394
E. Waldmann, E.M. Ooi, P.H.R. Barrett, D.C. Chan, S.M. Marcovina, G.F. Watts, K.G. Parhofer (Germany)

SAG055 DPP4 INHIBITOR, ANAGLIPTIN, AMELIORATES FASTING AND POSTPRANDIAL HYPERTRIGLYCERIDEMIA 395
M. Sairyo, D. Masuda, T. Kobayashi, H. Matsuda, T. Okada, R. Kawase, K. Nakatani, M. Koseki, T. Ohama, M. Nishida, Y. Sakata, S. Yamashita (Japan)

SAG056 FAMILIAL HYPERCHOLESTEROLEMIA IN PRIMARY CARE IN GERMANY - DIABETES AND CARDIOVASCULAR RISK EVALUATION: TARGETS AND ESSENTIAL DATA FOR COMMITMENT OF TREATMENT (DETECT) STUDY 396
N. Schmidt, B. Schmidt, A. Dressel, U. Fraass, I. Gergei, J. Klotsche, L. Pieper, H. Scharnagel, M.E. Kleber, W. März, H.U. Wittchen, T. Grammer (Germany)

Poster #

14:00 - 15:00 Exhibition Area

Imaging in Vascular Dysfunction and Myocardial Infarction

Chair: **W. Koenig** (Germany) 397

SAG057 A NOVEL TC-99M AND FLUORESCENCE LABELED PEPTIDE AS A MULTIMODAL IMAGING AGENT FOR TARGETING ANGIOGENESIS IN A MURINE HINDLIMB ISCHEMIA MODEL 398
D.W. Kim, S.G. Kim, M.H. Kim, C.G. Kim (Republic of Korea)

SAG058 REPRODUCIBILITY OF ENDOTHELIAL SHEAR STRESS AND LOW DENSITY LIPOPROTEIN TRANSPORT MODELING IN COMPUTED TOMOGRAPHY ANGIOGRAPHIC IMAGING DATA 399
A. Sakellarios, C.V. Bourantas, S.L. Papadopoulou, T. De Vries, P.H. Kitslaar, C. Gyrasis, K.K. Naka, S. Veldhof, G.W. Stone, J.H.C. Reiber, L.K. Michalis, P.W. Serruys, P.J. De Feyter, H.M. Garcia Garcia, D.I. Fotiadis (Greece)

SAG059 USAGE OF NOVEL HYBRID PIXEL DETECTORS FOR NATIVE ATHEROSCLEROTIC PLAQUE IMAGING BY HIGH RESOLUTION X-RAY COMPUTED TOMOGRAPHY 400
A. Zhemchugov, A. Svetlikov, D. Kozhevnikov, G. Shelkov, S. Urazgildeeva, **V. Gurevich** (Russia)

SAG060 COMPOSITION OF CORONARY PLAQUES BY CT ANGIOGRAPHY: VALIDATION BY NEAR-INFRARED SPECTROSCOPY 401
J.A. Goldstein, R.D. Madder, S. Dixon (USA)

SAG061 ACTIVATED-PLATELET TARGETED FIBRINOLYTIC DRUGS: NOVEL TARGETED-THERANOSTIC MICROBUBBLES FOR SIMULTANEOUS DIAGNOSIS, TREATMENT AND MONITORING USING MOLECULAR ULTRASOUND TECHNOLOGY 402
X. Wang, K. Peter (Australia)

SAG062 CARDIOVASCULAR EVENTS IN PATIENTS TREATED BY LIPOPROTEIN APHERESIS (LA) - ANALYSIS OF POSSIBLE REASONS 403
S. Tselmin, S. Fischer, F. Pistrosch, G. Müller, U. Julius (Germany)

SAG063 THE RELATIONSHIP BETWEEN INSULIN LIKE GROWTH FACTOR-1 AND CORONARY ARTERY CALCIUM SCORE IN CARDIOVASCULAR ASYMPTOMATIC ADULT MEN 404
K.C. Park, M.J. Kim, K.C. Kim, B.H. Choi, K.H. Park, H.C. Cho (Republic of Korea)

SAG064 2013 ACC/AHA VERSUS 2004 NCEP ATP III GUIDELINES IN THE PREDICTION OF CORONARY ARTERY CALCIFICATION PROGRESSION IN A KOREAN POPULATION 405
C.H. Jung, S. Kim, W.J. Lee, J.Y. Park, C.Y. Park (Republic of Korea)

Poster #

TUESDAY, MAY 31, 2016

13:00 - 14:00 Exhibition Area

CV Risk Factors and Atherosclerosis II

Chair: **W. März** (Germany) 406

SAG065 SERUM LEVELS OF ANTI-APOLIPOPROTEIN A-1 IGG ARE ASSOCIATED WITH LONG-TERM DISABILITY AND CEREBRAL LESION VOLUME IN ACUTE ISCHEMIC STROKE PATIENTS 407
N. Satta, F. Carbone, F. Montecucco, J. Virzi, F. Burger, A. Roth, G. Roversi, C. Tamborino, I. Casetta, S. Seraceni, A. Trentini, M. Padroni, F. Dallegri, P. Lalive, F. Mach, E. Fainardi, N. Vuilleumier (Switzerland)

SAG066 GLYCATION OF APOA-I LINKS DIABETES AND CVD 408
J. Domingo-Espin, O. Nilsson-Wolanin, J. Dalla-Riva, K. Bernfur, M. Lindahl, J. Lagerstedt (Sweden)

SAG067 APOLIPOPROTEIN CII AND CIII: PROGNOSTIC MARKERS OF CARDIOVASCULAR RISK? 409
H. Scharnagl, M.E. Kleber, T.B. Grammer, T. Stojakovic, M.M. Hoffmann, W. März (Austria)

SAG068 SERUM MMP-8 AND TIMP-1 ASSOCIATE WITH INCIDENT CVD EVENTS AND ALL-CAUSE MORTALITY IN A POPULATION-BASED COHORT 410
I. Kormi, A.S. Havulinna, V. Salomaa, T. Tervahartiala, T. Sorsa, P.J. Pussinen (Finland)

SAG069 PLASMA CONCENTRATIONS OF AFAMIN ARE ASSOCIATED WITH THE PREVALENCE AND INCIDENCE OF TYPE 2 DIABETES MELLITUS 411
B. Kollerits, C. Huth, S. Kiechl, C. Lamina, C. Meisinger, C. Herder, L. Kedenko, J. Willeit, B. Thorand, D. Dähnhardt, D. Stöckl, M. Roden, W. Rathmann, B. Paulweber, A. Peters, H. Dieplinger, F. Kronenberg (Austria)

SAG070 OMENTIN-1 AND RISK OF STROKE: RESULTS FROM THE EPIC-POTSDAM COHORT STUDY 412
J. Menzel, R. Di Giuseppe, R. Biemann, C. Wittenbecher, K. Aleksandrova, T. Pischon, A. Fritsche, M.B. Schulze, H. Boeing, B. Isermann, C. Weikert (Germany)

SAG071 AGE, GENDER AND BLOOD LIPID LEVELS: A CHANCE TO IMPROVE CARDIOVASCULAR RISK ASSESSMENT 413
W. Balder, J.K. De Vries, I.M. Nolte, J.A. Kuivenhoven, P.W. Kamphuisen (Netherlands)

SAG072 THE ADDED VALUE OF AORTIC PWV BEYOND TRADITIONAL RISK FACTORS IN CARDIOVASCULAR RISK STRATIFICATION 414
B. Benczur, R. Bocskei, A. Cziraki, M. Illyes (Hungary)

Poster #

13:00 - 14:00 Exhibition Area

Vascular Biology II

Chair: **H. Stangl** (Austria) 415

SAG073 ENDOTHELIAL DYNAMIC CHANGES IN CHONDROITIN SULFATE AND DERMATAN SULFATE PROTEOGLYCANS INDUCED BY VERY LOW DENSITY LIPOPROTEINS 416
R.E. Oberkersch, Y. Rasente, S. Yuschak, N. Volpi, G. Calabrese (Argentina)

SAG074 PRO-ATHEROGENIC OXIDIZED-LDL/B2-GLYCOPROTEIN I COMPLEXES IN CORONARY ARTERY DISEASE PATIENTS ARE ASSOCIATED WITH DISEASE SEVERITY 417
L.R. Lopez, K.P. Bliden, R. Chaudhary, R. Damrongwatanasuk, K.E. Guyer, M.G. Gesheff, C.J. Franzese, U.S. Tantry, P.A. Gurbel (USA)

SAG075 PAI-1 EXPRESSION RENDERS M2 POLARIZED MACROPHAGES PROTEOLYTICALLY QUIESCENT 418
P. Hohensinner, J. Baumgartner, B. Ebenbauer, B. Thaler, D. Konstantin, C. Kaun, S. Stoijkovic, M. Fischer, G. Maurer, K. Huber, J. Wojta (Austria)

SAG076 IN VITRO EVIDENCE OF A PRO-INFLAMMATORY ACTION OF PCSK9 IN THP-1-DERIVED MACROPHAGES 419
C. Ricci, A. Corsini, N. Ferri (Italy)

SAG077 INCREASED MITOCHONDRIAL ROS ACCELERATE ATHEROSCLEROSIS IN MITOCHONDRIAL CATALYTIC ENZYME 3 DEFICIENT MICE 420
S.H. Park, S.K. Hur, J.Y. Yoo, S.J. Jeong, G.T. Oh (Republic of Korea)

SAG078 COMPARATIVE EFFECT OF SILYMARIN AND SILYBIN TREATMENT ON INFLAMMATION AND OXIDATIVE STRESS IN TRANSGENIC SPONTANEOUSLY HYPERTENSIVE RATS OVEREXPRESSING HUMAN C-REACTIVE PROTEIN 421
O. Oliyarnyk, H. Malinska, I. Markova, J. Trnovska, V. Skop, L. Kazdova, R. Vecera, M. Pravenec (Czech Republic)

SAG079 PONATINIB AUGMENTS VASOCONSTRICTION AND ATTENUATES VASORELAXATION IN MOUSE AORTIC RINGS 422
A. Kirsch, R. Kirchmair, S. Frank (Austria)

SAG080 CARDIOVASCULAR RISK FACTORS DIFFER IN INFLAMMATION PATHOLOGY IN PATIENTS WITH CLINICALLY SYMPTOMATIC LOWER LIMB ATHEROSCLEROSIS 423
J. Jalkanen, M. Maksimow, S. Jalkanen, H. Hakovirta (Finland)

Poster #

13:00 - 14:00 Exhibition Area

Insulin Resistance, Diabetes, Metabolic Syndrome and Obesity

Chair: **G. Watts** (Australia) 424

SAG081 BARIATRIC SURGERY-INDUCED WEIGHT LOSS IN MORBIDLY OBESE PATIENTS PROMOTES A FAVORABLE DECREASE IN THE GENE EXPRESSION OF MARKERS OF SUBCUTANEOUS ADIPOSE TISSUE HOMEOSTASIS 425
J. Julve, E. Pardina, R. Ferrer, J. Rossell, J.A. Baena-Fustegueras, J.M. Fort, A. Lecube, J. Peinado-Onsurbe (Spain)

SAG082 EFFECTS OF OBESITY AND BARIATRIC SURGERY ON HDL FUNCTIONALITY AND MICROVASCULAR COMPLICATIONS OF OBESITY 426
Y. Liu, T. Siahmansur, J.D. Schofield, S. Hama, R. Yadav, S. Adam, M. France, S. Kwok, R. Donn, A. Stevens, J. Ho, B.J. Ammori, A. Syed, P.N. Durrington, H. Soran (United Kingdom)

SAG083 BODY MASS INDEX AND MORTALITY OVER 3 DECADES 427
S. Afzal, A. Tybjærg-Hansen, G.B. Jensen, B.G. Nordestgaard (Denmark)

SAG084 WAIST CIRCUMFERENCE AND BODY MASS INDEX CORRELATE WITH CEREBRAL GLUCOSE METABOLISM IN THE TEMPORAL LOBE IN DIABETIC PATIENTS 428
N. García-Casares, J. García-Arnés, A. Gutiérrez-Cardo, J. Rioja, M.J. Ariza, F. Alfaro, A. Nabrozidis, P. González-Santos (Spain)

SAG085 COMPONENTS OF THE METABOLIC SYNDROME AND RISK OF TYPE 2 DIABETES 429
S. Marott, B. Nordestgaard, A. Tybjærg-Hansen, **M. Benn** (Denmark)

SAG086 THE PLASMA PROTEOME OF TANGIER DISEASE PATIENTS REVEALS PERTURBATIONS OF DIABETIC AND INFLAMMATORY PATHWAYS 430
J. McParland, E. Pashos, D. Rader, **M. Cuchel** (USA)

SAG087 ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) IN OBESITY AND METABOLIC SYNDROME: BEYOND LDLR TARGETING 431
G. Balzarotti, G. Tibolla, M. Ruscica, M. Stramba-Badiale, A.L. Catapano, D.G. Norata (Italy)

SAG088 DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND PROTECTION AGAINST STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS 432
F. Barkas, M. Elisaf, V. Tsimihodimos, H. Milionis (Greece)

Poster #

13:00 - 14:00 Exhibition Area

Hypertension, Liver and Chronic Renal Disease

Chair: **A. Zambon** (Italy) 433

SAG089 PRO-ATHEROGENIC LIPOPROTEIN PROFILE ASSOCIATED WITH WHITE MATTER LESIONS IN CHRONIC KIDNEY DISEASE PATIENTS: A 1H-NMR METABOLOMIC APPROACH 434
N. Amigó, R. Fuertes, C. Cabré, M. Vinaixa, M. Romeu, M. Muñoz, M. Giralt, J. Soler, J. Aquilera, M.T. Compte, X. Correig, A. Martínez-Vea (Spain)

SAG090 ALTERED INFLAMMATORY PARAMETERS AND CHEMERIN LEVELS AFTER RENAL TRANSPLANTATION 435
R. Szentimrei, M. Harangi, H. Lőrincz, E.V. Varga, A. Szentpéteri, P. Fülöp, I. Seres, **G. Paragh** (Hungary)

SAG091 RENAL DISEASE IS ASSOCIATED WITH MODIFIED PON1 DISTRIBUTION AT HDL SUBCLASSES 436
M. Miljkovic, J. Kotur-Stevuljevic, A. Stefanovic, J. Vekic, A. Zeljkovic, T. Gojkovic, S. Simic-Ogrizovic, V. Spasojevic-Kalimanovska, Z. Jelic-Ivanovic (Serbia)

SAG092 HEPATIC TRANSCRIPTOMIC SIGNATURES IN A MOUSE MODEL OF THE METABOLIC SYNDROME 437
D. Nasias, I. Evangelakos, D. Kardassis (Greece)

SAG093 STRONGLY INCREASING PREVALENCE OF HYPERTENSION BY INCREASING OVERWEIGHT IN CHILDREN AND ADOLESCENTS 438
G.M. Haas, E. Liepold, T. Bertsch, P. Schwandt (Germany)

SAG094 ASSOCIATION OF CORONARY ARTERY CALCIFICATION AND ARTERIAL MICRO-CALCIFICATION OF THE VASCULAR ACCESS IN INCIDENT HEMODIALYSIS PATIENTS 439
B.M. Choi, Y.O. Kim, H.C. Song, Y.B. Lee (Republic of Korea)

SAG095 LIVER DISEASE ALTERS HIGH-DENSITY LIPOPROTEIN COMPOSITION, METABOLISM AND FUNCTION 440
M. Trieb, V. Stadlbauer, R. Birner-Gruenberger, **G. Marsche** (Austria)

SAG096 ENHANCED STATUS OF PROTHROMBOGENESIS AND ITS ASSOCIATION WITH SERUM LDL-C LEVELS IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA 441
N.A. Mohd Kasim, R. Rahmat, S. Abdul Razak, S. Muid, T. Rahman, **H. Nawawi** (Malaysia)

Poster #

14:00 - 15:00 Exhibition Area

Experimental Cadiovascular Medicine II

Chair: **M. Jauhiainen** (Finland) 442

SAG097 CONSEQUENCES OF LYSOSOMAL ACID LIPASE DEFICIENCY IN MACROPHAGES 443
M.C. Duta-Mare, B. Radovic, S. Schlager, M. Wegscheider, D. Kolb-Lenz, T. Madl, S. Stryeck, D. Kratky (Austria)

SAG098 PEROXIREDOXIN 1 HAVE PROTECTIVE ROLE IN THE VASCULAR DISEASE BY REGULATING MACROPHAGES 444
S. Kim, S.J. Jeong, G.T. Oh (Republic of Korea)

SAG099 THE ATHEROPROTECTIVE ACTIVITY OF *GANODERMA* AND ITS ACTION MECHANISM IN MICE 445
F.E. Mo, P.L. Hsu, Y.C. Lin (Taiwan)

SAG100 THE APOE*3LEIDEN.GK+/- MOUSE AS NOVEL TRANSLATIONAL MODEL FOR DYSLIPIDEMIA, TYPE 2 DIABETES AND MACROVASCULAR COMPLICATIONS 446
M. Pouwer, S. Heinonen, M. Behrendt, A.C. Andréasson, E. Pieterman, A. Van den Hoek, W. Jukema, B. Leighton, A.C. Jönsson-Rylander, H. Princen (Netherlands)

SAG101 PPARΓ ACTIVATION ATTENUATES OXIDATIVE STRESS AND IMPROVES CEREBRAL ARTERIES ENDOTHELIAL DYSFUNCTION IN AGING RAT THROUGH UP-REGULATING UCP2 447
P. Wang, G. Cai, F. Wang, P. Zhou, Q. Wang (China)

SAG102 EFFECTS OF CHRONIC INFLAMMATION ON MEGAKARYOCYTE AND PLATELET FUNCTION IN A CONDITIONAL MOUSE MODEL 448
M. Salzmann, M. Haase, C. Arzt, M. Mussbacher, A. Assinger, J.A. Schmid (Austria)

SAG103 GENETIC CORRELATIONS BETWEEN CIRCULATING MIRNAS AND LIPID PROFILES REVEAL NOVEL BIOMARKERS OF CVD RISK 449
L. Michael, S. McAhren, S. Kumar, J. Peralta, H. Kulkarni, W. Gerard, J. Weir, C. Barlow, M. Kowala, P. Meikle, J. Blangero, J. Curran (USA)

SAG104 ELEVATED LDL AND OXIDATIVE STRESS CONTRIBUTE TO ARRHYTHMOGENIC CARDIOMYOPATHY PHENOTYPIC MANIFESTATION 450
L. Arnaboldi, I. Stadiotti, S. Brambilla, G. Milano, A. Scopece, F. Cattaneo, A. Granata, C. Tondo, A. Corsini, G. Pompilio, E. Sommariva (Italy)

Poster #

14:00 - 15:00 Exhibition Area

Immunity and Atherosclerosis

Chair: **G. Caligiuri** (France) 451

SAG105 A NOVEL MECHANISM OF STATINS IN ATHEROSCLEROTIC AND IN HIGH-RISK SUBJECTS: MODULATION OF THE ADIPONECTIN RECEPTOR PATHWAY IN CIRCULATING MONOCYTES 452
K. Gasbarrino, H. Zheng, S.S. Daskalopoulou (Canada)

SAG106 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND THE RISK OF STROKE IN PATIENTS WITH RHEUMATOID ARTHRITIS 453
Y.R. Chen, H. Fang-I, W. Hsin-Chiao, C. Hung-Yi (Taiwan)

SAG107 THE PROTEIN COMPOSITION OF INTIMA AND MEDIA THORACIC AORTA LAYERS IN ATHEROSCLEROSIS WITH AUTOANTIGENS DETECTION AND IDENTIFICATION USING PROTEOMIC TECHNOLOGIES 454
R. Zhetisheva, V. Naumov, L. Kovalyov, M. Kovalyova, I. Kamenihina, L. Novikova, M. Shogenova, A. Karpov (Russia)

SAG108 EXPRESSION OF E06, A NATURAL MONOCLONAL ANTIBODY TARGETED TO OXIDIZED PHOSPHOLIPIDS (OXPL), ATTENUATES THE PROGRESSION OF AORTIC SCLEROSIS IN AGED HYPERLIPIDEMIC MICE 455
C. Yeang, M.Y. Hung, J. Pattison, K. Bowden, N. Dalton, K.L. Peterson, J.L. Witztum, S. Tsimikas, X. Que (USA)

SAG109 CCL22/ MACROPHAGE-DERIVED CHEMOKINE EXPRESSION VIA HISTAMINE IN THE ATHEROSCLEROSIS 456
S. Kimura, S. Yamada, H. Noguchi, K.Y. Wang, T. Nakayama (Japan)

SAG110 SOLUBLE URIC ACID PROMOTES DEVELOPMENT OF ATHEROSCLEROSIS LESIONS VIA ENHANCEMENT OF INNATE INFLAMMATION IN MICE 457
Y. Kimura, T. Yanagida, A. Onda, K. Asako, H. Kikuchi, H. Kono (Japan)

SAG111 PENTRAXIN 3 PLAYS A KEY ROLE IN THE IMMUNOMODULATION OF DIET INDUCED-OBESITY IN MICE 458
A. Moregola, F. Bonacina, U. Guerrini, E. Bonavita, C. Garlanda, A. Mantovani, A.L. Catapano, G.D. Norata (Italy)

SAG112 REGULATORY CD19+CD24HICD38HI B CELLS ARE DECREASED IN PATIENTS WITH CORONARY ATHEROSCLEROSIS AND HAVE IMPAIRED INTERLEUKIN-10 PRODUCTION IN RESPONSE TO CPG 459
I.E. Dumitriu, P. Baruah, J.C. Kaski (United Kingdom)

Poster #

14:00 - 15:00 Exhibition Area

Emerging Aspects in Pharmacological Treatment of Primary and Secondary Dyslipidemia

Chair: **B. Dieplinger** (Austria) 460

SAG113 EFFICACY AND SAFETY OF LONG-TERM COADMINISTRATION OF FENOFIBRATE AND EZETIMIBE IN PATIENTS WITH COMBINED HYPERLIPIDEMIA: RESULTS OF THE EFECTL TRIAL 461
S. Oikawa, S. Yamashita, N. Nakaya, J. Sasaki, S. Kono, G. EFECTL Study Investigators (Japan)

SAG114 EFFICACY AND SAFETY OF EVOLOCUMAB IN PATIENTS ON HIGH- VS MODERATE-INTENSITY BACKGROUND STATIN THERAPY 462
H. Soran, A. Lira, R. Dent, I. Bridges, R. Somaratne, M. Koren (United Kingdom)

SAG115 PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/ WITHOUT STATIN BACKGROUND 463
J.G. Robinson, M. Farnier, J.J. Kastelein, E.M. Roth, M.R. Taskinen, H.M. Colhoun, A. Brunet, A.T. DiCioccio, G. Lecorps, R. Pordy, M.T. Baccara-Dinet, C.P. Cannon (USA)

SAG116 OMEGA-3 CARBOXYLIC ACIDS IN SEVERE HYPERTRIGLYCERIDEMIA: EVOLVE II STUDY RESULTS 464
E. Stroes, T. De Bruin, M. Davidson, H. Yang, M. Kvarnstrom, T. Lundstrom (Netherlands)

SAG117 CARDIOVASCULAR EVENT RATES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): TRIAL ASSESSING LONG-TERM USE OF PCSK9 INHIBITION IN SUBJECTS WITH GENETIC LDL DISORDERS (TAUSSIG) STUDY INTERIM RESULTS 465
F. Raal, C. Kurtz, N. Honarpour, L. Tang, E.A. Stein (South Africa)

SAG118 TRANSITION FROM LDL APHERESIS TO EVOLOCUMAB IN HETEROZYGOUS FH IS EQUALLY EFFECTIVE IN LOWERING LDL- BUT WITHOUT LOWERING HDL CHOLESTEROL 466
A. Hovland, K.T. Lappegård (Norway)

SAG119 THE IMPACT OF SELECTIVE LDL APHERESIS ON SERUM ADIPOKINE LEVELS IN PATIENTS WITH HYPERCHOLESTEROLEMIA 467
V.E. Varga, H. Lőrincz, N. Zsíros, P. Fülöp, I. Seres, G. Paragh, J. Balla, M. Harangi (Hungary)

SAG120 THE MECHANISM OF STATIN-INDUCED MODULATION OF VITAMIN D METABOLISM 468
J. Beltowski (Poland)

Poster #

14:00 - 15:00 Exhibition Area

Vascular Biology III

Chair: **J. Herz** (USA) 469

SAG121 ACUTE EXPOSURE TO AIR POLLUTION AGGRAVATES ACUTE MYOCARDIAL INFARCTION AND SUBSEQUENT ISCHEMIC HEART FAILURE IN MICE 470

D. Wolf, T. Marchini, N. Anto Michel, D. Dürschmied, I. Hilgendorf, C. Bode, A. Zirlik (Germany)

SAG122 EFFECT OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON ARTERIAL ELASTICITY IN PATIETNS WITH FAMILIAL HYPERCHOLESTEROLAEMIA ON STATIN THERAPY 471

D. Chan, **J. Pang**, P.H.R. Barrett, D.R. Sullivan, T.A. Mori, J.R. Burnett, F.M. Van Bockxmeer, G.F. Watts (Australia)

SAG123 THE ABSENCE OF PCSK9 DETERMINES A LOWER NEOINTIMAL FORMATION IN RESPONSE TO PERIVASCULAR CAROTID COLLAR PLACEMENT 472

N. Ferri, G. Tibolla, A. Dhyani, R. Baetta, A. Catapano, A. Corsini (Italy)

SAG124 BLOOD LEVEL OF CD45+ PLATELETS AND DEVELOPMENT OF RESTENOSIS AFTER DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH CORONARY ARTERY DISEASE 473

Z. Gabbasov, S. Kozlov, I. Melnikov, **S. Byazrova**, O. Saburova (Russia)

SAG125 PLASMA FROM PATIENTS WITH CALCIFIED AORTIC DISEASE TRIGGERS AN OSTEOBLAST-LIKE PHENOTYPE SWITCH IN HUMAN AORTIC VALVE INTERSTITIAL CELLS 474

L. Cattan-Lévy, M.P. Jacob-Lenet, M. Dehoux, C. Deschildre, I. Codogno, M. Morvan, A.T. Gaston, G. Even, J.B. Michel, D. Messika-Zeitoun, A. Nicoletti, G. Caligiuri, **J. Khallou-Laschet** (France)

SAG126 A NOVEL PLAYER IN VASCULAR CALCIFICATION: HYPOXIA INDUCES OSTEOGENIC DIFFERENTIATION AND EXTRACELLULAR MATRIX MINERALIZATION OF VASCULAR SMOOTH MUSCLE CELLS 475

V. Jeney, B. Enikő, T. Emese, T. Andrea (Hungary)

SAG127 HH RESPONSIVE CELLS CONTRIBUTE TO VSMC ACCUMULATION FOLLOWING VASCULAR INJURY 476

P. Cahill, **E. Fitzpatrick**, H. Jay-Christian, S. Diana, R. Hakimjavadi, E. Redmond (Ireland)

SAG128 METABOLOMIC PROFILING OF ASCENDING THORACIC AORTIC ANEURYSMS AND DISSECTIONS - IMPLICATIONS FOR PATHOPHYSIOLOGY AND BIOMARKER DISCOVERY 477

C. Doppler, K. Arnhard, J. Dumfarth, K. Heinz, K. Danzl, B. Messner, C. Stern, D. Bernhard (Austria)

Board #

MONDAY, MAY 30, 2016

Vascular Biology: Endothelium and Smooth Muscle Cells

Board #

010 ANTIOXIDANT PROPERTIES OF SAFFRON AND CROCIN AND THEIR EFFECTS ON ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION IN STIMULATED HUMAN CORONARY ARTERY ENDOTHELIAL CELLS 487
R. Ahmad, N.A. Mohd Kasim, T. Rahman, G.A. Froemming, H. Nawawi (Malaysia)

011 GLYCATED LDL INDUCE ENDOPLASMIC RETICULUM STRESS ALONG WITH THE STIMULATION OF VCAM-1 EXPRESSION IN HUMAN ENDOTHELIAL CELLS, AND THE ENSUING MONOCYTE ADHESION 488
L. Toma, G.M. Sanda, M. Deleanu, C.S. Stancu, A.V. Sima (Romania)

012 ENDOTHELIAL CELL DEATH AND DISASSEMBLY IN ATHEROSCLEROSIS 489
S. Paone, G. Atkin-Smith, R. Tixeira, S. Caruso, L. Jiang, I. Poon, M. Hulett (Australia)

013 LEVOROTATORY-AMLODIPINE PLUS FLUVASTATIN CONFER ADDITIVE EFFECTS ON RETARDING ENDOTHELIUM-MESENCHYMAL TRANSITION THROUGH SUPPRESSING ROCK1 EXPRESSION 490
A. Cai, L. Liwen, Z. Yingling, C. Jiyan, L. Xida (China)

014 STUDIES ON THE MECHANISM OF ACTION OF THE ANTIPROLIFERATIVE EFFECT OF NO-DONORS FUROXANS IN SMOOTH MUSCLE CELLS 491
L. Arnaboldi, M. Lombardi, M. Sinelli, B. Rolando, L. Lazzarato, R. Fruttero, A. Gasco, A. Corsini (Italy)

015 THE DIACYLGLYCEROL ACETYLTRANSFERASE INHIBITORS XANTHOHUMOL AND AMIDEPSINE D REVEAL LIPID SYNTHESIS AS A PROMOTER OF ANGIOGENESIS 492
K. Astanina, J. Spang, R.T. Hahn, D. Oster, J. Hoppstaedter, **A.K. Kiemer** (Germany)

016 PROLIFERATION OF ENDOTHELIAL PROGENITOR CELLS BY 11,12-EPOXYEICOSATRIENOIC ACID IN I/R INJURED RAT 493
S. Kim, J.K. Chae, J.L. Young, Y.S. Kim, S.H. Lee, S.R. Lee, K.S. Rhee, W.H. Kim, J. Ko (Republic of Korea)

017 HIGH LEVELS OF SOLUBLE ENDOGLIN INDUCE INFLAMMATION AND OXIDATIVE STRESS IN AORTA COMPENSATED WITH PRESERVED NO-DEPENDENT VASODILATATION MICE FED HIGH FAT DIET 494
K. Jezkova, J. Rathouska, I. Nemeckova, P. Fikrova, E. Dolezelova, M. Varejckova, B. Vitverova, C. Bernabeu, J.M. Novoa, S. Chlopicki, P. Nachtigal (Czech Republic)

018 MEMBRANE CONTACT SITES IN ENDOTHELIAL CELLS 495
A. Kivelä, V. Olkkonen (Finland)

019 ENDOTHELIAL PROGENITOR CELLS BEFORE AND AFTER TREATMENT WITH METFORMIN IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA AND INSULIN RESISTANCE 496
C.O. Aragona, E. Imbalzano, V. Cairo, C. Conte, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, G. Mandraffino (Italy)

Board #

020 ENDOTELIAL DYSFUNCTION, BLOOD LIPID SPECTRUM,LEVEL OF LEPTIN AND MASS OF BODY IN PATIENT WITH CORONARY HEART DISEASE IN COMBINATION WITH HEPATIC STEATOSIS. 497
N. Grechanyk, A. Filippova, A. Kuryata (Ukraine)

021 UNDERSTANDING THE INTERACTIVE EFFECTS OF DOXORUBICIN AND RADIOTHERAPY ON ENDOTHELIAL CELL FUNCTION - THE ROLE OF JNK 498
G. Hargrave, M. Boyd, R. Plevin (United Kingdom)

022 THE CAPACITY OF EL MODIFIED SERUM / APO B DEPLETED SERUM TO PROTECT VASCULAR ENDOTHELIAL FUNCTION 499
S. Radulović, A. Kirsch, I. Schilcher, M. Lechleitner, C. Nusshold, S. Hallström, S. Frank (Austria)

023 ULTRASTRUCTURAL STUDY OF ENDOTHELIUM IN ADVANCED CAROTID ARTERY ATHEROSCLEROSIS 500
A. Evdokimenko, T. Gulevskaya, T. Gulevskaya, S. Scrylev, V. Shchipakin, M. Tanashyan (Russia)

024 THE ASSESSMENT OF VARIANT DOUBLE FILTRATION PLASMAPHERESIS (DFPP) IMPACT ON THE ADHESION MOLECULES CONTENT IN STABLE CORONARY ARTERY DISEASE (CAD) PATIENTS AFTER CORONARY STENTING 501
M. Pyatchenkov, V. Tishko, A. Sokolov (Russia)

025 THE EFFECTS OF HIV-INFECTION AND ANTI-RETROVIRAL TREATMENT ON ENDOTHELIAL FUNCTION IN A SOUTH AFRICAN COHORT 502
N. Mashele, S. Charania, F. Essop, I. Webster, C. Westcott, N. Goswami, P. De Boever, T. Nawrot, H. Strijdom (South Africa)

026 THE ROLE OF INHIBITORS OF WNT SIGNALING IN CARDIOVASCULAR EVENTS 503
C. Ress, A. Kirschner, M. Paulweber, K. Willeit, L. Kedenko, G. Goebel, K. Rufinatscha, K. Salzmann, G. Staudacher, H. Tilg, B. Igelseder, B. Paulweber, S. Kaser (Austria)

027 THE GOOD? THE BAD? THE UGLY! RETINOIC ACID IN MYOCARDIAL INFARCTION 504
K. Danzl (Austria)

028 ARTERIAL STIFFNESS CORRELATES WITH EXTRACELLULAR MATRIX TURNOVER IN HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS 505
M. Martínez-Marin, J. Perez-Calvo, C. Josa-Laorden, I. Lacambra-Blasco, I. Gimenez-Lopez, J. Rubio-Gracia, V. Garces-Horna, M. Sanchez-Marteles, F. Ruiz-Laiglesia, P. Samperiz-Legarre, I. Torres-Courchoud, B. Amores-Arriaga, R. Martinez-Marin, C. Sanz-Bescos, F. Roncales-Garcia Blanco (Spain)

029 BYGLICAN EXPRESSION, ARTERIAL STIFFNESS AND PROATHEROGENIC PROFILE IN FORMER SMOKERS AFTER 1-YEAR SMOKE CESSATION 506
G. Mandraffino, C.O. Aragona, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, E. Imbalzano (Italy)

Board #

030 HIGH, NOT LOW LEVELS OF ENDOGENOUS ENDOSTATIN SERUM LEVELS PREDICT EVENT-FREE SURVIVAL IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 507
B. Zierfuss, C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria)

031 HIGH FRUCTOSE CONSUMPTION IMPAIRS AORTIC FUNCTION AND METABOLIC PARAMETERS COMPARED TO GLUCOSE IN FEMALE RATS 508
G. Sanguesa, M.D.M. Cascales, S. Shaligram, F. Akther, M. Baena, R. Rahimian, J.C. Laguna, M. Alegret, N. Roglans (Spain)

032 MECHANICAL CONDITIONS AROUND NEOVESSELS IN POPLITEAL ATHEROSCLEROTIC PLAQUES - AN ANALYSIS USING FINITE ELEMENT METHOD 509
M. Mocan, M. Bogdan, B. Sorin Nicu (Romania)

033 LASER CONFOCAL MICROSCOPY OF ARTERIAL WALL: ROLE OF SIGNALING MOLECULES IN MECHANISMS OF RESTENOSIS 510
I. Kvetnoi, K. Kozlov, E. Sedova, I. Bolotov, V. Polyakova (Russia)

034 HOMOARGININE: A NEW POTENTIAL AVENUE IN THE MANAGEMENT OF NEOINTIMAL HYPERPLASIA? 511
F. Dellera, G.S. Ganzetti, A. Froio, S. Manzini, M. Busnelli, A. Meinitzer, G. Chiesa, C. Parolini (Italy)

035 SOLUBLE ST2 IS A NOVEL MARKER OF AORTIC STIFFNESS AND ARTERIOSCLEROSIS MEASURED BY INVASIVE HEMODYNAMIC STUDY 512
S.H. Kim, H.L. Kim, W.H. Lim, J.B. Seo, W.Y. Chung, J.H. Zo, H.L. Lee, M.A. Kim, D.G. Park, G.J. An (Republic of Korea)

036 VASCULAR RESPONSES TO INSULIN ARE IMPAIRED AFTER DIET-INDUCED OBESITY WHEREAS RESPONSES TO IGF-1 ARE MAINTAINED 513
G.K. Povlsen, I. Buza, H. Boonen, J. Worm (Denmark)

037 CARDIOMETABOLIC AND VASCULAR EFFECTS OF TREATMENT WITH A FIXED-DOSE COMBINATION ANTI-RETROVIRAL DRUG CONTAINING NUCLEOSIDE AND NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS AND NNRTIS) IN ADULT RATS 514
H. Strijdom, N. Goswami, P. De Boever, C. Westcott, T. Ogundipe, F. Everson, A. Genis (South Africa)

038 SHORT-TERM AEROBIC EXERCISE IMPROVES AORTIC STIFFNESS IN WOMEN AFTER MENOPAUSE 515
P. Wohlfahrt, J. Pitha, I. Kralova Lesna, O. Auzky, P. Suchanek, P. Stavek (Czech Republic)

039 EFFECTS OF ADIPONECTIN ON VASCULAR PROPERTIES OF CAROTID ARTERY ASSOCIATED WITH MATRIX REMODELING 516
W.C. Tsai, Y.T. Sun (Taiwan)

Board #

040 THE LABILE IRON POOL AND PARAMETERS OF ARTERIAL WALL ELASTICITY 517
P. Risko, J. Pláteník, R. Buchal, J. Potočková, P. Kraml (Czech Republic)

041 THE EFFECT OF HIGH-FAT DIET ON THE BARRIER FUNCTIONS AND INFLAMMATORY STATUS OF HUMAN VASCULAR ENDOTHELIAL CELLS 518
P. Gorzelak-Pabis, E. Luczak, K. Wojdan, **M. Broncel**, M. Chalubinski (Poland)

042 MODIFYING THE GUT MICROBIOME WITH POLYPHENOLS AND A LECTIN LIMITED DIET IMPROVES ENDOTHELIAL FUNCTION 519
S. Gundry (USA)

043 GENOMIC REARRANGEMENTS IN HUMAN ATHEROSCLEROTIC VASCULAR TISSUES 520
A. Sleptcov, M. Nazarenko, I. Lebedev, N. Skryabin, O. Barbarash, V. Puzyrev (Russia)

044 INTIMA-MEDIA THICKNESS OF THE DESCENDING AORTA IS INFLUENCED BY AORTIC VALVE DISEASE 521
J. Petrini, M. Ring, P. Eriksson, A. Franco-Cereceda, K. Caidahl, M.J. Eriksson (Sweden)

Vascular Biology: Macrophages, Inflammation, Immunity

045 EFFECTS OF OXIDAZED LDL IN M2 MACROPHAGES. IMPLICATIONS IN ATHEROSCLEROSIS 522
F. Goncalves, K. Alcantara, V. Moura, P. Nolasco, J. Kalil, M. Hernandez (Brazil)

046 HUMAN MACROPHAGES EXPOSED TO OXIDIZED LDL OR TUNICAMYCIN EXHIBIT INCREASED MMP-9 EXPRESSION, SECRETION AND ACTIVITY BY A MECHANISM INVOLVING ENDOPLASMIC RETICULUM STRESS 523
G.M. Sanda, M. Deleanu, C.S. Stancu, M. Simionescu, A.V. Sima (Romania)

047 RECOMBINANT DOMAIN V OF BETA(2)-GLYCOPROTEIN I INHIBITS OXLDL-INDUCED TF EXPRESSION IN MACROPHAGES 524
Y. Chi, T. Yu, Q. Liu, J. Qin, J. Li, Y. Chen, M. Li (China)

048 REDUCED DIETARY INTAKE OF TLR2 AND TLR4 STIMULANTS FAVOURABLY MODIFIES LIPID AND INFLAMMATORY MARKERS OF CARDIOMETABOLIC RISK IN HEALTHY MEN 525
T. Faraj, C. Erridge (United Kingdom)

049 THE ROLE OF OXIDIZED LOW-DENSITY LIPOPROTEINS AND AUTOANTIBODIES TO THEM IN ATHEROGENESIS IN PATIENTS WITH CORONARY ATHEROSCLEROSIS 526
M. Shogenova, A. Karpov, R. Zhetisheva, V. Masenko, V. Naumov (Russia)

Board #

050 CELL-SPECIFIC UPREGULATION OF APOLIPOPROTEIN E GENE EXPRESSION IN MACROPHAGES BY GLUCOCORTICOIDS 527
V.G. Trusca, E.V. Fuior, I.M. Fenyo, I.F. Tudorache, D. Kardassis, M. Simionescu, A.V. Gafencu (Romania)

051 INTERLEUKIN-*27* POLYMORPHISMS ARE ASSOCIATED WITH PREMATURE CORONARY ARTERY DISEASE AND INSULIN RESISTANCE. THE GENETICS OF ATHEROSCLEROTIC DISEASE (GEA) MEXICAN STUDY 528
R. Posadas-Sánchez, N. Pérez-Hernández, J.M. Rodríguez-Pérez, J. Angeles-Martínez, C. Posadas-Romero, G. Cardoso-Saldaña, T. Villarreal-Molina, G. Vargas-Alarcón (Mexico)

052 ENZYMATIC DEGRADATION OF 7-KETOCHOLESTEROL (7-KC), A NEW STRATEGY FOR THE TREATMENT OF ATHEROSCLEROSIS 529
I. Perveen, S. Ahmed (Pakistan)

053 HUMAN MONOCYTE-DERIVED MACROPHAGES FROM CORONARY ARTERY DISEASE PATIENTS SHOW AN IMPAIRED PHENOTYPE 530
S. Eligini, S. Fiorelli, N. Cosentino, V. Cavalca, S. Colli, G. Marenzi, E. Tremoli (Italy)

054 AGE-ALBUMIN REDUCES ABCA-1 CONTENT IN MACROPHAGES BY INDUCING ITS MODIFICATION BY AGE AND DEGRADATION BY THE UBIQUITIN-PROTEASOME AND LYSOSOMAL SYSTEM. 531
R. Tallada Iborra, A. Machado-Lima, U. Fabres Machado, L. Rui, E.R. Nakandakare, S. Yokoyama, M. Passarelli (Brazil)

055 MONOCYTE ACTIVATION CORRELATES WITH ATHEROGENIC MITOCHONDRIAL MUTATIONS 532
A. Orekhov, N. Nikiforov, N. Elizova, M. Sazonova, A. Zhelankin, I. Sobenin (Russia)

056 FOXO1 AND NF-κB REGULATE CYCLOOXEGENASE-2 EXPRESSION UNDER LYSOPHOSPHATIDYALCHOLINE TREATMENT IN HUMAN CARDIAC FIBROBLAST 533
H.C. Tseng, C.M. Yang (Taiwan)

057 DIVERGENT EFFECTS OF SODIUM SALICYLATE ON GLUCOSE METABOLISM AND REVERSE CHOLESTEROL TRANSPORT IN OBESITY 534
S. Kajani, M. O'Reilly, W. Guo, F. McGillicuddy (Ireland)

058 PRO-INFLAMMATORY GENE EXPRESSION IN ADIPOSE TISSUE IN PATIENTS WITH ATHEROSCLEROSIS 535
S. Cejková, I. Králová Lesná, J. Froněk, A. Králová, R. Poledne (Czech Republic)

059 RESPONSE GENE TO COMPLEMENT-32 REGULATES TGF-B EXTRACELLULAR MATRIX EXPRESSION IN HUMAN AORTIC ATHEROSCLEROTIC WALL 536
S.I. Vlaicu, A. Tatomir, D. Boodhoo, A.P. Mekala, C.A. Tegla, V. Rus, H. Rus (Romania)

Board #

060 THE ASSOCIATION BETWEEN PLASMA INTERLEUKIN-27 (IL-27) LEVELS AND THE SEVERITY OR INSTABLITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CAD 537
K. Miura, E. Saita, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami, Y. Kishimoto, K. Kondo, Y. Momiyama (Japan)

061 FEATURES OF CELLULAR AND VASCULAR INFLAMMATORY RESPONSE IN PATIENTS WITH UNSTABLE ANGINA AND MYOCARDIAL INFARCTION 538
N. Musikhina, T. Petelina, L. Gapon, O. Irina, V. Kuznetsov (Russia)

062 EVALUATION OF MMP-7 AND TIMP-1 IN PATIENTS WITH CORONARY ATHEROSCLEROSIS 539
C.R. Revnic, C. PENA, S. VOINEA, F. REVNIC, B. PALTINEANU (Romania)

063 RELATIONSHIP BETWEEN MMP-9, TIMP-1, HS CRP AND THE SEVERITY OF ATHEROSCLEROTIC CORONARY ARTERY DISEASE 540
C.R. Revnic, C. PENA, S. PRADA, F. REVNIC, G. PRADA (Romania)

064 INTERMEDIATE DENSITY LIPOPROTEIN IS ASSOCIATED WITH MONOCYTE SUBSET DISTRIBUTION IN PATIENTS WITH STABLE ATHEROSCLEROSIS 541
K. Krychtiuk, S. Kastl, T. Pongratz, G. Goliasch, L. Gaspar, G. Maurer, K. Huber, E. Dostal, S. Pfaffenberger, S. Oravec, J. Wojta, W. Speidl (Austria)

065 THE ROLE OF MYELOID DENDRITIC CELLS, CHEMOKINE CCL17 AND T-CELL RECEPTOR CCR4 IN ATHEROGENESIS 542
A. Karpov, A. Rvatcheva, M. Shogenova, R. Zhetisheva, V. Masenko, V. Naumov (Russia)

066 THE INFLAMMATORY PROCESS AS A RISK FACTOR OF DEVELOPING ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS 543
I. Starodubtseva (Russia)

067 MMP-12 AND TIMPS BEHAVIOUR IN STROKE RELATED TO CAROTID ARTERY STENOSIS 544
N. Cifani, F. Del Porto, **L. Ferri**, M. Proietta, D. Toni, R. Dito, M. De Michele, A. Falcou, M. Taurino (Italy)

068 ATHEROSCLEROTIC PATIENTS HAVE M1-SKEWED MONOCYTES: COMORBIDITIES AND RISK FACTORS CONTRIBUTE 545
H. Williams, V. Patel, G. Cassorla, N. Pertsoulis, **S. Li**, J. Fletcher, H. Medbury (Australia)

069 INCREASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) IS ASSOCCIATED WITH INFLAMMATION IN OBESE SUBJECTS 546
M. Malczewska-Malec, **M. Malczewska-Malec**, A. Polus, J. Goralska, U. Razny, A. Dembinska-Kiec, B. Solnica (Poland)

Board #

070 INCREASING B1A LYMPHOCYTES THROUGH APRIL OVEREXPRESSION IN APOLIPOPROTEIN E-DEFICIENT MICE STABILIZES ADVANCED ATHEROSCLEROTIC LESIONS BY DECREASING NECROTIC AREA AND INCREASING SMOOTH MUSCLE CELL CONTENT 547
K.H. Zheng, S. Bernelot Moens, S.I. Van Leuven, S. Havik, D. Baeten, E. Stroes (Netherlands)

071 CYTOMEGALOVIRUS DNA LOAD AND T-LYMPHOCYTES ACTIVATION IN ATHEROSCLEROTIC PLAQUES 548
A. Lebedeva, E. Nikitskaya, O. Ivanova, J.C. Grivel, E. Maryukhnich, A. Shpektor, E. Vasilieva, L. Margolis (Russia)

072 INTERLEUKIN-17-RELATED PATHWAYS ARE INVOLVED IN CAROTID ATHEROSCLEROSIS, BUT NOT IN STANFORD-A ACUTE AORTIC DISSECTION 549
F. Del Porto, N. Cifani, **L. Ferri**, S. Perrotta, R. Dito, M. Iaconi, R. Carletti, M. Proietta, L. Tritapepe, C. Di Gioia, M. Taurino (Italy)

073 ROLE OF T HELPER 17 LYMPHOCYTE SUBPOPOLATIONS IN CRITICAL CAROTID ARTERY STENOSIS 550
M. Proietta, N. Cifani, F. Del Porto, **L. Ferri**, G. Orgera, S. Perrotta, R. Dito, L. Tritapepe, M. Iaconi, M. Taurino (Italy)

074 INCREASED FREQUENCIES OF CIRCULATING T-HELPERS 17 AND DIMINISHED REGULATORY T-CELLS TO T-HELPERS 17 RATIO PREDICT CAROTID ATHEROSCLEROSIS PROGRESSION 551
A. Filatova, **A. Shchinova**, E. Pylaeva, A. Potekhina, A. Osokina, M. Tripoten, O. Pogorelova, T. Balakhonova, E. Noeva, E. Klesareva, O. Afanasieva, T. Arefieva (Russia)

075 DECREASED BONE MARROW ACTIVITY MEASURED BY USING 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH CEREBRAL ARTERY ATHEROSCLEROSIS 552
J.M. Kim, L. Eun Seoung, P. Kwang-Yeol, S. Ju Won, J. Keun-Hwa (Republic of Korea)

076 PSORIASIS AND CORONARY ARTERY DISEASE: THE ROLE OF INFLAMMATION 553
P. Altieri, H.L. Banchs, J. Nieves (Puerto Rico)

077 ABSENCE OF FIBRONECTIN-EDA CONTRIBUTES TO SEPSIS OUTCOMES IN A MURINE MODEL 554
A. Dhyani, V.K. Pulakazhi Venu, P. Uboldi, A.F. Muro, A.L. Catapano, D.G. Norata (Italy)

078 HUMAN HERPESVIRUS ACTIVATION IN PATIENTS WITH ACUTE CORONARY SYNDROME 555
E. Nikitskaya, O. Ivanova, M. Elena, G. Jean-Charles, A. Lebedeva, A. Shpektor, L. Margolis, E. Vasilieva (Russia)

Board #

079 BACILLE-CALMETTE-GU&EACUTE;RIN LOWERS PLASMA CHOLESTEROL AND DELAYS ATHEROSCLEROTIC LESION PROGRESSION IN MICE 556
A. Van Dam, S. Bekkering, M. Crasborn, L. Van Beek, S. Van den Berg, F. Vrieling, S. Joosten, V. Van Harmelen, M. De Winther, E. Lutgens, M. Boon, N. Riksen, P. Rensen, J. Berbée (Netherlands)

080 IDENTIFYING FEATURES OF VASCULAR INFLAMMATORY RESPONSE IN PATIENTS WITH MYOCARDIAL INFARCTION USING THE SYNTAX SCORE 557
T. Petelina, N. Musikhina, L. Gapon, I. Osipova, V. Kuznetsov (Russia)

081 REDOX-ACTIVE IRON IN MONOCYTES ISOLATED FROM PATIENTS WITH CHRONIC CARDIOVASCULAR DISEASE 558
P. Kraml, P. Riško, J. Pláteník, J. Potočková (Czech Republic)

082 PATIENTS WITH RHEUMATOID ARTHRITIS SHOWED ALTERED LIPOPROTEIN PROFILE WITH DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS TO EXACERBATES INFLAMMATION AND ATHEROSCLEROTIC PROCESS 559
J.Y. Kim, E.Y. Lee, K.H. Cho (Republic of Korea)

083 THE LEVEL OF NITRIC OXIDE REGULATES LIPOCALIN-2 EXPRESSION UNDER INFLAMMATORY CONDITION IN RINM5F BETA-CELLS 560
S.Y. Chang, Y.H. Jo, M.J. Kim (Republic of Korea)

084 DIFFERENTIAL WHITE BLOOD CELL COUNT AND METABOLIC SYNDROME IN JAPANESE MEN 561
Y. Ikeda, N. Hisakawa, T. Ohguro, J. Nishiuchi, Y. Kumon (Japan)

085 NON-HDL CHOLESTEROL RELATES TO PRO-INFLAMMATORY STATUS OF HUMAN VISCERAL ADIPOSE TISSUE 562
R. Poledne, I. Kralova Lesna, A. Kralova, A. Sekerkova, J. Fronek (Czech Republic)

086 EFFECT OF FAT COMPOSITION OF A MEAL ON THE ACUTE POSTPRANDIAL INFLAMMATORY RESPONSE 563
I. Shapira, O. Raz, S. Berliner (Israel)

087 THE RELATIONSHIP BETWEEN *HELICOBACTER PYLORI* INFECTION AND ARTERIAL STIFFNESS IN ADULTS WITH ABNORMAL GASTRIC ENDOSCOPIC FINDINGS 564
K.C. Park, M.J. Kim, K.S. Park, Y.S. Kim, H.C. Cho, H.R. Sung, K.H. Park, B.H. Choi, K.C. Kim (Republic of Korea)

088 PROTECTIVE EFFECT OF CAROTENOIDS ON CX40 AD CX43 EXPRESSION IN THE LEFT VENTRICLE OF NORMOTENSIVE WISTAR RATS AFTER ADMINISTRATION OF LPS 565
K. Frimmel, J. Krizak, B. Liptak, J. Navarova, V. Knezl, E. Breierova, I. Bernatova, L. Okruhlicova (Slovakia)

Board #

Vascular Biology: Myocardial Infarction, Stroke, Peripheral Vascular Disease

Board #

Board #

109 LOW NUMBER OF CIRCULATING CD34 POSITIVE CELL IS ASSOCIATED WITH GREATER PROGRESSION OF CORONARY CALCIUM DETERMINED BY MDCT 586
T. Miyoshi, M. Doi, K. Nakamura, H. Ito (Japan)

110 A GIANT LEFT ATRIUM 587
Y. Saleh, A. Almaghraby, B. Hammad, M. Elbahey, A. Samoka, A. Ghoneem, M. Seleem (Egypt)

111 ARTERIAL STIFFNESS AS A PREDICTOR OF RECOVERY OF LEFT VENTRICULAR SYSTOLIC FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION 588
G. Mandraffino, C.O. Aragona, S. Quartuccio, G. Trapani, A. Saitta, M. Vatrano, E. Imbalzano (Italy)

112 EVALUATION OF CHANGES OF GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH STEMI AFTER MYOCARDIAL REVASCULARIZATION 589
V. Oleynikov, V. Galimskaya, E. Romanovskaya (Russia)

113 ASSESSMENT OF EFFICIENT REVASCULARIZATION ON DYNAMICS OF VELOCITY PARAMETERS IN PATIENTS WITH STEMI 590
V. Oleynikov, V. Galimskaya, E. Romanovskaya, I. Avdeeva (Russia)

114 STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE MAJOR ARTERIES IN PATIENTS WITH CORONARY HEART DISEASE AND HEALTHY SUBJECTS 591
V. Oleynikov, A. Khromova, L. Salyamova (Russia)

115 LIVER DYSFUNCTION AND 18F-NAF ATHEROSCLEROTIC PLAQUE UPTAKE - ANALYSIS IN HIGH-CARDIOVASCULAR RISK INDIVIDUALS 592
M. Santos, M. Castelo-Branco, R. Silva, A. Gomes, P. Donato, J. Ferreira, C. Domingues, M. Pego, L. Gonçalves, M.J. Ferreira (Portugal)

116 THE RELATIONSHIP BETWEEEN CALCIFIED PLAQUES AND RESTENOSIS AFTER CAROTID ENDARTERECTOMY 593
H. Katano, K. Yamada, M. Mase (Japan)

117 ASSOCIATION BETWEEN SERUM ZINC LEVEL AND CAROTID ATHEROSCLEROSIS WITHOUT PLAQUE 594
M. Park (Republic of Korea)

118 PLAQUE CHARACTERISATION AND ANALYSIS IN THE RISK STRATIFYING PATIENTS WITH SYMPTOMATIC CAROTIS STENOSIS 595
D. Vanoli, P. Lindqvist (Sweden)

119 AREA MEASUREMENT OF CAROTID PLAQUE COMPARING B-MODE, DOPPLER COLOR AND CONTRAST-ENHANCED ULTRASOUND IMAGING 596
E. Nyman, D. Vanoli, C. Grönlund, U. Näslund, P. Lindqvist (Sweden)

Board #

120 DO STROKE PATIENTS WITH NORMAL CAROTID ARTERIES REQUIRE TEE FOR EXCLUSION OF RELEVANT AORTIC PLAQUE? 597
B. Muinjonov, **E. Giyazitdinova** (Uzbekistan)

121 QUANTIFICATION OF MICROVESSELS DENSITY IN CAROTID PLAQUE BY CONTRAST-ENHANCED ULTRASOUND WITH HISTOPATHOLOGIC VALIDATION 598
A. Evdokimenko, L. Druina, A. Chechetkin, S. Scrylev, T. Gulevskaya, M. Tanashyan (Russia)

122 REFERENCE VALUES FOR LOCAL ONE-POINT CAROTID STIFFNESS BY ECHO-TRACKING IN A LARGE POPULATION OF HEALTHY SUBJECTS 599
S. Favretto, S. Carerj, J. Jaroch, K. Łoboz-Grudzień, F. Antonini-Canterin, C. Zito, E. Bossone, M. Plrisi, O. Vriz (Italy)

123 INVESTIGATION OF PROTOPORPHYRIN IX-MEDIATED SONODYNAMIC THERAPY ON INTERMEDIATE STAGE ATHEROSCLEROSIS USING A NEW COMPUTERIZED B- MODE ULTRASOUND ANALYZING METHOD 600
H. Mehrad, M. Farhoudi (Iran)

124 NON-INVASIVE HIGH-FREQUENCY ULTRASOUND USING INTIMA AND INTIMA/MEDIA THICKNESS RATIO (BUT NOT CIMT), CORRECTLY MONITORED EXPECTED BENEFICIAL VASCULAR EFFECTS OF MENOPAUSAL HORMONE THERAPY 601
T. Naessen, M. Larsson (Sweden)

125 LIMITATIONS OF CONTRAST-ENHANCED ULTRASOUND WITH EVALUATION OF NEOVASCULARISATION IN THE ATHEROSCLEROTIC PLAQUE 602
A. Evdokimenko, L. Druina, A. Chechetkin, M. Tanashyan, T. Gulevskaya, S. Scrylev (Russia)

126 COMPARISON OF THE RESULTS OF CORONARY ANGIOGRAPHY AND PARAMETERS OF LOCAL RIGIDITY OF COMMON CAROTID ARTERY IN PATIENTS WITH CORONARY HEART DISEASE 603
V. Oleynikov, L. Salyamova, A. Khromova, **N. Burko** (Russia)

127 EFFICACY OF SCREENING OF SUBCLINICAL AORTAL ATHEROSCLEROSIS IN WORKING-AGE POPULATION DEPENDING ON INVESTIGATIONAL METHODS. 604
N. Koziolova, A. Chernyavina (Russia)

128 SUBCLINICAL CAROTID AND CEREBRAL ATHEROSCLEROSIS SCREENING IN WORKING-AGE POPULATION: EFFICACY OF DIFFERENT INVESTIGATIONAL METHODS. 605
N. Koziolova, A. Chernyavina (Russia)

129 RETINAL VASCULAR CALIBER, OCULAR BLOOD FLOW AND ENDOTHELIN-1 LEVEL IN BLOOD SERUM IN PATIENTS WITH SUBCLINICAL ATHEROSCLEROSIS 606
N. Adzhemian, V. Neroev, T. Kiseleva, M. Ezhov, N. Balatskaya, N. Ilina, V. Tankovskiy (Russia)

Board #

130 INVESTIGATING THE FEASIBILITY OF B-MODE ULTRASONOGRAPHY ACCOMPANIED BY PESDA MICROBUBBLES ADMINISTRATION FOR ACCURATE VISUALIZATION OF INTRAPLAQUE NEOVASCULARIZATION 607
H. Mehrad, M. Mokhtari-Dizaji, H. Ghanaati (Iran)

131 SUBCLINICAL ATHEROSCLEROSIS AND COGNITIVE IMPAIRMENT IN UZBEKISTAN 608
D. Akramova, A. Umarov (Uzbekistan)

132 THE RELATIONSHIP BETWEEN NONALCOHOLIC HEPATIC STEATOSIS AND CAROTID ATHEROSCLEROSIS AT THE ELDERLY 609
A. Capisizu, A. Zamfirescu, R. Dascalescu, O. Stanciu, S.M. Aurelian (Romania)

133 RELATIONSHIP BETWEEN THE CHOLESTEROL AND TRIGLYCERIDE CONTENT OF LIPOPROTEIN SUBCLASSES AND CAROTID INTIMA MEDIA THICKNESS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY 610
N. Furusyo, M. Shimizu, Y. Kato, Y. Tanaka, J. Hayashi (Japan)

134 CONFOCAL DUAL-PULSED ELECTROHYDRAULIC SHOCK WAVE THERAPY ACCOMPANIED BY PESDA MICROBUBBLES AND ATORVASTATIN ADMINISTRATION REDUCE THE ATHEROSCLEROTIC INTRAPLAQUE NEOVESSELS IN THE RABBIT CAROTID ARTERY 611
H. Mehrad, S.A. Seyedikhosroshahi (Iran)

Vascular Biology: Immune Disease and Cardiovascular Pathologies

135 EVALUATION OF SERUM CHEMERIN LEVEL IN PATIENTS WITH HASHIMOTO'S THYROIDITIS 612
E. Berta, **M. Harangi**, V.E. Varga, H. Lőrincz, I. Seres, E.V. Nagy, G. Paragh, M. Bodor (Hungary)

136 RISK FACTORS OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH THYROID GLAND LESION 613
R. Sayfutdinov, **O. Bugrova**, K. Nagornova, M. Dobrolubov, N. Artemova (Russia)

137 CARDIOVASCULAR MORTALITY AND MORBIDITY IN A GROUP OF PATIENTS WITH HIV DIAGNOSIS 614
E. Sifuentes Diaz, M. Monsalvo Hernando, C. Palomar Muñoz, N. Caro Gomez, E. Lopez Tinoco, R. Toro (Spain)

138 ARE CARDIOVASCULAR RISK FACTORS THE NEW THREAT TO HIV PATIENTS? 615
M. Monsalvo, E. Sifuentes Diaz, A. Caceres Gestoso, P. Perez Guerrero, I. Tinoco Racero, A. De los Santos Moreno (Spain)

Board #

139 SYSTEMIC LUPUS ERYTHEMATOSUS FLARE-UP IS ASSOCIATED WITH INCREASED 5-YEARS CAROTID INTIMA-MEDIA THICKNESS PROGRESSION 616
A. Baragetti, M. Magnoni, K. Garlaschelli, L. Grigore, M. Berteotti, I. Scotti, E. Bozzolo, A. Berti, A.A. Manfredi, E. Ammirati, A.L. Catapano, G.D. Norata (Italy)

140 PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS 617
K. Tziomalos, I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, E. Makri, N. Raptis, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece)

141 PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS 618
K. Tziomalos, I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, N. Raptis, E. Makri, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece)

142 ARTERIAL STIFFNESS IN A BLACK SOUTH AFRICAN COHORT INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) 619
C.M. Fourie, J.M. Van Rooyen, H.W. Huisman, C.M. Mels, W. Smith, R. Kruger, S. Botha, L. Lammertyn, L. Gafane, A.E. Schutte (South Africa)

Lipoproteins and Lipid Metabolism: ApoB Containing Lipoproteins

143 DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR REMNANT LIPOPROTEINS 620
N. Satoh, M. Ikaida, Y. Ito (Japan)

144 MOST OF THE HEPATIC TRIGLYCERIDE LIPASE (HTGL) IS BOUND TO APOE-RICH HDL IN POST-HEPARIN PLASMA 621
K. Nakajima, S. Usui, R. Shinohata, K. Miyashita, S. Imamura, J. Kobayashi, T. Machida, H. Sumino, M. Murakami (Japan)

145 NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM 622
V. Sachdev, C. Leopold, R. Bauer, J.V. Patankar, J. Iqbal, S. Obrowsky, M. Doktorova, M. Goeritzer, B. Scheicher, D. Kolb, G. Hoefler, A.V. Turnbull, A. Zimmer, M.M. Hussain, A.K. Groen, D. Kratky (Austria)

146 THE ROLE OF ANGPTL3 IN HUMAN LIPOPROTEIN METABOLISM 623
A. Tikka, J. Metso, M. Jauhiainen (Finland)

147 ASSOCIATION OF THE POSTPRANDIAL CHYLOMICRON TRIGLYCERIDE/APOB INDEX AND CARDIOVASCULAR EVENTS 624
H. Scharnagl, C. Werner, T. Stojakovic, W. März, U. Laufs (Austria)

Board #

148 SYSTEMATIC ASSAY OF LIPOPROTEIN LIPASE ACTIVITY AND MASS IN COHORT OF PATIENTS WITH HISTORY OF TYPE V HYPERLIPIDEMIA 625
O. Marmontel, M. Di Filippo, S. Nony, C. Marcais, C. Caussy, S. Charriere, A. Sassolas, P. Moulin (France)

149 APOLIPOPROTEIN C-III GLYCOFORMS CORRELATE HETEROGENEOUSLY WITH PLASMA LIPID PROFILE IN SUBJECTS WITH CORONARY ARTERY DISEASE 626
C. Chiariello, A. Castagna, N. Martinelli, P. Guarini, M. Manfredi, E. Ranzato, S. Martinotti, E. Marengo, D. Cecconi, O. Olivieri (Italy)

150 PLASMA APOLIPOPROTEIN CIII LEVELS AND INCIDENT CORONARY ARTERY DISEASE RISK: THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY. 627
J. Van Capelleveen, S.J. Bernelot Moens, X. Yang, N.T. Wareham, K.T. Khaw, E.S.G. Stroes, J.L. Witztum, G.K. Hovingh, S.M. Boekholdt, S. Tsimikas (Netherlands)

151 14C MIRISTIC ACID AND 3H CHOLESTEROL UPTAKE STUDIES IN AGING RABBIT AORTA AND HEART MUSCLE.THE IMPACT OF SERUM FACTORS FROM PATIENTS WITH LIPID METABOLIC DISORDERS 628
C.R. Revnic, C. Pena, F. Revnic, S. Voinea, B. Paltineanu (Romania)

152 LDL SUBFRACTIONAL ANALYSIS: A LABORATORY DIAGNOSTIC ASSAY IN PATIENTS WITH CAROTID AND CORONARY ATHEROSCLEROSIS 629
N. Gavrilova, V. Metelskaya, I. Ozerova, E. Yarovaya, S. Boytsov (Russia)

153 THERMAL STABILITY OF HUMAN PLASMA LDL(-): A PARADOXICAL BEHAVIOR OF LDL AGGREGATION 630
A. Rull, S. Jayaraman, A. Rivas, M. Pérez Cuellar, J. Ordóñez Llanos, **J.L. Sánchez Quesada**, O. Gursky (Spain)

154 LIPOPROTEINS FROM CORD BLOOD OF SMALL BABY FOR GESTATIONAL AGE SHOWED ELEVATED TRIGLYCERIDE AND DIMINISHED APOA-I CONTENT WITH MORE PRO-ATHEROSCLEROTIC AND PRO-INFLAMMATORY ACTIVITY 631
S.M. Kim, C. Kyung-Hyun (Republic of Korea)

155 POLOXAMERS INHIBIT ASSOCIATION OF MULTIPLY MODIFIED LDL, BUT DO NOT REDUCE THEIR ATHEROGENIC POTENTIAL 632
A. Melnichenko, N. Elizova, **A. Orekhov** (Russia)

156 MULTIPLE MODIFICATION OF LDL CIRCULATING IN BLOOD OF ATHEROSCLEROTIC PATIENTS 633
A. Orekhov, I. Sobenin, A. Melnichenko (Russia)

157 COMPARABILITY STUDY OF CANDIDATE REFERENCE METHODS FOR LDL-P MEASUREMENTS 634
N. Clouet Foraison, S. Vaslin-Reimann, C. Cobbaert, P. Gillery, V. Delatour (France)

Board #

158 THE DETERMINATION OF APOLIPOPROTEIN B BY CALCULATION AND BY MEASUREMENT ON SET OF DYSLIPIDEMIC PATIENTS 635
L. Cibickova, R. Gasko, H. Vaverkova, D. Karasek (Czech Republic)

159 ADIPONECTIN AS A BLOCKER OF OXIDIZED LDL 636
A. Kakino, Y. Fujita, T. Sawamura (Japan)

160 STRUCTURAL CHANGES INDUCED BY ACIDIC PH IN HUMAN APOLIPOPROTEIN B-100 637
A. Benito-Vicente, J.A. Fernández-Higuero, J.C.G. Milicua, A. Etxebarria, H. Ostolaza, J.L.R. Arrondo, C. Martin (Spain)

161 OXIDIZED LOW-DENSITY LIPOPROTEINS AND LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 ARE POSITIVELY ASSOCIATED TO PCSK9 IN TYPE 2 DIABETES MELLITUS 638
Y. Nekaies, **B. Baudin**, S. Kalbousi, M. Sakly, N. Attia (France)

162 LIPIDOMICS OF PLASMA, LIVER AND AORTA OF PCSK9-KO MICE 639
G. Chiesa, M. Busnelli, C. Parolini, S. Manzini, G.S. Ganzetti, F. Dellera, M. Suoniemi, M. Hilvo, R. Hurme, K. Ekroos, C.R. Sirtori, R. Laaksonen (Italy)

163 SUBFRACTIONAL DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS: A NEW MARKER FOR DETECTION OF INDIVIDUAL CARDIOVASCULAR RISK 640
V. Metelskaya, I. Ozerova, N. Gavrilova, E. Yarovaya, S. Boytsov (Russia)

Lipoproteins and Lipid Metabolism: Lipoprotein Metabolism

164 NOVEL CHIMERAS PROVIDE INSIGHT INTO STRUCTURE/FUNCTION ACTIVITY IN APOLIPOPROTEIN E3 AND APOLIPOPROTEIN AI 641
V. Narayanaswami, M. Lek, N. Ibe, W. Beck, J. Bielicki, P. Weers (USA)

165 EFFECTS OF TUMOR BEARING ON SERUM AND LIVER LIPID LEVELS IN SATO LUNG CARCINOMA (SLC)-IMPLANTED RATS: EFFECT OF A DIFFERENCE IN IMPLANTED CELL NUMBERS 642
M. Kawasaki (Japan)

166 EFFECTS OF ROSUVASTATIN ON GENE EXPRESSION OF LIVER LDL-R, PCSK9, SREBP-2, AND LRP1 IN OVARIECTOMIZED RATS SUBMITTED OR NOT TO VOLUNTARY EXERCISE 643
J.M. Lavoie, **E.T. Ngo Sock**, G. Mayer (Canada)

167 BLOOD LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN MEN OF DIFFERENT POPULATION SUBGROUPS AND ITS RELATIONSHIP WITH UNFAVORABLE LONG-TERM PROGNOSIS 644
K. Astrakova, Y. Ragino, E. Shakhtshneider, S. Astrakov, M. Voevoda (Russia)

Board #

168 LDL RECEPTOR (LDLR) EXPRESSION AND FUNCTION IN HUMAN PANCREATIC BETA CELLS 645
A. Thedrez, R. Scharfmann, P. Parnet, E. Nobécourt, G. Lambert (France)

169 HIGH INTAKE OF SODIUM CHLORIDE EXACERBATES DEGRADATION OF HUMAN LIPOPROTEINS AND IMPAIRMENT OF REPRODUCTIVE CAPACITY VIA TESTICULAR TOXICITY IN ZEBRAFISH 646
E.Y. Lee, K.H. Cho (Republic of Korea)

170 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN THE ISCHEMIC HEART 647
M. Klevstig, M. Scharin Täng, M. Ståhlman, M. Levin, J. Borén (Sweden)

171 STABLE ISOTOPE KINETIC STUDY OF APOLIPOPROTEIN M IN HEALTHY SUBJECTS 648
M. Croyal, M. Chétiveaux, K. Ouguerram, S. Billon-Crossouard, E. Nobécourt, M. Krempf (France)

172 HEPATOSTEATOSIS AND ESTROGEN INCREASE APOLIPOPROTEIN O PRODUCTION IN THE CHICKEN 649
B. Schmidinger, A. Weijler, W.J. Schneider, M. Hermann (Austria)

173 NORMALIZATION OF LIPOPROTEIN PROFILE DURING PREGNANCY IN LCAT DEFICIENCY 650
A. Ossoli, E. Hanna, S. Simonelli, R. Mullan, S. Chamney, J. Chestnutt, F. Stewart, G. Franceschini, L. Calabresi (Italy)

174 CHARGED RESIDUES IN THE C-TERMINAL DOMAIN OF APOLIPOPROTEIN A-I MEDIATE OLIGOMERIZATION 651
P. Weers, V. Narayanaswami, L. Fuentes, J. Horn, R. Ellena, K. Cong (USA)

175 EFFECTS OF APOE VARIANTS ON PLTP INTERACTION AND ACTIVATION OF LOW AND HIGH ACTIVITY FORMS OF PLTP 652
M. Jauhiainen, I. Dafnis, J. Metso, V. Zannis, A. Chroni (Finland)

176 HIGH-PERFORMANCE GEL PERMEATION CHROMATOGRAPHY ANALYSIS DEMONSTRATES ATHEROGENIC PROPERTIES OF LIPOPROTEINS IN PATIENTS WITH CHOLESTERYL ESTER TRANSFER PROTEIN DEFICIENCY 653
T. Okada, T. Ohama, M. Okazaki, H. Matsuda, M. Sairyo, Y. Zhu, R. Kawase, D. Masuda, M. Koseki, M. Nishida, Y. Sakata, S. Yamashita (Japan)

177 COMPARISON OF FATTY ACID COMPOSITION OF SUBCUTANEOUS, PERICARDIAL AND EPICARDIAL ADIPOSE TISSUE AND ATRIAL TISSUE IN PATIENTS WITH HEART DISEASE 654
R. Bülow Eschen, J. Gu, J.J. Andreasen, A. Andreasen, S. Lundbye-Christensen, E. Berg Schmidt (Denmark)

178 DIETARY SATURATED FATTY ACIDS AGGRAVATE PRESSURE OVERLOAD-INDUCED CARDIOMYOPATHY IN MICE IN THE ABSENCE OF CARDIAC STEATOSIS 655
I. Muthuramu, R. Amin, N. Singh, A. Postnov, O. Gheysens, P. Van Veldhoven, **B. De Geest** (Belgium)

Board #

179 MYRISTIC ACID PLASMA LEVELS ARE STRONGLY CORRELATED WITH TRIGLYCERIDE AND APOLIPOPROTEIN C-III PLASMA CONCENTRATION IN A COHORT OF SUBJECTS WITH OR WITHOUT CORONARY ARTERY DISEASE 656
G. Speziali, D. Cecconi, N. Martinelli, O. Olivieri, A. Castagna, P. Guarini (Italy)

180 SPHINGOMYELIN CONTENT OF ERYTHROCYTE MEMBRANES IS IN LINEAR ASSOCIATION WITH MEMBRANES' LOADING WITH CHOLESTEROL IN CORONARY ARTERY DISEASE PATIENTS. 657
G. Chalikias, **P. Kikas**, I. Drosos, M. Pavlaki, A. Thomaidis, S. Konstantinides, D. Tziakas (Greece)

181 COMPLEX PHOSPHOLIPIDS ASSOCIATE WITH ARTERIAL NOREPINEPHRINE, NON-ESTERIFIED FATTY ACIDS AND HEART RATE, MARKERS OF SYMPATHETIC NERVE SYSTEM IN METABOLIC SYNDROME SUBJECTS INDEPENDENTLY OF INSULIN RESISTANCE 658
P. Nestel, N. Straznicky, A. Anwar, M. Pyush, P. Meikle (Australia)

182 ATHEROGENIC INDEX OF PLASMA FOR PREDICTION OF FUTURE CARDIOVASCULAR DISEASE IN PREDIABETES AND DIABETES POPULATION 659
P. Regmi, B. Baral, M. Raut, M.P. Khanal (Nepal)

183 INVESTIGATION OF LPL INDEPENDENT PATHWAYS OF TG-RICH LIPOPROTEIN METABOLISM IN LPL DEFICIENCY 660
D. Gaudet, D. Brisson, K. Tremblay (Canada)

184 EFFECT OF SALSALATE ON METABOLIC SYNDROME-RELATED PARAMETERS AND ACTIVITY OF BROWN ADIPOSE TISSUE IN WISTAR AND HEREDITARY HYPERTRIGLYCERIDEMIC RATS 661
V. Skop, J. Trnovska, M. Huttl, H. Malinska, I. Markova, O. Oliyarnyk, L. Kazdova (Czech Republic)

185 SPECIFIC CIRCULATING PHOSPHOLIPIDS, ACYLCARNITINES, AMINO ACIDS AND BIOGENIC AMINES ARE AEROBIC EXERCISE MARKERS 662
T. Felder, S. Ring-Dimitriou, S. Auer, S. Soyal, L. Kedenko, M. Rinnerthaler, J. Cadamuro, E. Haschke-Becher, E. Aigner, B. Paulweber, W. Patsch (Austria)

186 HETEROGENEITY OF PLASMA LOW DENSITY LIPOPROTEINS AND HIGH DENSITY LIPOPROTEINS: SOME GENDER PECULIARITIES IN SUBFRACTIONAL DISTRIBUTION 663
V. Metelskaya, I. Ozerova, N. Gavrilova, S. Boytsov (Russia)

187 IDENTIFICATION OF A NOVEL LXR TARGET 664
E.C.L. Cook, J.K. Nelson, V. Sorrentino, N. Zelcer (The Netherlands)

Board #

Lipoproteins and Lipid Metabolism: Lp(a)

188 PROGNOSTIC VALUE OF COMBINED LIPOPROTEIN(A) AND HOMOCYSTEINE IN ANGIOGRAPHICALLY PROVEN PATIENTS WITH CORONARY ARTERY DISEASE 665
S.W. Kwon, H.M. Kwon (Republic of Korea)

189 LIPOPROTEIN(A) MEASUREMENT AND ASSOCIATION WITH MEDICAL HISTORY IN SECONDARY CARE LIPID CLINICS 666
K.E. Shipman, A.J. Lawson, W. Alkaaby, A.F. Jones, R. Cramb (United Kingdom)

190 ELEVATED LIPOPROTEIN(A) AND ISCHEMIC STROKES- A CASE REPORT 667
P. Moriarty, N. Sehar, L. Denney, F. Perez-Marques, A. Panchal, P. Luna (USA)

191 RATIONALE AND DESIGN OF A CLINICAL TRIAL TO ASSESS LP(A) LOWERING WITH IONIS-APO(A)-LRX IN PATIENTS UNDERGOING APHERESIS FOR ELEVATED LP(A) AND RECURRENT CARDIOVASCULAR EVENTS 668
P.M. Moriarty, E.S. Thiessen, J.L. Witztum, N.J. Viney, S. Tsimikas (USA)

192 PREVALENCE OF LPA SINGLE NUCLEOTIDE POLYMORPHISMS AND ISOFORMS IN PATIENTS ENROLLED IN A PHASE 2 IONIS-APO(A)RX CLINICAL TRIAL 669
E.S. Stroes, F.M. Van der Valk, D. Gaudet, I. Gouni-Berthold, N.P. Riksen, E. Steinhagen-Thiessen, B. Isermann, B. Nordestgaard, N.J. Viney, S. Marcovina, S.G. Hughes, J. Tami, S. Xia, J.L. Witztum, S. Tsimikas (Netherlands)

193 NATURAL TEMPORAL VARIABILITY IN LP(A) LEVELS IN PATIENTS ENROLLED IN THE PLACEBO ARMS OF IONIS-APO(A)RX ANTISENSE OLIGONUCLEOTIDE CLINICAL TRIALS 670
N.J. Viney, S. Marcovina, J. Tami, S. Xia, J.L. Witztum, **S. Tsimikas** (USA)

194 PROGNOSTIC VALUE OF SERUM LIPOPROTEIN(A) LEVELS ON LONG-TERM MORTALITY IN A LARGE SAMPLE OF SUBJECTS IN PRIMARY CARDIOVASCULAR PREVENTION: DATA FROM THE BRISIGHELLA HEART STUDY 671
F. Fogacci, **S. D'Addato**, A.F.G. Cicero, E. Bertagnin, S. Palmisano, L. D'Agostini, E. Grandi, M. Giovannini, C. Borghi (Italy)

195 A SYSTEMATIC REVIEW AND META-ANALYSIS COMPARING THE EFFECTS OF STATINS AND FIBRATES ON PLASMA LIPOPROTEIN(A) LEVELS 672
A. Sahebkar, L.E. Simental-Mendía, M. Banach, M.C. Serban, G.F. Watts (Iran)

196 DEFINING THE MECHANISM OF LIPOPROTEIN(A) [LP(A)] LOWERING BY ALIROCUMAB IN TRANSGENIC MOUSE MODELS 673
C. Yeang, P. Miu, S. Green, X. Yang, M.Y. Hung, J.L. Witztum, S. Tsimikas (USA)

Board #

197 LIPOPROTEIN(A)-CHOLESTEROL (LP(A)-C) LEVELS DETERMINED BY VERTICAL AUTO PROFILE (VAP) CORRELATES WEAKLY WITH LP(A) MASS BUT MODESTLY WITH HDL-C: IMPLICATIONS FOR APPROPRIATE INTERPRETATION OF CLINICAL DATA 674
C. Yeang, S. Tsimikas (USA)

198 LIPOPROTEIN(A) AND INSULIN RESISTANCE: A POSSIBLE INVERSE RELATIONSHIP BETWEEN TWO WELL-KNOWN CARDIOVASCULAR RISK FACTORS 675
C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, G. Mandraffino (Italy)

199 A NOVEL MODIFIED LIPID TETRAD INDEX AS PREDICTOR OF PREMATURE CORONARY ARTERY DISEASE IN INDIANS 676
S. Das (India)

200 CIRCULATING LIPOPROTEIN (A) [LP(A)] LEVELS AND RISK OF CARDIOVASCULAR DISEASE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 677
R. Hoogeveen, W. Sun, V. Salim, B. Christie (USA)

201 THE ROLE OF LP(A) LEVELS AND APOPROTEIN(A) PHENOTYPE IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN PATIENTS WITH CORONARY ARTERY DISEASE 678
D. Labudovic, K. Toseska-Trajkovska, S. Alabakovska, J. Bogdanska, S. Jovanova (FYR Macedonia)

202 LIPOPROTEIN(A) AND T-HELPER CELLS AS INDEPENDENT PREDICTORS OF RAPID PROGRESSION OF CAROTID ATHEROSCLEROSIS 679
O. Afanasieva, E. Pylaeva, T. Arefieva, E. Klesareva, M. Afanasieva, A. Potekhina, A. Shchinova, T. Balakhonova, O. Pogorelova, M. Tripoten, S. Pokrovsky (Russia)

203 POPULATION AND ASSAY THRESHOLDS FOR THE PREDICTIVE VALUE OF LIPOPROTEIN(A) FOR RISK OF CORONARY ARTERY DISEASE: THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY 680
R. Verbeek, S.M. Boekholdt, R.M. Stoekenbroek, G.K. Hovingh, J.L. Witztum, N.J. Wareham, M.S. Sandhu, K.T. Khaw, S. Tsimikas (Netherlands)

204 STATUS OF INFLAMMATION, ENDOTHELIAL ACTIVATION AND PROTHROMBOGENESIS AMONG NEGRITOS AND MALAYS WITH METABOLIC SYNDROME 681
S.S. Mokhtar, N.A. Mohd Mokhsin, F. Mohd Nor, S.A. Shaari, H. Nawawi, B.P. Hoh, T. Rahman (Malaysia)

205 ELEVATED LIPOPROTEIN(A) LEVELS RESULT IN A HIGH CARDIOVASCULAR RISK – A PROSPECTIVE ANALYSIS OF A LIPIDOLOGY OUTPATIENTS UNIT 682
U. Schatz, S. Fischer, U. Julius, S.R. Bornstein, S. Tselmin (Germany)

Board #

206 PROFILE OF CIRCULATING MIRNAS IN PATIENT WITH HIGH LP(A) TREATED BY LDL/LP(A) APHERESIS 683
D. Dlouha, J. Pitha, Z. Eretova, O. Viklicky, A. Parikova (Czech Republic)

207 FAMILIAL HYPERCHOLESTEROLEMIA (FH) WITH ELEVATED LIPOPROTEIN(A) (LP(A)) LEVELS AND AGGRESSIVE CORONARY HEART DISEASE: A CASUISTIC APPROACH 684
A. Dybvig, A. Græsdal (Norway)

208 LIPOPROTEIN(A) IS A PREDICTOR OF ONE-YEAR VEIN GRAFT OCCLUSIONS IN STABLE ANGINA PATIENTS RECEIVED LIPOPROTEIN APHERESIS FOR REFRACTORY HYPERCHOLESTEROLEMIA AFTER CORONARY ARTERY BYPASS GRAFTING 685
R. Adzhiev, M. Ezhov, O. Afanasieva, S. Pokrovsky (Russia)

209 LIPOPROTEIN(A) LEVEL AS A PREDICTOR OF LONG-TERM CARDIOVASCULAR OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTIONS 686
M. Mitroshkin, M. Ezhov, M. Safarova, O. Afanasieva, Y. Matchin, S. Pokrovsky (Russia)

210 EFFECT OF NIACIN ON LIPOPROTEIN SUBFRACTIONS CONCENTRATION IN PATIENTS WITH ELEVATED LIPOPROTEIN(A) 687
E. Utkina, O. Afanasieva, N. Artemieva, M. Ezhov, I. Adamova, Y. Berestetskaya, S. Pokrovsky (Russia)

Lipoproteins and Lipid Metabolism: HDL

211 FUNCTIONAL DIFFERENCES BETWEEN APOLIPOPROTEIN E- AND APOLIPOPROTEIN A-I- CONTAINING HDL PARTICLES 688
S. Filou, E. Karavia, C. Constantinou, E. Zvintzou, K. Kypreos (Greece)

212 APOA-I DEPLETION IN CHOW-FED APOEKO MICE SEVERELY WORSENS CORONARY ATHEROSCLEROSIS DEVELOPMENT 689
G.S. Ganzetti, M. Busnelli, C. Parolini, S. Manzini, F. Dellera, C.R. Sirtori, G. Chiesa (Italy)

213 EVALUATION OF NOVEL APOA-I TWO-SITE IMMUNOASSAYS 690
J. Lövgren, P. Negi, T. Heikkilä, T. Tallgren, K. Pettersson, M. Jauhiainen, U. Lamminmäki (Finland)

214 EICOSAPENTAENOIC ACID (EPA) MEMBRANE INCORPORATION REDUCES ABCA1-DEPENDENT CHOLESTEROL EFFLUX IN UNLOADED AS WELL AS IN CHOLESTEROL-LOADED PRIMARY HUMAN MACROPHAGES THROUGH DIFFERENT MECHANISMS 691
N. Fournier, S. Tardivel, B. Vedie, J.F. Benoist, F. Allaoui, J.L. Paul (France)

Board #

215 EFFECTS OF MODERATE AND EXCESS ALCOHOL CONSUMPTION ON THE REVERSE CHOLESTEROL TRANSPORT IN VIVO 692
D. Greco, L. Mele, A. Piemontese, S. Battista, A. Poli, F. Bernini, I. Zanotti (Italy)

216 PROBUCOL OXIDIZED PRODUCTS, SPIROQUINONE AND DIPHENOQUINONE, PROMOTE REVERSE CHOLESTEROL TRANSPORT IN MICE 693
K. Shiotani, E. Yakushiji, M. Ayaori, T. Nishida, S. Takiguchi, H. Uto-Kondo, M. Sasaki, M. Yogo, T. Komatsu, R. Lu, S. Yokoyama, K. Ikewaki (Japan)

217 INFLAMMATION POTENTLY SUPPRESSES ABCA1-MEDIATED CHOLESTEROL EFFLUX FROM MACROPHAGES, AND NOT ADIPOCYTES, VIA ACTIVATION OF JAK/STAT PATHWAY 694
M. O'Reilly, M. Goodwin, O. Ansmidte, H. Roche, F. McGillicuddy (Ireland)

218 IDENTIFICATION OF A NOVEL UPREGULATOR OF ABCA1 AND SRB1 EXPRESSION WITH THE ACTION OF REGULATING CHOLESTEROL METABOLISM IN VITRO AND IN VIVO 695
S. Si, Y. Xu, C. Liu, P. Liu, X. Wang, B. Hong (China)

219 ELEVATED LEVELS OF LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT) ARE ASSOCIATED WITH REDUCED ATHEROMA BURDEN – AN IVUS STUDY 696
D. Rhainds, C. Gebhard, M. Cossette, M.C. Guertin, E. Rhéaume, J.C. Tardif (Canada)

220 EVALUATION OF HDL CHOLESTEROL EFFLUX CAPACITY (CEC) AFTER CONSUMPTION OF AN INNOVATIVE PASTA ENRICHED WITH BIOACTIVE COMPONENTS AND FUNCTIONAL PROBIOTICS 697
E. Cipollari, F. Zimetti, M.P. Adorni, N. Ronda, D. Angelino, N. Pellegrini, F. Bernini, E. Favari (Italy)

221 AEROBIC EXERCISE TRAINING DOES NOT SYSTEMATICALLY AFFECT MACROPHAGE GENE EXPRESSION INVOLVED IN REVERSE CHOLESTEROL TRANSPORT AND CHOLESTEROL EFFLUX IN CETP TRANSGENIC MICE 698
P.R. Pinto, K.S. Silva, D.J. Gomes, A. Machado-Lima, R.T. Iborra, G.S. Ferreira, E.C.R. Quintao, E.R. Nakandakare, U.F. Machado, M.L.C. Corrêa-Giannella, S. Catanozi, M. Passarelli (Brazil)

222 HDL CHOLESTEROL EFFLUX IS NOT PREDICTIVE OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS ON HEMODIALYSIS 699
C. Kopecky, S. Ebtehaj, B. Genser, C. Wanner, M.D. Saemann, U. Tietge (Austria)

223 XANTHOHUMOL, A PRENYLATED FLAVONOID IN HOPS, PROMOTES MACROPHAGE REVERSE CHOLESTEROL TRANSPORT IN HAMSTER 700
H. Hirata, H. Uto-Kondo, M. Ogura, M. Ayaori, K. Ikewaki (Japan)

Board #

224 FAT-ACTIVATED ER STRESS INDUCES THE REDUCTION OF ABCG5/8 EXPRESSION IN THE SMALL INTESTINE AND LIVER OF HYPERLIPIDEMIC HAMSTERS AND THE APPEARANCE OF DYSFUNCTIONAL HDL 701
C.S. Stancu, M.G. Carnuta, G.M. Sanda, L. Toma, M. Deleanu, L.S. Niculescu, M. Simionescu, A.V. Sima (Romania)

225 ASSOCIATIONS BETWEEN LIPID SUBFRACTIONS AND SERUM MYELOPEROXIDASE LEVELS IN UNTREATED HYPERLIPIDEMIC PATIENTS 702
A. Szentpéteri, H. Lőrincz, N. Zsíros, V.E. Varga, I. Seres, M. Katkó, P. Fülöp, G. Paragh, M. Harangi (Hungary)

226 ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN SUBCLASSES WITH CAROTID INTIMA-MEDIA THICKNESS SHIMANE COHRE STUDY 703
Y. Notsu, T. Nabika, S. Yano, A. Nagai (Japan)

227 HIGH DENSITY LIPOPROTEINS EXERT PRO-INFLAMMATORY EFFECTS ON MACROPHAGES VIA PASSIVE CHOLESTEROL DEPLETION AND PKC-NF-KB/STAT1-IRF1 SIGNALING 704
E. Van der Vorst, K. Theodorou, Y. Wu, M. Hoeksema, P. Goossens, C. Bursill, L. Huitema, S. Tas, M. Gijbels, K. McDaniels, C.C. Wang, M. Leitges, T. Lawrence, L. Touqui, J. Plat, M. Van Eck, K.A. Rye, M. De Winther, E. Biessen, M. Donners (Germany)

228 RELATIONSHIP BETWEEN FRAMINGHAM SCORE, HDL-CHOLESTEROL AND C-REACTIVE PROTEIN AT ELDERLY PATIENTS 705
S. Opris, G. Constantin, M. Grigorie (Romania)

229 THE LIPID FRACTIONS AS RISK FACTORS FOR ATHEROSCLEROSIS IN DIFFERENT AGE GROUPS IN BOSNIAN POPULATION 706
B. Pojskic, E. Stimjanin, L. Pojskic, H. Selimovic, A. Macic-Dzankovic, S. Palo, I. Sisic (Bosnia and Herzegovina)

230 METRICS OF HIGH-DENSITY LIPOPROTEIN FUNCTION AND HOSPITAL MORTALITY IN ACUTE HEART FAILURE PATIENTS 707
I. Potočnjak, V. Degoricija, M. Trbušić, S. Dokoza Terešak, B. Radulović, G. Pregartner, B. Andrea, B. Tiran, G. Marsche, **S. Frank** (Austria)

231 CAUSAL LINK BETWEEN SERUM AMYLOID A AND OXIDATIVE DAMAGES TO HIGH-DENSITY LIPOPROTEIN 708
S. Jayaraman, C. Haupt, O. Gursky (USA)

232 INFLUENCE OF HDL-CHOLESTEROL LEVELS ON HDL PARTICLES LIPID COMPOSITION IN HEALTHY INDIVIDUALS. AN NMR-BASED LIPIDOMIC STUDY 709
C. Kostara, V. Tsimihodimos, E. Bairaktari, **M. Elisaf** (Greece)

233 HIGH-DENSITY LIPOPROTEIN (HDL) FUNCTION AND SUBCLASS DISTRIBUTION IN OBESE AND NORMAL-WEIGHT BLACK AND WHITE AFRICAN WOMEN. 710
N. Woudberg, J. Goedecke, D. Blackhurst, M. Frias, R. James, L. Opie, S. Lecour (South Africa)

Board #

234 SMALL, DENSE HDL DISPLAY POTENT VASORELAXING ACTIVITY, REFLECTING THEIR ELEVATED CONTENT OF S1P 711
L. Persègol, **M. Darabi**, C. Dauteuille, M. Lhomme, R. Salvayre, A. Nègre-Salvayre, S. Monier, A. Kontush (France)

235 ESTIMATION OF HDL ANTIOXIDATIVE ACTIVITY IN SUBJECTS WITH ACUTE CORONARY SYNDROME 712
H. Thakkar, V. Vincent, A. Roy, S. Singh, L. Ramakrishnan, A. Singh (India)

236 HDL-SPHINGOMYELIN REDUCTION AFTER WEIGHT LOSS BY AN ENERGY-RESTRICTED DIET IS ASSOCIATED WITH THE IMPROVEMENT OF METABOLIC SYNDROME COMPONENTS IN OVERWEIGHT PATIENTS 713
O. Pérez-Méndez, M. Martínez-Ramírez, M. Madero (Mexico)

237 A PHASE III MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (TANGO) TO EVALUATE CER-001 ON CAROTID ATHEROSCLEROSIS (VESSEL WALL AREA) IN PATIENTS WITH FAMILIAL PRIMARY HYPOALPHALIPOPROTEINAEMIA 714
E. Stroes, R. Benghozi, J.L. Dasseux, J. Genest, H. Ginsberg, C. Keyserling, E. Leitersdorf, P. Raggi, A. Von Eckardstein (Netherlands)

238 VITAMIN D STATUS AND HDL FUNCTIONALITY IN HEALTHY PRE-MENOPAUSAL WOMEN 715
F. Zimetti, D. Kocyigit, D. Greco, M.P. Adorni, N. Ronda, K.M. Gurses, S.H. Oguz, A. Gurlek, L. Tokgozoglu (Italy)

239 STATUS OF INFLAMMATION AND ENDOTHELIAL ACTIVATION IN SUBJECTS WITH LOW HIGH DENSITY LIPOPROTEIN CHOLESTEROL AMONG ABORIGINES IN MALAYSIA 716
N.A. Mohd Mokhsin, W.N.H. Wan Ahmad, F.H. Sakri, N.A. Mohd Kasim, N. Mohd Nasir, S. Abdul Razak, M. Md Yasin, A. Mohd Ismail, T. Rahman, H. Nawawi (Malaysia)

240 EFFECT OF STATINS ON HDL IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS 717
M. Licona-Rashid, R. Yahya, D. Wattimena, J. Roeters van Lennep, C. Christoffersen, E. Sijbrands, A. Verhoeven, M. Mulder (Netherlands)

241 HDL AS A CRUCIAL INDICATOR OF AN EARLY CLINICAL MANIFESTATION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 718
S. Urazgildeeva, M.V. Muzalevskaya, A.V. Tregubov, T.V. Nekrasova, V.S. Gurevich (Russia)

242 ENDOTHELIAL PROTECTIVE PROPERTIES OF HDL IMPROVE EARLY AFTER ROUX-EN-Y GASTRIC BYPASS BUT NOT AFTER DIET-INDUCED WEIGHT LOSS: THE SUPERIOR CARDIOMETABOLIC BENEFITS OF RYGB 719
E. Osto, E. McLoughlin, **P. Doytcheva**, M. Charakida, L. Van Gaal, J. Deanfield, T. Lüscher (Switzerland)

Board #

243 EFFECTS OF BARIATRIC SURGERY ON HIGH-DENSITY LIPOPROTEIN SUBTYPES 720
G. Rega-Kaun, C. Kaun, E. Dostal, S. Oravec, M. Prager, J. Wojta, W. Speidl (Austria)

244 INTERLEUKIN-6 REDUCES PARAOXONASE-1 ACTIVITY IN A DOSE-DEPENDENT MANNER; EVIDENCE FOR A POTENTIAL NOVEL LIPOPROTEIN-BASED MODULATORY MECHANISM 721
A. Abedpour Dehkordi, **H. Nayeri**, G.A. Naderi, N. Jafari Dinani, M. Boshtam (Iran)

245 TERMINALIA ARJUNA MODULATES LIPID EFFLUX AND INFLAMMATION IN HYPERCHOLESTEROLEMIC RABBITS 722
V. Dhawan, R. Rather, D. Trikha (India)

CVD Risk Factors

246 ELEVATED NEUTROPHILS, MONOCYTES AND WHITE CELL COUNTS IN PATIENTS WITH MYOCARDIAL INFARCTION COMPARED WITH STABLE CORONARY ARTERY DISEASE 723
I. Trakarnwijitr, B. Li, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia)

247 THE RISK FACTORS OF ATHEROSCLEROSIS IN ROMA POPULATION IN SOUTH BOHEMIA 724
V. Adamkova, J. Hubacek, D. Novakova, V. Adamek, V. Lanska, V. Tothova (Czech Republic)

248 LIPOPROTEIN PHENOTYPE IN NAÏVE PATIENTS WITH KLINEFELTER SYNDROME 725
A. Antonucci, A. Bonaldo, P. Scarinzi, M. Barichello, P. Bigolin, N. Caretta, M. Ghezzi, R. Selice, M. Terrin, D. Vianello, R. Marin, A. Ferlin, C. Foresta, E. Manzato, F. Fabris, S. Bertocco, S. Zambon, A. Zambon (Italy)

249 RISK OF DEMENTIA HOSPITALISATION ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS IN MIDLIFE AND OLDER AGE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 726
B. Muinjonov, **E. Giyazitdinova** (Uzbekistan)

250 PULSE WAVE VELOCITY IS CORRELATED WITH THE SERUM N-TERMINAL FRAGMENT OF BRAIN NATRIURETIC PEPTIDE LEVEL INDEPENDENTLY OF CENTRAL BLOOD PRESSURE AND THE AUGMENTATION INDEX 727
M. Shimizu, N. Furusyo, Y. Kato, Y. Tanaka, J. Hayashi (Japan)

251 ATHEROSCLEROTIC LESIONS OF AORTO-ILIAC SEGMENT AND LONG-TERM CONSEQUENCES OF RECONSTRUCTIVE OPERATIONS 728
A. Kozireva, M. Ivanov, P. Bondarenko, M. Ermina, D. Kozhevnikov, P. Puzdriak, A. Yadernaya, A. Kebryakov (Russia)

252 COMBINED EFFECTS OF ADIPONECTIN AND VISCERAL FAT ON THE RISK OF METABOLIC SYNDROME 729
K.H. Ha, D.J. Kim, H.C. Kim (Republic of Korea)

Board #

253 THE NEED TO CREATE AWARENESS TOWARDS CHOLESTEROL 730
J. Frutuoso, M. Bourbon (Portugal)

254 CORONARY ARTERY DISEASE AS A RISK FOR DEVELOPING TYPE 2 DIABETES MELLITUS 731
C. Saely, A. Vonbank, P. Rein, D. Zanolin, **A. Leiherer**, A. Muendlein, H. Drexel (Austria)

255 C-REACTIVE PROTEIN SIGNIFICANTLY PREDICTS CARDIOVASCULAR EVENTS BOTH IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH AND IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITHOUT THE METABOLIC SYNDROME 732
A. Vonbank, C. Saely, P. Rein, D. Zanolin, **A. Leiherer**, H. Drexel (Austria)

256 PRO B-TYPE NATRIURETIC PEPTIDE SIGNIFICANTLY PREDICTS FUTURE VASCULAR EVENTS IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH TYPE 2 DIABETES 733
A. Vonbank, C. Saely, P. Rein, D. Zanolin, **A. Leiherer**, H. Drexel (Austria)

257 OVERWEIGHT IN CHILDREN OF PATIENTS WITH EARLY CORONARY HEART DISEASE: RELATION TO OWN AND PARENTAL CHARACTERISTICS` 734
M. Konnov, **A. Deev** (Russia)

258 AGE-DEPENDENCE OF THE MAGNITUDE OF LIPID PROFILE VARIABLES RESEMBLANCE BETWEEN FIRST DEGREE RELATIVES IN FAMILIES OF PATIENTS WITH EARLY CORONARY HEART DISEASE 735
M. Konnov, **A. Deev**, N. Gratsiansky (Russia)

259 THE EFFECT OF MOXONIDINE ON LIPID PROFILE OF PATIENTS WITH ARTERIAL HYPERTENSION, GRADE 1 AND 2 736
E. Karlafti, A. Hatzitolios, T. Didangelos, M. Baltatzi, G. Koliakos, A. Kalkavouri, E. Liorda, V. Chasiotis, C. Savopoulos (Greece)

260 RISK OF INCIDENT HYPERTENSION ACCORDING TO METABOLIC HEALTH AND OBESITY: DEFINITION OF METABOLIC HEALTH DOES NOT MATTER 737
C.H. Jung, W.J. Lee, J.Y. Park, C.Y. Park, S. Kim (Republic of Korea)

261 BRACHIAL-ANKLE PULSE WAVE VELOCITY IS ASSOCIATED WITH COMPOSITE CAROTID AND CORONARY ATHEROSCLEROSIS IN A MIDDLE-AGED ASYMPTOMATIC POPULATION 738
H.J. Joo, S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong, C.W. Yu, D.S. Lim (Republic of Korea)

262 SUSTAINED METABOLIC SYNDROME AFTER LIFESTYLE COUNSELING WAS ASSOCIATED WITH HIGHER RISK OF SUBCLINICAL CORONARY ATHEROSCLEROSIS 739
H.J. Joo, S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong, C.W. Yu, K.J. An, D.S. Lim (Republic of Korea)

Board #

263 ASSOCIATION OF PRO12ALA PPARγ AND -308G/A TNFα WITH PPARγ AND TNFα MRNA LEVELS IN VISCERAL ABDOMINAL TISSUE IN FERTILE WOMEN IN RUSSIA 740
A. Kopytova, T. Usenko, V. Miroshnikova, E. Bazhenova, M. Nikolaev, A. Panteleeva, I. Semenova, A. Neimark, E. Baranova, S. Pchelina (Russia)

264 CAN NON-CHOLESTEROL STEROLS AND LIPOPROTEIN SUBCLASSES DISTRIBUTION PREDICT DIFFERENT PATTERNS OF CHOLESTEROL METABOLISM AND STATIN THERAPY RESPONSE? 741
T. Gojković, S. Vladimirov, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić, D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia)

265 SERUM LIPID PROFILE ON ADMISSION FOR ISCHEMIC STROKE/ TRANSIENT ISCHEMIC ATTACK 742
T. Vassalo, F. Faria, T. Duarte, I. Colaço, **D. Cruz**, J.L. Ducla Soares (Portugal)

266 DETERMINATION OF FACTORS CONTRIBUTING TO ATHEROSCLEROTIC DISEASE PROGRESSION IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE (PAD) 743
L.P. Zielinski, **M.M. Chowdhury**, B.P. Worsfold, S.C. Harrison, J.R. Boyle, P.D. Hayes, P.A. Coughlin (United Kingdom)

267 COMPLIANCE INITIATIVES IN MANAGEMENT OF PATIENTS WITH CORONARY ARTERY DISEASE AND PARKINSONISM SYNDROME 744
A. Shalaeva, N. Dadabaeva, M. Bozorboev, G. Kasimdjanova (Uzbekistan)

268 HEART RATE TURBULENCE AS A MORTALITY PREDICTOR IN 5 YEARS STUDY IN PATIENTS WITH CRORONARY HEART DISEASE 745
N. Zagidullin, D. Gareeva, I. Lackman, I. Sagitov, S. Zagidullin (Russia)

269 EFFECTS OF ASTHMA SEVERITY ON CHANGE OF PRESSURE OF PULMONARY ARTERY IN PATIENTS WITH ARTERIAL HYPERTENSION 746
A. Odegova, **E. Tarlovskaya** (Russia)

270 CLINICAL CHARACTERISTICS OF PATIENTS ON HEMODIALYSIS WITH PERIPHERAL ARTERIAL DISEASE 747
N. Aoyama (Japan)

271 ASSOCIATIONS BETWEEN OSTEOPOROSIS AND SIGNIFICANT CORONARY ARTERY DISEASE IN ASYMPTOMATIC POSTMENOPAUSAL WOMEN 748
S.N. Lee (Republic of Korea)

272 ADJUSTED NECK CIRCUMFERENCE AND METABOLIC SYNDROME: RESULTS FROM THE BRISIGHELLA HEART STUDY 749
E. Bertagnin, **S. D'Addato**, F. Fogacci, S. Palmisano, L. D'Agostini, A.F.G. Cicero, M. Giovannini, M. Rosticci, C. Borghi (Italy)

273 NON-CORONARY ATHEROSCLEROSIS PREVALENCE ACCORDING TO THE DATA OF THE ADULT POPULATION SCREENING 750
R. Khokhlov, L. Tribuntseva, V. Burlachuk, L. Khokhlov (Russia)

Board #

274 EPICARDIAL FAT THICKNESS IS ASSOCIATED WITH HIGHER VAGAL TONE 751
S. Lee, Y.S. Lee, B. Kim (Republic of Korea)

275 PREVALENCE OF RISK FACTORS AND CARDIOVASCULAR DISEASES IN EMPLOYEES OF A SINGLE PLANT IN DIFFERENT AGE GROUPS 752
R. Allanov, R. Rakhimov, E. Shalaeva, N. Dadabaeva (Uzbekistan)

276 CHADS2 AND CHA2DS2-VASC SCORES PREDICT CARDIOVASCULAR DISEASE IN STATIN-TREATED INDIVIDUALS WITHOUT ATRIAL FIBRILLATION 753
F. Barkas, E. Klouras, G. Liamis, M. Elisaf, E. Liberopoulos (Greece)

277 ACCURATE CARDIOVASCULAR EVENT RISK ESTIMATION CAN BE OBTAINED USING CORONARY ARTERY SCAN 754
M. Gracia, D. Craiem, A. Simon (Spain)

278 THE ASSOCIATION OF AN ELEVATED SERUM ENDOSTATIN LEVEL AND CAROTID ATHEROSCLEROSIS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) 755
Y. Kato, M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan)

279 SERUM ENDOSTATIN IS CORRELATED TO RENAL FUNCTION INDEPENDENTLY OF CAROTID ATHEROSCLEROSIS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) 756
Y. Kato, M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan)

280 SYSTEMATIC REVIEW OF HERPES ZOSTER AND ITS ASSOCIATION WITH CARDIOVASCULAR EVENTS 757
N. Erskine, H. Tran, L. Levin, C. Ulbricht, R. Goldberg (USA)

281 EXPOSURE TO CARDIOVASCULAR DISEASE RISK FACTORS IN CHILDHOOD IS ASSOCIATED WITH INCREASED CAROTID EXTRA MEDIAL THICKNESS IN ADULTHOOD: THE CHILDHOOD DETERMINANTS OF ADULT HEALTH STUDY 758
H. West, M. Skilton, B. Fraser, T. Dwyer, A. Venn, C. Magnussen (Australia)

282 CANDIDATE GENE POLYMORPHISMS RELATED TO LIPID AND CARBOHYDRATE METABOLISM SHOW AN ASSOCIATION WITH RISK FACTOR COMPONENTS OF THE METABOLIC SYNDROME IN ASIAN INDIANS. 759
T. Maistry (South Africa)

283 CLINICAL CHARACTERISTICS AND LDL-CHOLESTEROL MANAGEMENT IN PATIENTS WITH CARDIOVASCULAR EVENT AND/OR DIABETES IN THE NETHERLANDS 760
E. Heintjes, J. Kuiper, B. Lucius, F. Penning-van Beest, **L. Kutikova**, A. Liem, R. Herings (Switzerland)

284 WAIST-HIP-RATIO AND 1-YEAR CLINICAL OUTCOME IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME 761
H.W. Lee, **T.J. Hong**, J.H. Choi, B.W. Kim (Republic of Korea)

Board #

285 GLOMERULAR FILTRATION RATE (GFR) MODERATES THE PROTECTIVE EFFECT OF MEDITERRANEAN DIET AGAINST CARDIOVASCULAR INCIDENCE: 10-YEAR FOLLOW-UP (2002-12) OF THE ATTICA STUDY 762
E. Georgousopoulou, **C. Pitsavos**, D. Panagiotakos, C. Chrysohoou, I. Skoumas, M. Chatzigeorgiou, D. Tousoulis, C. Stefanadis (Greece)

286 PLAQUE CHARACTERIZATION AND REMODELING BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY AND CORONARY EVENTS 763
S.U. Kwon (Republic of Korea)

287 DURATION OF DIABETES IS AN INDEPENDENT DETERMINANT AND INTERACTED WITH GENDER FOR ACUTE MYOCARDIAL INFARCTION 764
Y.D. Jiang (Taiwan)

288 PRESENCE OF CAROTID PLAQUES AND CARDIOVASCULAR DISEASE EVENTS: A PROSPECTIVE STUDY 765
A. Bea, E. Jarauta, R. Mateo-Gallego, S. Perez-Calahorra, V. Marco-Benedi, I. Lamiquiz-Moneo, L. Baila-Rueda, A. Cenarro, F. Civeira (Spain)

289 TWO-GENERATION CARDIOVASCULAR DISEASE PREVALENCE IN FAMILIAL HYPERCHOLESTEROLEMIA 766
R. Mateo-Gallego, S. Perez-Calahorra, M. Laclaustra, N. Plana, C. Lahoz, J. Pedro-Botet, J.F. Ascaso, A. Vila Belmonte, P. Valdivielso, A. Brea, F. Civeira (Spain)

290 RAPID RISE IN PREVALENCE OF HYPERTENSION IN YOUNG IN NATIONAL CAPITAL REGION (NCR) OF DELHI, INDIA 767
A. Roy, P.A. Praveen, R. Amarchand, D. Prabhakaran, A. Krishnan, K.S. Reddy (India)

291 VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL, BLOOD PRESSURE, AND HEART RATE: THE GAIN IN CONTEXT OF CIRCUMSTANCES 768
E. Pello, T. Kouznetsova, Y. Nikitin, J. Staessen (Russia)

292 IMPROVING CARDIOVASCULAR PREVENTION IN PATIENTS WITH HIGH CARDIOVASCULAR RISK THROUGH AN INNOVATIVE APPROACH: "THE COACHING" CARE MODEL 769
S. Mosteoru, K. Kotseva, O.C. Cosor, L. Gaita, R. Pleava, A. Dumitrescu, G. Mut-Vitcu, D. Gaita, S. Mancas, D. Wood (Romania)

293 OVERWEIGHT/OBESITY AND CORONARY HEART DISEASE: AGE DEPENDENCIES IN METABOLIC MEDIATION 770
J. Fritz, S. Strohmaier, G. Nagel, H. Concin, H. Ulmer (Austria)

294 DECREASED SERUM LEVELS OF SOLUBLE DIPEPTIDYL PEPTIDASE IV ARE ASSOCIATED WITH ALL-CAUSE DEATH IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 771
M.T. Howanietz, C.T. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria)

Board #

295 FACTORS PREDICTING SURVIVAL OVER TWO DECADES OF OBSERVATION AFTER PERIPHERAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY: A RETROSPECTIVE STUDY 772
M. Schneider, C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria)

296 ANALYSIS OF THE DIRECT CAUSES OF DEATH IN PATIENTS WITH ACUTE STEMI TREATED WITH PRIMARY PCI FROM 2005 TO 2014 773
Y.H. Li, P.T. Lee, T.H. Chao, W.C. Tsai (Taiwan)

297 KLOTHO GENE POLYMORPHISMS ARE ASSOCIATED WITH PROGRESSION OF ATHEROMATOSIS IN PATIENTS WITH CKD. RESULTS OF TWO YEARS FOLLOW-UP OF THE NEFRONA COHORT 774
M. Gracia, A. Betriu, M. Martínez, D. Arroyo, M. Abajo, E. Fernández, J.M. Valdivielso (Spain)

298 RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS: WHY IS IMPORTANT TO EVALUATE THIS? 775
M. Parvu, S. Coman, S. Voidazan (Romania)

299 COMPARISON OF COMBINED THERAPY OF CAD ACCOMPANIED BY GASTRODUODENAL PATHOLOGY 776
Y. Balandina, Z. Simonova, **Y. Tarlovskaya** (Russia)

300 INCREASED VISCERAL FAT AND LOWER MUSCLE STRENGTH ASSOCIATED WITH ACUTE MYOCARDIAL INFARCTION 777
E. Okuyan, B. Ayca, S. Varol (Turkey)

301 HIGH PREVALENCE OF CVD RISK FACTORS AND UNSATISFACTORY CONTROL OF LDL-C LEVELS IN 40-YEARS-OLD MEN AND 50-YEARS-OLD WOMEN IN THE CZECH REPUBLIC 778
Z. Chmelik, M. Vrablík (Czech Republic)

302 PLASMA METHIONINE IS NOT ASSOCIATED WITH RISK OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS 779
I. Dhar, V. Lysne, P. Ueland, A. McCann, O. Nygård (Norway)

303 THE DIFFERENCE IN BLOOD PRESSURE READINGS BETWEEN ARMS AND CARDIOVASCULAR RISK: AN URBANITE INDIAN STUDY 780
P. Bhasin, S. Kapoor (India)

304 ASSOCIATION BETWEEN PREPROCEDURAL NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH THE INFLAMMATORY RESPONSE FOLLOWING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION 781
F. Rached, F. Brito Jr, C. Garzillo, T. Nascimento, M.A. Perin, C.V. Serrano Jr (Brazil)

Board #

305 THE INCIDENCE AND SEVERITY OF ANGINA PECTORIS IN PATIENTS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (OPTIMA II) 782
N. Logunova, Y. Karpov, V. Buza, D. Tomilova (Russia)

306 HYBRID INTERVENTION ON FEMOROPOPLITEAL ARTERIAL SEGMENT IN COMPARISON WITH CONVENTIONAL SURGICAL TECHNIQUE 783
P. Puzdriak, V. Shlomin, Y. Didenko, Y. Yurtaev, M. Ivanov, **P. Bondarenko**, R. Magomedov (Russia)

307 PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN MIDDLE-AGED SUBJECTS OF HIGH RISK LITHUANIAN POPULATION 784
S. Kutkiene, M. Petrylaite, Z. Petrulioniene (Lithuania)

308 MULTIPLE CORONARY FISTULAE INTO LEFT VENTRICLE AS A RARE CAUSE OF MYOCARDIAL ISCHEMIA 785
A. Averkova, K. Savostyanov, D. Zateyshchikov (Russia)

309 SUBCLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN HYPERTENSIVE FEMALES WITH RHEUMATOID ARTHRITIS AND ITS RELATIONSHIP WITH THE ADIPONECTIN LEVEL, INSULIN RESISTANCE, ENDOTHELIAL FUNCTION 786
O. Sirenko, O. Kuryata, T. Lysunets (Ukraine)

310 THE PREVALENCE OF CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUCOENCEPHALOPATHY (CADASIL) IN UZBEKISTAN 787
B. Muinjonov, E. Giyazitdinova (Uzbekistan)

311 7 T MRI REVEALS DIFFUSE IRON DEPOSITION IN PUTAMEN AND CAUDATE NUCLEUS IN CADASIL 788
B. Muinjonov, E. Giyazitdinova (Uzbekistan)

312 TENASCIN-C DEFICIENCY ATTENUATES ABDOMINAL AORTIC ANEURYSM FORMATION 789
A.K. Schaefer, F. Nagel, P. Kaiser, D. Santer, K. Trescher, A. Kiss, B.K. Podesser (Austria)

313 A CASE OF FATAL OBSTRUCTIVE SHOCK 790
A. Almaghraby, Y. Saleh, B. Hammad, A. Samoka, M. Elbahey, M. Seleem (Egypt)

314 CARDIOVASCULAR RISK FACTORS IN WOMEN AND MEN 791
A. Nikolova, M. Milanova (Bulgaria)

315 CAROTID INTIMA-MEDIA THICKNESS AS A PROGNOSTIC RISK MARKER OF DEMENTIA AT THE ELDERLY 792
R. Dascalescu, A. Zamfirescu, S.M. Aurelian, O. Stanciu, A. Capisizu (Romania)

Board #

316 PATHOPHYSIOLOGICAL MECHANISMS FOR PRESERVING GRAFT PATENCY IN PATIENTS WITH COMPROMISED OUTFLOW TRACT AFTER DISTAL RECONSTRUCTION 793
A. Zotikov, Z. Adyrkhaev, V. Mitish, N. Ascerov, A. Kozhanova, **A. Ivandaev**, M. Abdulgamidov, A. Pokrovsky (Russia)

317 OUTDOOR AIR POLLUTION AND ISCHEMIC STROKE SEVERITY: AN ECOLOGICAL STUDY IN THESSALONIKI 794
N. Kakaletsis, K. Tziomalos, C. Savopoulos, M. Riga, S. Bouziana, M. Spanou, S. Kostaki, S. Angelopoulou, K. Karatzas, I.A. Hatzitolios (Greece)

318 GENDER FEATURES OF MYOCARDIAL INFARCTION AND STROKE RISK IN GENERAL POPULATION WITH VITAL EXHAUSTION IN RUSSIA / SIBERIA: WHO PROGRAM MONICA-PSYCHOSOCIAL 795
V. Gafarov, E. Gromova, I. Gagulin, D. Panov, A. Gafarova, **M. Voevoda** (Russia)

319 RELATIONSHIP OF STRESS WITH METABOLIC SYNDROME AND CORONARY HEART DISEASE IN MIDDLE-AGED POLICE OFFICERS 796
M. Janczura, J. Dropinski, A. Stanisz, K. Kotula-Horowitz, R. Rosa, T. Domagala (Poland)

320 PRELIMINARY RESULTS OF THE EGYPTIAN CARDIOVASCULAR RISK FACTORS PROJECT:MULTICENTER OBSERVATIONAL STUDY OF THE PATTERN OF RISK FACTOR PROFILE IN EGYPTIAN PATIENTS WITH ACUTE CORONARY SYNDROME 797
W. Hamed, A. Reda, A. El-Kersh, A. Shalaby, M. Beshay (Egypt)

Abstract not Registered

Board #

TUESDAY, MAY 31, 2016

Metabolic Abnormalities and Atherosclerosis: Diabetes

Board #

010 ASSOCIATION OF INSULIN RESISTANSE WITH CAROTID INTIMA-MEDIA THICKNESS AND BRACHIAL FLOW-MEDIATED DILATION IN THE SUBJECTS WITH METABOLIC SYNDROME 840
T. Domagala, M. Janczura, K. Kotula-Horowitz, J. Dropinski, T. Iwaniec, J. Zagajewski, A. Stanisz (Poland)

011 ASSOCIATION OF INSULIN RESISTANCE, AS DETERMINED BY HOMEOSTASIS MODEL ASSESSMENT (HOMA), WITH METABOLIC SYNDROME AMONG MIDDLE-AGED SUBJECTS 841
M. Janczura, K. Kotula-Horowitz, T. Iwaniec, A. Stanisz, J. Dropinski, T. Domagala (Poland)

012 DYSLIPIDEMIA WITH AND WITHOUT INSULIN RESISTANCE: SIMILARITIES AND DIFFERENCES 842
I. Pchelin, N. Hudiakova, A. Shishkin, O. Vasilkova (Russia)

013 DYSLIPIDEMIA CONTROL IN TYPE 2 DIABETES: EXPERIENCE OF A PORTUGUESE CENTRE IN THE LAST DECADE 843
J. Sequeira Duarte, C. Tavares Bello, R. Fonseca, R. Ferreira, M. Oliveira, C. Saraiva, C. Gouveia, F. Santos, J. Azinheira, C. Vasconcelos (Portugal)

014 CORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONSCORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONS 844
M. Akhvlediani, M. Emukhvari, N. Zabakhidze, T. Kvantaliani (Georgia)

015 SERUM APOLIPOPROTEIN B48 CONCENTRATION IS HIGH IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE AND INCREASES AFTER ORAL GLUCOSE INGESTION IN PATIENTS WITH DIABETES MELLITUS 845
D. Masuda (Japan)

016 FASTING INSULIN LEVELS PREDICT FATAL CARDIOVASCULAR (CVD) EVENTS MORE ACCURATELY THAN ANY OTHER MARKER OF GLUCOSE METABOLISM. THE 10-YEAR FOLLOW-UP OF THE ATTICA STUDY (2002-2012) 846
E. Georgousopoulou, D. Panagiotakos, C. Chrysohoou, I. Skoumas, A. Laskaris, C. Stefanadis, **C. Pitsavos** (Greece)

017 ALTERATIONS OF METABOLIC PARAMETERS AND ANTIOXIDANT ENZYMES IN DIABETIC AGING FEMALE RAT BRAIN: NEUROPROTECTIVE ROLE OF METFORMIN 847
P. Kumar, N. Baquer (India)

018 CARDIO- AND NEPHROPROTECTIVE EFFECTS OF EZETIMIBE/ SIMVASTATIN COMBINATION IN TYPE 2 DIABETES MELLITUS 848
R. Sayfutdinov, O. Bugrova, O. Boeva (Russia)

019 ROLE OF NEW ADIPOKINES IN THE PATHOGENESIS OF ATHEROSCLEROSIS IN MORBIDLY OBESE SUBJECTS 849
A. Gentili, P. Trayhurn, S.Y. Alomar, M.S. Zaibi, S. De Vuono, M.A. Ricci, A. Alaeddin, D. Siepi, M. Boni, G. Vaudo, G. Lupattelli (Italy)

Board #

020 DOES TYPE 2 DIABETES ASSOCIATE ATHEROSCLEROTIC PROCESS? 850
D. Gabrielyan, L. Gabrielyan, A. Artemova, D. Zhokhov, M. Ivanov, P. Bondarenko, M. Ermina, A. Yadernaya (Russia)

021 SEVERITY OF ATHEROSCLEROTIC LESIONS AND FOOT SYNOVIAL TENDON COMPLEX INJURY AS FACTORS OF SEPSIS DEVELOPMENT IN PATIENTS WITH DIABETIC FOOT 851
E. Shalaeva, B. Janabaev, Q. Matmurotov, U. Kasimov, U. Pulatov, A. Bobabekov (Uzbekistan)

022 RELATIONSHIP BETWEEN CAROTID ARTERY INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH DIABETES 852
V. Vasilkova, T. Mokhort, E. Naumenko (Belarus)

023 SERUM LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED END PRODUCTS ARE ASSOCIATED WITH RESTENOSIS OCCURRENCE IN PATIENTS WITH DIABETES MELLITUS AFTER DRUG-ELUTING STENT IMPLANTATION 853
S. Kozlov, Z. Gabbasov, **S. Byazrova**, O. Saburova, V. Masenko (Russia)

024 EFFECT OF THE EDUCATION IN HOSPITALIZATION OF DIABETIC INDIVIDUALS FOR DIABETES CONTROL AND PREVENTION OF COMPLICATIONS AS A TOOL OF HOSPITAL AND CLINIC COOPERATION 854
T. Hayashi, K. Ina, M. Kuzuya (Japan)

025 BMI IS NOT AN IMPORTANT FACTOR FOR THE DEVELOPMENT OF SUBCLINICAL ATHEROSCLEROSIS IN ELDERLY DIABETIC SUBJECTS WITH METABOLIC SYNDROME 855
G. Yoshino, H. Yoshino, T. Ann, K. Kawakami, T. Akiyama, Y. Inoue (Japan)

026 RESVERATROL AND QUERCETIN PROTECT ISOLATED MOUSE CORPORA CAVERNOSA FROM IN VITRO-INDUCED DIABETIC ERECTILE DYSFUNCTION 856
C. Boydens, B. Pauwels, L. Vandendaele, **J. Van de Voorde** (Belgium)

027 DIABETIC VASCULAR DISEASE AND MATURITY-ONSET DIABETES OF THE YOUNG 857
J.M. Mafra, G. Gaspar, M. Bourbon (Portugal)

028 RELATIONSHIP BETWEEN 25 HYDROXY-VITAMIN D AND ANKLE BRACHIAL INDEX IN TYPE 2 DIABETIC PATIENTS 858
S. Lahiani, I. Oueslati, K. Bouzid, K. Khiari, S. Ghezaiel, H. Ben Ahmed, H. Belhadj Hassen, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia)

029 ANKLE BRACHIAL INDEX IN THE PREDICTION OF CORONARY HEART DISEASE IN TYPE 2 DIABETIC PATIENTS 859
K. Bouzid, H. Ben Ahmed, I. Oueslati, S. Lahiani, K. Khiari, N. Khessairi, J. Belagha, S. Ghezaiel, N. Ben Abdallah, H. Baccar, J. Abdelmoula (Tunisia)

030 CARDIOVASCULAR EFFECTS OF INCRETINS IN PATIENTS WITH TYPE 1 DIABETES 860
M. Arutyunova, A. Glazunova, S. Martynov, I. Klephortova, A. Ilyin, O. Manchenko, I. Ulianova, M. Shamkhalova, M. Shestakova (Russia)

Board #

031 SEVERITY OF CORONARY ARTERY STENOSIS IN PATIENTS WITH CRITICAL PERIPHERAL ARTERY DISEASE UNDERGOING HIGH AMPUTATION 861
E. Shalaeva, B. Janabaev, B. Babadjanov, Q. Matmurotov, U. Kasimov, U. Pulatov, A. Bobabekov (Uzbekistan)

032 HIGH PREVALENCE OF NON DIPPERS HYPERTENSIVE DIABETIC PATIENTS: THE ROLE OF AMBULATORY BLOOD PRESSURE MONITORING IN EFFECTIVE TREATMENT 862
V. Manea, C. Pop, L. Pop (Romania)

033 THE IMPACT OF BARIATRIC SURGERY ON CARDIOMETABOLIC PROFILE AND ADIPOKINE LEVELS 863
F. Reis de Azevedo Rabello, S. Santoro dos Santos Pereira, M.L. Corrêa-Giannella, D. Giannella Neto, E. Sant'Anna Melo, B. Caramelli (Brazil)

034 BARIATRIC SURGERY IMPROVES LIPID PROFILE IN MORBIDLY OBESE PATIENTS BY LOWERING LDL-C AND INCREASING HDL-C AND THE LARGE HDL-PARTICLES 864
C.A. Kjellmo, T. Nestvold, K.T. Lappegård, A. Hovland, M. Mathisen (Norway)

035 EFFECTS OF BARIATRIC SURGERY ON MICROVASCULAR DYSFUNCTION AND METABOLIC PROFILE IN MORBID OBESITY 865
M. Naeimi Kararoudi, G. Lupattelli, S. Ministrini, V. Bianconi, M.A. Ricci, S. De Vuono, P. Mariani, A. Moriconi, M. Boni, E. Mannarino, L. Pasqualini (Italy)

036 FACTORS DETERMINING AND STRATEGIES FOR IMPROVING TREATMENT ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELIITUS: DOCTOR, COMMUNITY PHARMACIST AND PATIENT PERSPECTIVES. ADHERI2 STUDY. 866
E. Labrador-Barba, A. Hernández-Mijares, M. Rodríguez-de Miguel, M.J. Faus-Dader, **M.L. Orera-Peña**, F.J. Alonso Moreno (Spain)

037 PREVALENCE OF 25 HYDROXY-VITAMIN D DEFICIENCY AND ITS CORRELATION WITH GLYCEMIC CONTROL IN DIABETIC PATIENTS 867
S. Lahiani, K. Bouzid, I. Oueslati, K. Khiari, N. Bchir, A. Melki, A. Bartkiz, H. Ben Ahmed, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia)

038 COMBINED DEVELOPMENT OF MACROVASCULAR AND CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES ASSOCIATED WITH POLYMORPHISM OF TNF-α GENE 868
O. Vikulova, **N. Lebedeva**, A. Zheleznyakova, A. Nikitin, M. Shamkhalova, M. Shestakova (Russia)

039 FEATURES OF VASCULAR REMODELING AND METABOLIC DISORDERS IN PATIENS WITH ESSENTIAL HYPERTENSION AND CONCOMITANT TYPE 2 DIABETES DEPENDING ON GENETIC POLYMORPHISM PPARγ2 869
A. Shalimova, A. Belovol, L. Bobronnikova, M. Kochueva (Ukraine)

040 NEUTROPHIL/LYMPHOCYTE RATIO AND VASCULAR INFLAMMATION IN OBESE WOMEN 870
B. Ilincic, M. Djeric, E. Stokic, R. Mijovic, S. Nikolic, Z. Stosic (Serbia)

Board #

041 GENE FOR CONNEXIN 37 IS ASSOCIATED WITH ATHERSCLEROTIC CHANGES IN WOMEN WITH DIABETES MELLITUS TYPE 2. 871
J. Piťha, P. Pithova, P. Stavek, J.A. Hubacek, O. Auzky, T. Neskudla, T. Pelikanova, M. Kvapil (Czech Republic)

042 LPPLA2 IN GESTATIONAL DIABETES MELLITUS - A PROTECTIVE SYSTEM FOR PLACENTA AND FETUS? 872
C. Wadsack (Austria)

043 CINNAMALDEHYDE ATTENUATES HIGH GLUCOSE-INDUCED OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION AS AN NRF2 ACTIVATOR 873
F. Wang, P. Wang, J. Wan, J. Hou, P. Zhou (China)

044 ASSOCIATION OF DIFFERENT CHOLESTEROL HOMEOSTASIS PATTERNS WITH ABDOMINAL OBESITY IN PATIENTS WITH CORONARY ARTERY DISEASE 874
S. Vladimirov, T. Gojković, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić, D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia)

045 ASSOCIATION BETWEEN NT-PROBNP AND VISCERAL ADIPOSITY 875
J. Suwa (Japan)

046 INCREASED INFLAMMATORY EFFECT ON MONOCYTES OF ELECTRONEGATIVE LDL AND DECREASED PROTECTION BY HDL FROM POORLY CONTROLLED TYPE 2 DIABETIC PATIENTS 876
M. Estruch-Alrich, I. Miñambres, J.L. Sánchez-Quesada, A. Pérez-Pérez, J. Ordóñez-Llanos, S. Benítez (Spain)

047 TRANSGENIC OVEREXPRESSION OF THE NRF2 AMELIORATES INSULIN RESISTANCE AND CHANGES FATTY ACIDS IN MEMBRANE PHOSPHOLIPIDS IN SPONTANEOUSLY HYPERTENSIVE RATS 877
I. Markova, H. Malinska, O. Oliyarnyk, L. Kazdova, M. Pravenec (Czech Republic)

048 HYPOLIPIDEMIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: ANALYSIS TYPICAL APPROACHES 878
I. Sapozhnikova, **E. Tarlovskaya** (Russia)

049 DIABETES AWARENESS AMONG CORONARY DISEASE PATIENTS DIFFERS SIGNIFICANTLY BETWEEN MEN AND WOMEN 879
C. Saely, D. Zanolin, A. Vonbank, **A. Leiherer**, H. Drexel (Austria)

050 INDIAN DIABETES RISK SCORE (IDRS) FOR TYPE 2 DIABETES MELLITUS SCREENING IN YOUNG ADULTS: EFFECT OF YOGA AND MEDITATION 880
V. Sharma (India)

051 ASSOCIATION OF RED CELL DISTRIBUTION WIDTH WITH CORONARY ARTERY DISEASE IN PATIENTS WITH DIABETES IN MULTI-ETHNIC SINGAPORE 881
C. Chiong, Y.J. Chee, X. Gao, R. Dalan (Singapore)

Board #

052 PREDICTORS OF 10-YEAR MORTALITY ARE DIFFERENT IN DIABETIC AND NON-DIABETIC PATIENTS WITH CHRONIC LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE 882
T. Mueller, F. Hinterreiter, W. Poelz, M. Haltmayer, B. Dieplinger (Austria)

053 HAND GRIP STRENGTH SIGNIFICANTLY PREDICTS CARDIOVASCULAR EVENT RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 883
P. Rein, C. Saely, A. Vonbank, D. Zanolin, **A. Leiherer**, H. Drexel (Austria)

054 TELMISARTAN ATTENUATES HYPERGLYCEMIA-AGGRAVATED VCAM-1 EXPRESSION AND MONOCYTES ADHESION IN TNFα-STIMULATED ENDOTHELIAL CELLS BY INCREASING GSK3β-SER9 PHOSPHORYLATION 884
D.H. Cho, J.E. Lee, K.H. Song (Republic of Korea)

055 GENETIC VARIANTS AND LIPID TRAITS IN THE HONG KONG CHINESE PATIENTS WITH TYPE 2 DIABETES 885
M. Hu, C. Tam, W.Y. So, J. Chan, **B. Tomlinson**, R. Ma (Hong Kong- China)

056 ANTIATHEROGENIC EFFECT OF METFORMIN IN TWO MOUSE LINES WITH DIFFERENT SUSCEPTIBILITY TO GLUCOSE INTOLERANCE 886
A. Asai, Y. Shuto, M. Nagao, T. Miyazawa, H. Sugihara, S. Oikawa (Japan)

Metabolic Abnormalities and Atherosclerosis: Adipose Tissue

057 EPICARDIAL FAT ,CARDIAC CHAMBERS AND CORONARY CALCIFICATION IN HYPERTENSIVE PATIENTS 887
A. Almusawi, H. Nafakhi, **H. Alnafakh**, A. Albasri (Iraq)

058 ADIPOKINES AND CYTOKINES SERUM LEVELS IN CHILDREN AND ADOLESCENTS AND ITS RELATIONSHIP WITH OBESITY 888
C. Rodriguez-Leal, M. Monsalvo-Hernando, I. Tinoco-Racero, E. Segura, N. Caro, M. Lagares Carballo, A. Perez, C. Perez, M. Rodriguez -Rosety, T. Pery, A. Mangas, **T. Rocio** (Spain)

059 INUCIBILITY OF TRIGLYCERIDE TURNOVER IN WHITE FAT – A MARKER OF LEAN PHENOTYPE 889
K. Adamcova, P. Flachs, P. Zouhar, K. Bardova, M. Svobodova, P. Janovska, A. Keenan, L. Madsen, J. Jones, K. Kristiansen, J. Kopecky (Czech Republic)

060 RELATIONSHIP OF ORPHAN RECEPTOR RORA AND CHOLESTEROL TRANSPORTERS ABCA1 AND ABCG1 EXPRESSION IN VISCERAL ADIPOSE TISSUE 890
V. Miroshnikova, A. Panteleeva, E. Demina, T. Usenko, E. Bazhenova, I. Semenova, O. Berkovich, E. Baranova, S. Pchelina (Russia)

Board #

061 EPICARDIAL FAT AND BMI RELATIONSHIPS WITH CORONARY ATHEROSCLEROTIC MARKERS IN PATIENTS WITH CORONARY CALCIUM SCORE >0: THE EFFECT OF AGE AND GENDER 891
A. Albasri, H. Nafakhi, A. Almusawi, **H. Alnafakh** (Iraq)

062 COLD-INDUCED CHANGES IN WHITE ADIPOSE TISSUE OF A/J AND C57BL/6J MICE 892
K. Bardova, P. Flachs, K. Adamcova, M. Svobodova, J. Kopecky (Czech Republic)

063 RELATION BETWEEN EPICARDIAL FAT TISSUE AND INFLAMMATORY MARKERS IN PREGNANTS WITH PREECLAMPSIA 893
H.A. Cakmak, B. Dincgez Cakmak, C. Yayla Abide, E. Inci Coskun, M. Erturk (Turkey)

064 LIPOSOMES FOR MICRORNA DELIVERY TO HUMAN ADIPOCYTES 894
G. Schratter, M. Karbiener, G. Almer, H. Mangge, M. Scheideler, R. Prassl (Austria)

065 OVARIECTOMY AFFECTS SUBSTRATE UTILIZATION IN BROWN ADIPOSE TISSUE AND INDUCES LIVER DICARBONYL STRESS IN RATS 895
J. Trnovska, H. Malinska, V. Skop, L. Kazdova (Czech Republic)

066 EFFECT OF BMI ON EPICARDIAL FAT ,CARDIAC CHAMBERS AND CORONARY CALCIFICATION CORRELATIONS 896
H. Alnafakh, H. Nafakhi, A. Albasri, A. Almusawi (Iraq)

Metabolic Abnormalities and Atherosclerosis: Kidney

067 ARE WE FOLLOWING THE GUIDELINES TO PREVENT CONTRAST INDUCED ACUTE KIDNEY INJURY? A CLINICAL AUDIT ON PATIENTS WITH CHRONIC KIDNEY DISEASE(CKD) UNDERGOING CORONARY ANGIOGRAM 897
V. Kanthasamy, S. Gill (United Kingdom)

068 EFFECT OF RECOMMENDED DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF KIDNEY DISEASE 898
C. Visinoni, A. Baragetti, I. Baragetti, C. Biazzi, K. Garlaschelli, L. Grigore, C. Pozzi, N. Giuseppe Danilo, C. Alberico L (Italy)

069 VERY MILD RENAL ENDOTHELIAL DAMAGE AND GLOMERULAR HYPERFILTRATION MAY PRECEDE INCIDENT HYPERTENSION IN THE JAPANESE GENERAL POPULATION: THE WATARI STUDY 899
M. Munakata, T. Hattori, S. Konno (Japan)

070 EARLY BIOMARKERS OF CHRONIC KIDNEY DISEASE IN DIABETIC PATIENTS 900
Z. Zuraeva, O. Mikhaleva, O. Vikulova, A. Ilyin, M. Shamkhalova, M. Shestakova (Russia)

Board #

071 CHOLESTEROL LEVELS AND GLOMERULAR FILTRATION RATE - IS THERE ANY ASSOCIATION? 901
J. Frutuoso, M. Bourbon (Portugal)

072 HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND CONTRAST-INDUCED ACUTE KIDNEY DISEASE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION 902
Y. Liu, L. Hua-Long, W. Dengxuan, Z. Jianbin, C. Shiqun, D. Chong-Yang, C. Ping-Yan, T. Ning, C. Ji-Yan (China)

073 EVALUATION OF THE ASSOCIATION OF PLASMA PENTRAXIN 3 LEVELS WITH TYPE 2 DIABETES AND DIABETIC NEPHROPATHY IN PATIENTS WITH RENAL FAILURE. 903
P. Miarka, **M. Walus-Miarka**, D. Fedak, M. Kuzniewski, A. Pietrzycka, E. Wieczorek-Surdacka, P. Jasik, B. Przepiorkowska-Hoyer, M. Kapusta, B. Idzior-Walus, W. Sulowicz (Poland)

074 CARDIOMETABOLIC RISK IN PATIENTS WITH CHRONIC RENAL DISEASE RELATED TO HYPERTRIGLYCERIDEMIA-LOW HDL -CHOLESTEROL ASSOCIATION 904
R. Toro, I. Tinoco, B. Ruiz-Estevez, C. Rodriguez-Leal, E. Segura, N. Caro, C. Perez, I. Garcia, D. Gomez -Villarejo, M. Rodriguez-Rosety, M. Lagares, A. Mangas (Spain)

075 CORRELATION OF THYROID STIMULATING HORMONE TO KIDNEY FUNCTION OF HEALTHY RESIDENTS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) 905
Y. Tanaka, M. Shimizu, N. Furusyo, Y. Kato, J. Hayashi (Japan)

076 EX VIVO ORGAN-PRESERVING SURGERY ON KIDNEYS FOR RENAL CELL CARCINOMA AND RENAL ARTERY ANEURYSMS 906
A. Teplov, A. Zotikov, A. Gritskevich, Z. Adyrkhaev, S. Pyanikin, I. Timina, I. Pyatkova, A. Kozhanova, **A. Ivandaev**, A. Pokrovsky (Russia)

077 ISHCEMIC PRECONDITIONING IN CONTRAST-INDUCED NEPHROPATHY PROPHYLACTICS IN PATIENTS WITH MILD CHRONIC KIDNEY FAILUTE 907
N. Zagidullin, A. Dunaeva, E. Sherbakova, S. Zagidullin (Russia)

078 CHARACTERISTICS OF LONG-TERM SURVIVORS IN A DIABETIC DIALYSIS PATIENT COLLECTIVE (4D STUDY) 908
S. Triebswetter (Germany)

079 EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE 909
I. Oueslati, S. Lahiani, K. Bouzid, K. Khiari, H. Kaaroud, E. Elfaleh, A. Bartkiz, N. Ben Abdallah, J. Abdelmoula (Tunisia)

080 ADULT RELAPSING FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MAINTAINED IN PARTIAL REMISSION FOLLOWING LIPOPROTEIN APHERESIS: CASE STUDY 910
A. Haikal, N. Sehar, L. Denney, P. Moriarty (USA)

Board #

081 SURGICAL TREATMENT OF ANEURYSM AND ARTERIOVENOUS FISTULA OF RENAL ARTERIES 911
A. Zotikov, A. Gritskevich, Z. Adyrkhaev, I. Timina, I. Pyatkova, V. Cigankov, A. Varava, A. Kozhanova, **A. Ivandaev**, M. Demina, A. Pokrovsky (Russia)

Metabolic Abnormalities and Atherosclerosis: NASH and Liver Abnormalities

082 APO-B48 IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALKOHOLIC FATTY LIVER DISEASE 912
B. Idzior-Waluś, M. Walus-Miarka, A. Trojak, P. Miarka, M. Kapusta (Poland)

083 ASSOCIATION BETWEEN SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1(MCP-1) LEVELS, INSULIN RESISTANCE AND SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS 913
N. Leach, S.C. Vesa, T. Alexescu, E. Dronca, V. Negrean, S. Dorel P. (Romania)

084 CARDIOMETABOLIC RISK FACTORS IN YOUNG V/S MIDDLE-AGED PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE 914
R. Ivanova, C. Marinova, A. Alexiev, L. Mateva (Bulgaria)

085 CONTINUOUS GRADING OF EARLY FIBROSIS IN NAFLD USING LABEL-FREE IMAGING 915
J. Pirhonen, J. Arola, S. Sädevirta, P. Luukkonen, S.M. Karppinen, T. Pihlajaniemi, A. Isomäki, M. Hukkanen, H. Yki-Järvinen, E. Ikonen (Finland)

086 THE ROLE OF VITAMIN D3 IN HIGH FAT DIET INDUCED FATTY LIVER DISEASE AND OBESITY. 916
R. Kheder, J. Hobkir, M. Browning, C. Stover (United Kingdom)

087 COMPARATIVE ANALYSIS OF SERUM LIPIDS IN PATIENTS WITH CHRONIC HEPATITIS C, NONALCOHOLIC FATTY LIVER DISEASE, AND HEALTHY CONTROLS 917
R. Ivanova, I. Valkov, C. Marinova, A. Alexiev, K. Antonov, D. Jelev, L. Mateva (Bulgaria)

088 LIPID-MODIFYING EFFECTS OF CURCUMIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE 918
Y. Panahi, P. Kianpour, R. Mohtashami, R. Jafari, **A. Sahebkar** (Iran)

089 EFFECTS OF BODY WEIGHT ON HEPATIC STEATOSIS IN ESSENTIAL HYPERTENSION 919
C.H. Chou, W.C. Tsai (Taiwan)

090 HEPATIC STEATOSIS IS INDEPENDENTLY ASSOCIATED WITH ERECTILE DYSFUNCTION: ONE MORE LINK BETWEEN THE LIVER AND CARDIOVASCULAR RISK? 920
F. Rached, A. Laurinavicius, R. Conceição, R. Santos (Brazil)

Board #

Dyslipidemias: Dyslipidemias, Screening and Treatment

Board #

Board #

111 FH CLINICS - TWO SHORT YEARS OF EXPERIENCE 941
I. Colaço, T. Vassalo, F. Faria, **D. Cruz**, J.L. Ducla Soares (Portugal)

112 ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) TARGETS WITH LOMITAPIDE, A MICROSOMAL TRANSFER PROTEIN INHIBITOR IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH) 942
H. Phillips, M. Ager, A. Hutchings (United Kingdom)

113 USING PERCENTILES TO DIAGNOSE FAMILIAL HYPERCHOLESTEROLEMIA IN PORTUGAL 943
A. Pereira, A.C. Alves, A.M. Medeiros, C. Mariano, M. Bourbon (Portugal)

114 LOW-DENSITY LIPOPROTEIN GENE SCORE TO IDENTIFY POLYGENIC FORMS OF FAMILIAL HYPERCHOLESTEROLEMIA IN A SPANISH POPULATION 944
J.M. Martín-Campos, J. Julve, N. Plana, R. Figueras, E. Esteve, M. Mauri, M. Bueno, A. Caixàs, E. Llargués, A. Vila, C. Morales, C. Soler, J. Argimón, J. Mayos, J. Grau, A. Zamora, L. Matas, L. Vila, L. Masana, **F. Blanco-Vaca** (Spain)

115 GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA IN IBEROAMERICAN COUNTRIES 945
J. Chora, P. Mata, R. Santos, A. Cárdenas Vázquez, M. Stoll, L. Schreier, A. Cuevas, A.C. Alves, A.M. Medeiros, L. Perez Isla, C. Jannes, A. Pereira, N. Dell'Oca, X. Reyes, P. Corral, V. Bañares, T. Magaña-Torres, C. Aguilar-Salinas, R. Alonso, **M. Bourbon** (Argentina)

116 IDENTIFICATION OF A NEW MUTATION IN THE N-TERMINAL REGION OF THE APOLIPOPROTEIN B GENE IN FAMILIAL HYPERCHOLESTEROLEMIA 946
M. Abifadel, S. Elbitar, Y. Ghaleb, G. Peloso, N. Stitziel, P. El Khoury, J.P. Rabes, V. Carreau, E. Bruckert, S. Kathiresan, M. Varret, C. Boileau (France)

117 PRELIMINARY RESULTS OF RUSSIAN FAMILIAL HYPERCHOLESTEROLEMIA REGISTRY 947
I.V. Sergienko, A.A. Ansheles, A.B. Popova, M.I. Voevoda, V.S. Gurevich, V.V. Henkel, V.V. Kukharchuk, **M.V. Ezhov** (Russia)

118 CLINICAL CHARACTERISTICS OF COMMON PCSK9 GAIN-OF-FUNCTION E32K VARIANT WITH HIGHER TG ELEVATION, AND DOUBLE HETEROZYGOTES WITH COMMON PCSK9 VARIANTS AND LDLR MUTATIONS 948
A. Nohara, M.A. Kawashiri, H. Tada, M. Yoshida, M. Mori, C. Nakanishi, K. Yagi, A. Inazu, M. Yamagishi, H. Mabuchi (Japan)

119 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (*PCSK9*) V4I VARIANT WITH *LDLR* MUTATIONS MODIFIES THE PHENOTYPE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 949
M. Hori, N. Ohta, A. Takahashi, M. Ogura, H. Makino, T. Tamanaha, Y. Miyamoto, M. Harada-Shiba (Japan)

120 HEREDITARY DEFECT OF APOLIPOPROTEIN B 100 - ANALYSIS OF GROUP OF PATIENTS TREATED WITH STANDARD PERORAL LIPID-LOWERING THERAPY IN ST. ANNE´S UNIVERSITY HOSPITAL BRNO 950
O. Kyselak, V. Soska (Czech Republic)

Board #

121 D374Y MUTATION IN THE PCSK-9 GENE IN TURKISH PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: LONG TERM FOLLOW-UP WITH GOOD CLINICAL COURSE 951
M. Kayıkcıoglu, E.K. Kocabas, A.T. VARDARLI, Z. EROGLU, H. DOKMEN, N. SALMAN, S. PAYZIN, L.H. CAN (Turkey)

122 ATHEROSCLEROSIS IN MONOGENIC FAMILIAL HYPERCHOLESTEROLEMIA VERSUS POLYGENIC HYPERCHOLESTEROLEMIA 952
M. Sharifi, A. Gallivan, D. Harvey, L. Ka Wah, J. Cooper, M. Futema, S.E. Humphries, D. Nair (United Kingdom)

123 FIRST PCSK-9 MUTANT PATIENT IN TURKEY 953
E. Kaya Kocabas, M. Kayikcioglu, A. Tetik Vardarli, Z. Eroglu (Turkey)

124 GENETIC EPIDEMIOLOGY OF ARH IN SICILY 954
R. Spina, V. Valenti, V. Ingrassia, M.P. La Spada, C. Scrimali, G. Misiano, D. Noto, O. Palesano, G.I. Altieri, V. Licata, F. Fayer, C.M. Barbagallo, A.B. Cefalù, M. Averna (Italy)

125 CONSTRUCTION OF A NEW FAMILIAL HYPERCHOLESTEROLAEMIA VARIANT DATA BASE: A SYSTEMATIC REVIEW FOR A 2015 UPDATE 955
S. Azevedo, J.R. Chora, A.C. Alves, A.M. Medeiros, **M. Bourbon** (Portugal)

126 MOLECULAR BASIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN POLAND – UPDATE FROM THE POLISH NATIONAL CENTRE OF DIAGNOSTICS AND TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA 956
M. Chmara, M. Zuk, A. Mickiewicz, A. Brandt, K. Chlebus, J. Kubalska, J. Bautembach-Minkowska, M. Stroniawska-Woźniak, M. Bednarska-Makaruk, L. Kłosiewicz-Latoszek, A. Rynkiewicz, M. Mysliwiec, M. Gruchala, J. Limon, B. Wasag (Poland)

127 MORTALITY OF CARDIOVASCULAR DISEASE IN PATIENTS WITH GENETICALLY VERIFIED FAMILIAL HYPERCHOLESTEROLEMIA 957
K. Retterstøl, J. Igland, L. Ose, K.B. Holven, T.P. Leren, M.B. Veierød, L. Mundal (Norway)

128 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) IN CHILDREN: AN ITALIAN EXPERIENCE 958
F. Guaraldi, M.D. Di Taranto, C. Giacobbe, G. Fortunato, O. Guardamagna (Italy)

129 GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN MEXICO 959
A. Vazquez Cardenas, M.T. Magaña Torres, Y. Sanchez Lopez, T. Hernandez Flores, A.G. Colima Fausto, J.R. González Garcia, F. Escalante, D. Gonzalez Marines, C. Aguilar Salinas, M. Bourbon (Mexico)

130 35 YEARS OF EXPERIENCE WITH CHILDREN AFFECTED WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): A CASE SERIES OF NINE PATIENTS 960
K. Widhalm, K. Derfler, G. Kostner, O. Helk (Austria)

Board #

131 PROGRAM STRATEGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA IN URUGUAY 961
M. Stoll, X. Reyes, N. Dell'Oca, F. Machado, A. Ressia, G. Fernandez, Zelarayán M(1) (Uruguay)

132 EFFECT OF APOE GENOTYPE ON LDL CHOLESTEROL LEVELS IN FH AND FDB PATIENTS: IS THERE SEX-SPECIFICALLY PROTECTIVE GENOTYPE? 962
L. Schwarzova, A. Horinek, J. Hubacek, M. Vrablik, T. Freiberger, L. Tichy, H. Vaverkova, R. Ceska (Czech Republic)

133 GENETIC AND PHENOTYPIC CHARACTERIZATION OF LDL-RECEPTOR IN PATIENTS WITH A CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA: TWO NOVEL MUTATIONS 963
C. Pavanello, C. Tarlarini, S. Penco, L. Calabresi, S. Castelnuovo, G. Mombelli, C. Sirtori (Italy)

134 THE R46L POLYMORPHISM OF PCSK9 GENE AND LIPID PROFILE IN CAUCASIAN POPULATION OF RUSSIA 964
K. Astrakova, E. Shakhtshneider, D. Ivanoshchuk, Y. Ragino, S. Astrakov, M. Voevoda (Russia)

135 FAMILIAL HYPERCHOLESTEROLAEMIA IN PRIMARY CARE: AWARENESS, KNOWLEDGE AND PRACTICES AMONG PRIMARY CARE DOCTORS IN MALAYSIA 965
A.S. Ramli, **N.A. Mohd Mokhsin**, S. Abdul Razak, M. Md Yasin, Z. Ismail, N.A. Mohd Kasim, T. Rahman, H. Nawawi (Malaysia)

136 PERCEPTIONS ON HEALTH COMMUNICATION, SYMPTOMS AND CAUSES IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA TREATED IN SPECIALIST CLINICS 966
N.A. Mohd Mokhsin, S. Abdul Razak, A.S. Ramli, M. Md Yasin, N.A. Mohd Kasim, S.S. Kasim, T. Rahman, H. Nawawi (Malaysia)

137 CARDIOVASCULAR DISEASE RESEARCH BY USING DATA FROM ELECTRONIC HEALTH RECORDS 967
L. Majnaric, S. Sabanovic (Croatia)

138 LDL APHERESIS IN CHILDREN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A CASE SERIES 968
I. Luirink, A. Wiegman, B. Hutten, J. Groothoff (Netherlands)

139 EVALUATION OF PLASMA-FED LIPID APHERESIS IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA. 969
P. Downie, G. Bayly, L. Hart, S. Douglas, J. Griffin (United Kingdom)

140 LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - FIRST EXPERIENCES IN CLINICAL PRACTICE 970
A. Vogt (Germany)

Board #

141 ANALYSIS OF CANDIDATE SINGLE NUCLEOTIDE VARIATIONS ASSOCIATED WITH POLYGENIC HYPERCHOLESTEROLEMIA IN FAMILIES WITH THE CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA 971
I. Lamiquiz Moneo, M.R. Perez-Ruiz, E. Jarauta, M.T. Tejedor, L. Baila-Rueda, A.M. Bea, R. Mateo-Gallego, A. Cenarro, F. Civeira (Spain)

142 STUDY OF *APOB* MUTATIONS AND FAMILIAL HYPERCHOLESTEROLEMIA PHENOTYPES 972
J. Bassani Borges, G. Medeiros Bastos, T.K. Almendros Afonso, E. Da Silva Rodrigues, H. Strelow Thurow, T. Dominguez Crespo Hirata, **A. Arpad Faludi**, R. Marques Gonçalves, R. Dominguez Crespo Hirata, M. Hiroyuki Hirata (Brazil)

143 FUNCTIONAL ANALYSIS OF MUTATIONS LOCATED IN THE LDL RECEPTOR SIGNAL SEQUENCE CODING REGION 973
T. Freiberger, J. Pavlouskova, K. Reblova, L. Tichy, L. Fajkusova (Czech Republic)

144 ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES 974
M.L. Hartgers, J. Besseling, G.K. Hovingh (Netherlands)

145 CARDIOVASCULAR DISEASE IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS ON STATIN TREATMENT 975
V. Marco-Benedi, S. Perez-Calahorra, N. Plana, J.C. Pedro-Botet, J. Ascaso, C. Lahoz, F. Almagro, E. Ros, A. Brea, M. Suarez-Tembra, R.M. Sanchez-Hernández, A. Vila Belmonte, F. Civeira (Spain)

146 LONG-TERM TREATMENT WITH EVOLOCUMAB HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: RESULTS FROM THE TRIAL ASSESSING LONG-TERM USE OF PCSK9 INHIBITION IN SUBJECTS WITH GENETIC LDL DISORDERS (TAUSSIG) 976
E.A. Stein, T. Sampietro, R. Santos, M. Harada-Shiba, E. Bruckert, D. Blom, G.K. Hovingh, P. Couture, V. Blaha, M. Farnier, O. Descamps, H. Soran, S. Kasichayanula, J. Gibbs, C. Kurtz, L. Tang, N. Honarpour, S.M. Wasserman, **F.J. Raal** (South Africa)

147 LIPID-LOWERING THERAPY AND TARGET ATTAINMENT AMONG HYPELIPIDEMIC INDIVIDUALS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: EVIDENCE FROM A LIPID CLINIC 977
F. Barkas, E. Klouras, T. Dimitriou, G. Liamis, E. Liberopoulos, M. Elisaf (Greece)

148 INCIDENCE OF CARDIOVASCULAR DISEASE AMONG INDIVIDUALS WITH AND WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA ATTENDING A LIPID CLINIC 978
F. Barkas, E. Klouras, T. Dimitriou, G. Liamis, M. Elisaf, E. Liberopoulos (Greece)

Board #

149 CHANGES IN PLASMA LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH POLYGENIC HYPERCHOLESTEROLEMIA, FAMILIAL COMBINED HYPERLIPOPROTEINEMIA, AND FAMILIAL HYPERCHOLESTEROLEMIA AFTER ATORVASTATIN 979
B. Muinjonov, E. Giyazitdinova (Uzbekistan)

150 PREVALENCE OF DYSLIPIDAEMIA AMONG ADULTS AGED 50-64 YEARS IN IRELAND: THE IRISH LONGITUDINAL STUDY ON AGEING (TILDA) 980
C. Murphy, E. Shelley, T. Fahey, R.A. Kenny (Ireland)

151 IMPACT OF SOCIAL AND CLINICAL PARAMETERS ON NON-HDL CHOLESTEROL IN SCHOOL CHILDREN 981
A. Pereira, F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)

152 STATIN PRESCRIPTION PATTERNS, ADHERENCE, AND ATTAINMENT OF CHOLESTEROL TREATMENT GOALS IN CLINICAL CARE IN ELDERLY WITH HYPERLIPIDEMIA AND CORONARY HEART DISEASE: A RUSSIAN OBSERVATION STUDY 982
M. Bubnova, D. Aronov (Russia)

153 STUDY OF THE PREVALENCE OF DYSLIPIDEMIAS IN CHILDREN AND ADOLESCENTS ATTENDED BY THE NATIONAL HEALTH SYSTEM IN CAMPINAS - SÃO PAULO - BRAZIL 983
E. De Faria, E.I. Gomes, V.H. Zago, E.S. Parra, N.B. Panzoldo, G. Redezuk (Brazil)

154 CLINICAL MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID-APHERESIS IN TURKEY: FIRST RESULTS OF A NATION-WIDE SURVEY (A-HIT REGISTRY) 984
M. Kayıkcıoglu, L. Tokgozoglu, S. Pirildar, M. Yilmaz, L. Kaynar, M. Aktan, R. Durmus, A. Temizhan, O. Ozcebe, T. Akyol, H. Okutan, S. Sag, B. Altunkeser, M. Yenercag, E. Kurtoglu, S. Demircioglu, O. Salcioglu, M. Demir, H. Yilmaz, O. (Turkey)

155 FUNCTIONALLY CHARACTERIZATION OF LDLR MISSENSE ALTERATIONS FOUND IN CLINICAL FH PATIENTS 985
A.C. Alves, S. Azevedo, A. Benito-Vicente, A. Etxebarria, P. Barros, A.M. Medeiros, C. Martin, M. Bourbon (Portugal)

156 GENETIC VARIANTS OF PCSK9 GENE IN CORONARY ARTERY DISEASE AMONG SOUTH INDIAN PATIENTS 986
M. Ganesan (India)

157 FAMILIAL COMBINED HYPERLIPIDEMIA IN CHILDREN: BIOCHEMICAL CHARACTERIZATION IN PEDIATRIC AGE 987
F. Abello, E. Barabesi, A. Bosusco, O. Guardamagna, D. Vianello, A. Zambon (Italy)

Board #

158 VALIDATION OF SERUM APOB/CHOLESTEROL AND APOB/NON-HDL CHOLESTEROL RATIOS AS SCREENING TESTS FOR TYPE III HYPERLIPIDAEMIA 988
C. Boot, **E. Holmes**, D. Neely, F. Jenkinson, H. Datta, L. Hughes (United Kingdom)

159 TREATMENT OF THERAPY-REFRACTORY HYPERCHOLESTEROLEMIA WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 ANTIBODIES (PCSK9-I) IN CARDIOVASCULAR HIGH RISK PATIENTS - EFFECTIVITY AND SAFETY IN CLINICAL ROUTINE 989
T. Hollstein, D. Spira, N. Buchmann, N. El-Zidy Ibrahim, T. Bobbert, E. Steinhagen-Thiessen, U. Kassner (Germany)

160 SEARCHING FOR THE *ELUSIVE* FAMILIAL HYPERCHOLESTEROLAEMIA GENE MUTATIONS FOR INDEX PATIENTS - USING HISTORICAL LABORATORY LDL-C RESULTS IN PRIMARY CARE. A NORTH WALES EXPERIENCE. 990
Y.P. Teoh, R. Gingell (United Kingdom)

161 HIGH TRIGLYCERIDES, LOW HDL CHOLESTEROL AND A LOW LDL CHOLESTEROL PER APOLIPOPROTEIN B RATIO PREDICT INCIDENT DIABETES IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE 991
C. Saely, P. Rein, A. Vonbank, D. Zanolin, **A. Leiherer**, A. Muendlein, H. Drexel (Austria)

162 CARDIOVASCULAR COMORBIDITIES LINKED TO OBESITY IN FORMER ATHLETES FROM TRANSYLVANIA 992
V. Negrean, O. Orășan, T. Alexescu, N. Leach, I. Para, M. Milaciu (Romania)

163 E_LIPID: CHARACTERIZATION OF THE LIPID PROFILE IN THE PORTUGUESE POPULATION 993
C. Mariano, M. Antunes, Q. Rato, **M. Bourbon** (Portugal)

164 SEVERE HYPERCHOLESTEROLEMIA IN HOSPITAL PRACTICE-SINGLE CENTRE EXPERIENCE IN SINGAPORE 994
S. Dissanayake, S.P. Li Tin, J.F. Choi Wan, M.S. Wong, S. Tavintharan (Singapore)

165 HIGH PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN ARGENTINA: RESULTS OF THE FIRST DETECTION PROGRAM. 995
P. Corral, G.I. López, A. Cristaldi, J.C. Tuseddo, L. Cacciagiú, G. Berg, L. Schreier (Argentina)

166 NETWORK ANALYSIS APPROACH TO FIND NEW CANDIDATE GENES AND PATHWAYS INVOLVED IN THE PATHOPHYSIOLOGY OF FAMILIAL HYPERCHOLESTEROLEMIA 996
N. Rossi, **M. Bourbon**, F. Enguita (Portugal)

167 PARAMETRES OF ARTERIAL REMODELING IN FAMILAL HYPERCHOLESTEROLEMIA PATIENTS 997
V. Korneva, T. Kuznettsova (Russia)

Board #

Dyslipidemias: Treatment

168 EFFECTS OF DIFFERENT DOSES OF ATORVASTATIN ON PLATELET AGGREGATION, ENDOTHELIAL FUNCTION, LEVELS OF SEROTONIN, ANGIOTENSIN II, BLOOD PRESSURE, CEREBRAL BLOOD FLOW IN HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA 998
M. Bubnova, D. Aronov, E. Semenova (Russia)

169 EFFECT OF STATIN ON FASTING BLOOD SUGAR LEVEL; COMPARISONS OF KINDS OF STATINS AND ASSOCIATED PARAMETERS 999
C.J. Kim, M.A. Kim (Republic of Korea)

170 DIFFERENT ROLE OF ACHIEVED LDL-CHOLESTEROL AND HS-CRP LEVEL IN FUTURE CARDIOVASCULAR DISEASE OUTCOMES IN NON-PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH ONGOING STATIN THERAPY OF MODERATE INTENSITY 1000
M.H. Hyun, E. Lee, B.G. Choi, H.S. Seo, J.O. Na, C.U. Choi, H.E. Lim, J.W. Kim, S.W. Rha, E.J. Kim, C.G. Park, D.J. Oh (Republic of Korea)

171 COMPARISON THE EFFECT ON FASTING BLOOD SUGAR BETWEEN ATORVASTATIN, ROUSUVASTATIN AND PITAVASTATIN IN KOREAN POPULATION 1001
Y.S. Lee, Y.W. Park, S.P. Hong, J.B. Lee, J.K. Ryu, J.Y. Choi, K.S. Kim (Republic of Korea)

172 COMPARISON OF LIPID MANAGEMENT BETWEEN ELDERLY AND NON-ELDERLY PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE (CHD) 1002
N. Kume, R. Shimizu, H. Torii, D. Yasuda, Y. Hiraoka, T. Hashida (Japan)

173 STATIN ESCAPE PHENOMENON: DOES IT REALLY EXIST? EVIDENCE FROM A LIPID CLINIC 1003
F. Barkas, E. Klouras, T. Dimitriou, M. Elisaf, E. Liberopoulos (Greece)

174 EFFECTS OF LOW-DOSE VS. MODERATE-DOSE PITAVASTATIN ON LONG-TERM CARDIOVASCULAR EVENTS IN KOREAN PATIENTS WITH CORONARY ARTERY DISEASE REQUIRING STENT IMPLANTATION: PROSPECTIVE, 3-YEAR FOLLOW-UP TRIAL 1004
D.S. Lim, H.J. Kim, Y.C. Kim, B.G. Kang, S.M. Jeon, **S.J. Hong**, J.Y. Cho, S.H. Lee, H.J. Joo, J.H. Park, C.W. Yu (Republic of Korea)

175 GENE VARIANTS ASSOCIATED WITH STATIN-INDUCED MYOPATHY: DETERMINATION IN A CZECH POPULATION 1005
J. Petrkova, L. Kocourkova, V. Zizkova, M. Taborsky, M. Petrek (Czech Republic)

176 THE SAFETY OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE 1006
Y.K. Cho (Republic of Korea)

177 ONE YEAR PERSISTENCE OF ATORVASTATIN AND AMLODIPINE FIXED DOSE COMBINATION VERSUS ATORVASTATIN THERAPY 1007
G. Simonyi, F. Tamás (Hungary)

Board #

178 IMPACT OF FENOFIBRATE THERAPY ON ENDOTHELIAL FUNCTION IN THE SUBJECTS WITH METABOLIC SYNDROME 1008
K. Kotula-Horowitz, M. Janczura, T. Iwaniec, R. Rosa, J. Zagjewski, **T. Domagala** (Poland)

179 THE EFFICACY OF EVOLOCUMAB AND OTHER LIPID-LOWERING THERAPIES (LLT) FOR THE MANAGEMENT OF LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA) 1009
G. Worthy, S.R. Gandra, I. Bridges, G. Worth, R. Dent, L.I. Cheng, C. Forbes, S. Deshpande, J. Ross, J. Kleijnen, **E.S.G. Stroes** (Netherlands)

180 EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF OLMESARTAN MEDOXOMIL AND ROSUVASTATIN IN KOREAN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA 1010
S.H. Kim, H.L. Lee, W.H. Lim, H.L. Kim, J.B. Seo, W.Y. Chung, J.H. Zo, M.A. Kim, H.S. Kim (Republic of Korea)

181 THE EFFECTS OF ALIROCUMAB ON LDL CHOLESTEROL LEVELS IN PATIENTS RECEIVING STATINS 1011
H. Habibinejad (Iran)

182 TESTOSTERONE UNDECANOATE IMPROVES LIPID PROFILE IN PATIENTS WITH TYPE 1 DIABETES AND HYPOGONADOTROPHIC HYPOGONADISM. RESULTS FROM TEST-T1D RANDOMIZED CLINICAL TRIAL. 1012
J.J. Chillarón, **J. Pedro-Botet**, M. Fernández-Miró, M. Albareda, L. Vila, D. Benaiges, J.A. Flores Le-Roux (Spain)

183 EFFECT OF TOCILIZUMAB ON CARDIAC BIOMARKERS HIGH-SENSITIVITY TROPONIN T AND NT-PROBNP IN RHEUMATOID ARTHRITIS: POST HOC ANALYSIS OF A RANDOMISED CONTROLLED TRIAL 1013
P. Welsh, K. Tuckwell, N. Sattar (United Kingdom)

184 CCAAT/ENHANCER BINDING PROTEIN DELTA CONTRIBUTES TO AN EARLIER PHASE OF PRO-INFLAMMATORY RESPONSE IN DOXORUBICIN RELATED CARDIOMYOPATHY 1014
J.T. Wen, **L.W. Hsu**, P.Y. Liu (Taiwan)

185 EFFECT OF ENDOTOXIN AND NATURAL CAROTENOIDS ON AORTIC ENDOTHELIAL TIGHT JUNCTIONS´ OCCLUDIN EXPRESSION 1015
J. Krizak, K. Frimmel, E. Breierova, R. Sotnikova, J. Navarova, I. Bernatova, L. Okruhlicova (Slovakia)

186 EFFECT OF DHA/EPA SUPPLEMENTATION ON ENDOTHELIAL DAMAGE MARKERS. THE BIOCLAIMS STUDY 1016
J. Góralska, M. Malczewska-Malec, U. Razny, A. Zdzienicka, A. Gruca, A. Chabowski, M. Sanak, A. Dembinska-Kiec, B. Solnica (Poland)

Board #

187 IN VITRO PHARMACOLOGICAL EVALUATION OF MULTITARGET THROMBOXANE PROSTANOID RECEPTOR/ COX-2 AGENTS: A POSSIBLE STRATEGY TO SOLVE THE CARDIOVASCULAR ISSUES OF COXIBS 1017
M. Hoxha, C. Buccellati, V. Capra, C. Cena, A. Sala, M. Bertinaria, G. Rovati (Italy)

188 THE USE OF N-ACETYLCYSTEINE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIASTOLIC LEFT VENTRICULAR DYSFUNCTION, IN ACCORDANCE WITH THE LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN. 1018
A. Nizomov, B. Toshev, J. Berdiqulov (Uzbekistan)

189 THREE TIMES A WEEK AND FIVE TIMES A WEEK WALKING EXERCISE FREQUENCIES ARE EQUALLY EFFECTIVE IN IMPROVING WALKING CAPACITY IN EXPERIMENTAL PERIPHERAL ARTERY DISEASE 1019
M. Pellegrin, J. Lavier, K. Bouzourene, L. Mazzolai (Switzerland)

190 SONODYNAMIC THERAPY OF THE RABBIT CAROTID ARTERY NEOINTIMAL HYPERPLASIA USING LOW- LEVEL COMBINED ELECTROHYDRAULIC SHOCK WAVES AND ULTRASONIC WAVES ACCOMPANIED BY PROTOPORPHYRIN IX ADMINISTRATION 1020
H. Mehrad, B. Mahvi (Iran)

191 A NOVEL COMPOUND (D-47), THE HYPOLIPIDEMIC EFFECTS AND THE MECHANISM IN AN ANIMAL MODEL OF HYPERCHOLESTEROLEMIA (WHHLMI RABBIT) 1021
S. Tamura, Y. Yu, T. Nakagawa, R. Nagasaka, T. Tsunoda, K. Ogawa, M.O. Tori, T. Koike, **M. Shiomi** (Japan)

192 NOVEL ROLE OF BERBERINE IN LOX1-MEDIATED ENDOTHELIAL DYSFUNCTION 1022
A. Cicero, **C. Caliceti**, P. Rizzo, R. Ferrari, F. Fortini, G. Aquila, J. Shehu, E. Leoncini, L. Zambonin, B. Rizzo, M. Guardigli, A. Roda, S. Hrelia (Italy)

193 EXPERIENCE OF TAKAYASU`S ARTERITIS SURGICAL TREATMENT 1023
A. Pokrovskiy, A. Zotikov, **V. Kulbak**, E. Burtceva (Russia)

194 DOWN-REGULATION OF THE CHEMOKINE (C-C MOTIF) RECEPTOR 9 (CCR9) CONTRIBUTES TO THE ATHEROSCLEROSIS-LOWERING ACTIVITY OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR CAPTOPRIL 1024
J. Abd Alla, A. Langer, U. Quitterer (Switzerland)

195 INCIDENCE OF VALVULAR HEART DISEASE AFTER COMBINATION OF DOPAMIN AGONISTS WITH STATINS 1025
E. Giyazitdinova, B. Muinjonov, G. Rakhimbayeva, Y. Musayeva (Uzbekistan)

196 HYPOLIPIDEMIC EFFECT OF RHEOPHERESIS AND RESTORATION OF RETINAL PHOTORECEPTOR JUNCTION 1026
M. Blaha, E. Rencova, H. Langrova, M. Lanska, A. Stepanov, **V. Blaha** (Czech Republic)

Board #

197 REMNANT CHOLESTEROL REDUCTION BY EZETIMIBE AND SIMVASTATIN DOES NOT AFFECT BILIARY LIPID CONCENTRATION IN GALLSTONE PATIENTS 1027
M. Eriksson, O. Ahmed, U. Gustafsson, K. Littman, S. Sahlin, C. Pramfalk, P. Parini (Sweden)

198 CROSS-CLASS SERINE PROTEASE INHIBITOR SERP-2 BLOCKS LIVER ISCHEMIA REPERFUSION INJURY 1028
S. Ambadapadi, H. Chen, J. Fuentes, S. Morshed, J. Davids, B. Marques, A. Lucas (USA)

199 STATIN THERAPY REDUCES PHOSPATE LEVELS IN DIALYSIS PATIENTS: RESULTS FROM THE EPIDEMIOLOGICAL VITAMIN K ITALIAN STUDY (VIKI STUDY) 1029
C. Panzavolta, L. Benvegnù, A. Aghi, M. Biolo, S. Giannini, M. Noale, G. Tripepi, M. Plebani, N. Veronese, P. Messa, M. Rossini, M. Gallieni, S. Sella, F. Fabris, E. Manzato, L. Previato, S. Bertocco, A. Zambon, M. Fusaro, S. Zambon (Italy)

Dyslipidemias: Coagulation

200 PLASMA ADVANCED OXIDIZED PROTEIN PRODUCTS PROMOTE PLATELET-ENDOTHELIAL CROSSTALK AND ENDOTHELIAL TISSUE FACTOR EXPRESSION 1030
G. Marsche, A. Heinemann, L. Pasterk (Austria)

201 PLASMA FIBRINOGEN IS AN IMPORTANT CLINICAL MARKER FOR PROSPECTIVE ALL-CAUSE MORTALITY IN THE LIFEWAYS CROSS-GENERATION COHORT STUDY 1031
R. Somerville, K. Viljoen, S. McKey, A. Shrivastava, J. Mehegan, R. Segurado, C. Murrin, C. Kelleher (Ireland)

202 ADJUSTING FOR THE INFLUENCE OF THE HEMATOCRIT LEVEL IMPROVES THE PROGNOSTIC VALUE OF THE VERIFYNOW P2Y12 ASSAY 1032
J.W. Suh, Y.G. Kim, Y.S. Cho, T.J. Youn, I.H. Chae (Republic of Korea)

203 PLATELET-ASSOCIATED TISSUE FACTOR AS A NEW MECHANISM INVOLVED IN THE PROTHROMBOTIC PHENOTYPE OF STABLE ANGINA PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) 1033
L. Rossetti, P. Canzano, M. Mapelli, D. Trabattoni, F. Santilli, G. Davì, A. Lualdi, E. Tremoli, **M. Camera** (Italy)

204 IMPACT OF TYPE-2 DIABETES MELLITUS (T2DM) ON THE PLATELET TRANSCRIPTOME PROFILE IN STABLE ANGINA (SA) PATIENTS 1034
L. Rossetti, M. Brambilla, P. Canzano, L. Piacentini, E. Bono, M. Mapelli, D. Trabattoni, A. Lualdi, G. Colombo, E. Tremoli, **M. Camera** (Italy)

Board #

205 NTEGRIN αIIBβ3 AS POTENTIAL BIOMARKER OF HIGH ON-TREATMENT PLATELET REACTIVITY TO CLOPIDOGREL IN PATIENTS WITH AN ACUTE CORONARY SYNDROME 1035
A. Gkourogianni, M. Tsoumani, I. Ntallas, D. Tsoukatos, I. Goudevenos, A. Tselepis (Greece)

206 THE COMBINATION OF N-ACETYLCYSTEINE WITH FIBRINOLYTIC THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME. 1036
A. Nizomov (Uzbekistan)

207 FEASIBILITY OF TARGETING THROMBUS USING FOCUSED-ELECTROHYDRAULIC SHOCK WAVES ACCOMPANIED BY SIMULTANEOUSLY B-MODE ULTRASOUND IMAGING IN THE RABBIT MODEL OF COMMON CAROTID ARTERY ATHEROTHROMBOTIC OCCLUSION 1037
H. Mehrad (Iran)

208 NON-INVASIVE TREATMENT OF THE RABBIT CAROTID ARTERY ATHEROTHROMBOTIC OCCLUSION USING COMBINED ND:YAG LASER AND PULSED- FOCUSED ULTRASOUND ACCOMPANIED BY THROMBOLYTIC AGENT ADMINISTRATION 1038
H. Mehrad, A. Akrami (Iran)

209 PROTHROMBOTIC PHENOTYPE IN HYPERTENSION: CONTRIBUTION OF MEGAKARYOCYTE- AND PLATELET-ASSOCIATED TISSUE FACTOR EXPRESSION IN STROKE-PRONE RATS 1039
M. Brambilla, P. Gelosa, L. Rossetti, L. Castiglioni, P. Canzano, S. Luigi, E. Tremoli, **M. Camera** (Italy)

210 SILENCING ANTICOAGULANT PROTEIN C CAUSES SPONTANEOUS ATHEROTHROMBOSIS IN APOE KNOCKOUT MICE 1040
A.B. Ouweneel, M. Heestermans, R.A.F. Verwilligen, M. Van Eck, B.J.M. Van Vlijmen (Netherlands)

Dyslipidemias: Endothelial Dysfunction

211 LOW-FLOW MEDIATED CONSTRICTION INCORPORATED INDICES AS INDICATORS OF CARDIOVASCULAR RISK IN SMOKERS 1041
N. Norioka, Y. Takemoto, M. Kobayashi, A. Makuuchi, J. Yoshikawa, Y. Yamazaki, Y. Kamiyama, T. Shuto, M. Yoshiyama (Japan)

212 ENDOTHELIAL SHEAR RATE IN PATIENTS WITH CAROTID ATHEROSCLEROSIS 1042
V. Genkel, A. Salashenko, O. Alekseeva, M. Denisenko, I. Shaposhnik (Russia)

213 ANALYSIS OF BIOLOGICAL, STRUCTURAL AND FUNCTIONAL MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION, TREATED WITH ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 1043
M. Andor, V. Buda, C. Cristescu, M. Voicu, L. Suciu, C. Muntean, M. Tomescu (Romania)

Board #

214 INFLUENCE OF CARBOHYDRATE METABOLISM DISORDERS ON STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE LARGE ARTERIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 1044
N. Burko, L. Salyamova, Y. Tomashevskaya, V. Oleynikov (Russia)

215 THE PROGNOSTIC IMPORTANCE OF ENDOTHELIAL DYSFUNCTION IN METABOLIC SYNDROME WITH CORONARY ARTERY DISEASE 1045
T. Ueda (Japan)

216 VASCULAR AGE - A HELPFUL TOOL IN ASSESSING CARDIOVASCULAR RISK 1046
A. Dumitrescu, S. Mosteoru, L. Gaita, R. Pleava, D. Gaita (Romania)

217 REMOTE ISCHEMIC PRECONDITIONING AND ENDOTHELIAL FUNCTION IN HEALTHY VOLUNTEERS 1047
N. Ryazankina, M. Vagida, V. Manchurov, A. Lebedeva, A. Arakelyan, J.C. Grivel, L. Margolis, E. Vasilieva, A. Shpektor (Russia)

218 THE ENDOTHELIAL FUNCTION IMPROVEMENT ON STATIN THERAPY IN TYPE 2 DIABETES ASSOCIATED WITH TNFα G(308)A AND G(238)A POLYMORPHIC MARKERS 1048
N. Lebedeva, O.K. Vikulova, A.G. Nikitin, M.S. Shamkhalova, M.V. Shestakova (Russia)

219 BENEFICIAL EFFECT OF AZILSARTAN AND AMLODIPINE ON ENDOTHELIAL FUNCTION IN HYPERTENSIVE PATIENTS 1049
T. Nishida, M. Ayaori, K. Shiotani, H. Uto-Kondo, M. Sasaki, T. Komatsu, Y. Endo, M. Ito, M. Ishizuka, M. Sakurada, K. Ikewaki (Japan)

220 CIRCULATING PROGENITOR CELLS IN HYPERTENSIVE SUBJECTS: EFFECTIVENESS OF A TREATMENT WITH OLMESARTAN IN IMPROVING CELL NUMBER AND MIRS PROFILE BESIDES EXPECTED PHARMACOLOGICAL EFFECTS 1050
G. Mandraffino, C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone, M.A. Sardo, A. Saitta (Italy)

Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation

221 A CASE OF SEVERE CHYLOMICRONAEMIA SYNDROME, IN A PATIENT WITH NORMAL LIPOPROTEIN LIPASE ACTIVITY, DUE TO A PREVIOUSLY UNIDENTIFIED MUTATION IN THE GPIHBP1 GENE 1051
P. Downie, G. Bayly (United Kingdom)

222 MOLECULAR ANALYSIS OF GENES INVOLVED IN LIPOPROTEIN LIPASE DEFICIENCY IN SLOVAK PATIENTS WITH FAMILIAL CHYLOMICRONEMIA 1052
D. Gabcova, D. Stanikova, M. Huckova, V. Bzduch, J. Stanik, I. Klimes, K. Raslova, D. Gasperikova (Slovakia)

Board #

223 DISSECTION OF CLINICAL AND GENE EXPRESSION SIGNATURES OF FAMILIAL VS MULTIFACTORIAL CHYLOMICRONEMIA 1053
D. Gaudet, D. Brisson, K. Tremblay (Canada)

224 A NOVEL HOMOZYGOUS MUTATION IN *GPD1* LEADING TO SEVERE HYPERTRIGLYCERIDEMIA 1054
J. Levels, R. Piña-Aguilar, J. Peter, G.M. Dallinga-Thie (Netherlands)

225 IDENTIFICATION AND CHARACTERIZATION OF TWO NOVEL MUTATIONS IN THE LPL GENE CAUSING TYPE I HYPERLIPOPROTEINEMIA 1055
P. Pingitore, S.M. Lepore, C. Pirazzi, R.M. Mancina, B.M. Motta, L. Valenti, K.E. Berge, K. Retterstøl, T.P. Leren, O. Wiklund, S. Romeo (Sweden)

226 STATINS UPREGULATE MICRORNA-122 IN HEPG2 CELLS 1056
A. Etxebarria, X. Moreno, A. Benito-Vicente, S. Jebari, U. Galicia, H. Ostolaza, C. Martin (Spain)

227 THE HYPERTRIGLYCERIDEMIC EFFECT OF APOC3 3'UTR VARIANT SST1 IS NOT MEDIATED BY A HEPATIC OR INTESTINAL MIRNA REGULATION 1057
M. Dancer, C. Marcais, C. Caussy, M. Di filippo, P. Moulin, S. Charrière (France)

228 PLASMA LIPOPROTEINS OF PATIENTS WITH GENETIC LAL DEFICIENCY ARE ENRICHED IN CHOLESTERYL ESTERS: RELEVANCE OF CHOLESTEROL ESTERIFICATION BY LCAT 1058
M. Gomaraschi, L. Arnaboldi, F. Abello, C. Pavanello, F. Zimetti, E. Favari, L. Calabresi, O. Guardamagna (Italy)

229 LYSOSOMAL ACID LIPASE DEFICIENCY IN GREECE: A RARE INBORN ERROR OF METABOLISM PRESENTING WITH DYSLIPIDAIMIA AND LIVER DISEASE 1059
E. Drogari, V. Mollaki, H. Christomanou, K. Stamatelopoulos, N. Manolaki (Greece)

230 WILL FAMILIAL HYPERCHOLESTEROLAEMIA COHORTS HIDE MANY MORE LISOSOMAL ACID LIPASE DEFICIENCY PATIENTS? 1060
J.R. Chora, A.C. Alves, A.M. Medeiros, C. Mariano, G. Loubarinhas, A. Guerra, H. Mansilha, M. Bourbon (Portugal)

231 SCREENING OF LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS WITH SEVERE DYSLIPIDEMIA AND PREMATURE CORONARY HEART DISEASE 1061
O. Azevedo, N. Marques, H. Antunes, P. Azevedo, M. Oliveira, D. Bento, J. Guedes, B. Marmelo, R. Faria, E. Correia (Portugal)

232 GENETIC VARIANTS OF ABO BLOOD GROUP WITH CORONARY ARTERY DISEASE AMONGST INDIANS 1062
P. Chawla, T. Ashavaid, C. Ponde, R. Rajani, A. Deshpande, R. Sawant (India)

233 GPER P.P16L POLYMORPHISM IS NOT ASSOCIATED WITH ALTERED LIPID PHENOTYPES AND CIMT PROGRESSION- A PLIC STUDY 1063
A. Dhyani, A. Baragetti, K. Garlaschelli, F. Pellegatta, L. Grigore, D. G.Norata, A.L. Catapano (Italy)

Board #

234 NFE2L2 RS2364723 CC GENOTYPE SIGNIFICANTLY INCREASED THE RISK OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY IN AN ARSENIASIS-ENDEMIC AREA IN TAIWAN 1064
T. Chia-Yin, C. Hung-Yi, H. Fang-I (Taiwan)

235 THE GG GENOTYPE OF VITAMIN D METABOLISM-RELATED GENE DHCR7 RS12785878 IS MORE PREVALENT IN THE INDIANS AND ASSOCIATED WITH HIGHER OXIDATIVE STRESS INDEX IN SINGAPORE 1065
R. Dalan, H. Liew, L.L. Goh, X. Gao, D. Chew, B.O. Boehm (Singapore)

236 ASSOCIATION OF THE HETEROPLASMY LEVEL OF MUTATION IN GENE *MT-CYB* WITH CAROTID ATHEROSCLEROSIS IN WOMEN 1066
V. Sinyov, M. Sazonova, M. Chicheva, N. Nikitina, I. Sobenin, **A. Orekhov** (Russia)

237 SINGLE NUCLEOTIDE POLYMORPHISMS AT THE HYDROXY-METHYL-GLUTARYL-COA REDUCTASE GENE LOCUS SIGNIFICANTLY PREDICT CARDIOVASCULAR EVENTS IN CORONARY PATIENTS WITH TYPE 2 DIABETES 1067
A. Leiherer, A. Muendlein, C. Saely, E. Kinz, P. Rein, A. Vonbank, P. Fraunberger, H. Drexel (Austria)

238 RS6922269 MARKER AT THE *MTHFD1L* GENE PREDICT CARDIOVASCULAR MORTALITY IN MALES AFTER ACUTE CORONARY SYNDROME 1068
J. Hubacek, V. Stanek, R. Poledne, V. Adamkova, J. Pitha (Czech Republic)

239 PHENOTYPE OF VULNERABLE ATHEROSCLEROTIC PLAQUES SHOWS STRONG ASSOCIATION WITH SINGLE NUCLEOTIDE POLYMORPHISM ALLELES OF COMMON RISK VARIANTS FOR CORONARY ARTERY DISEASE 1069
R. Furtmair, C. Kuehn, C. König, A. Ekici, L. Klinghammer, S. Achenbach, A. Reis, M. Tauchi, B. Dietel (Germany)

240 GENETIC DETERMINATION OF THE ATHEROSCLEROTIC PLAQUE STABILITY 1070
I. Goncharova, M. Golubenko, O. Makeeva, **V. Kashtalap**, N. Tarasenko, A. Markov, V. Puzyrev (Russia)

241 MAY THE TRANSCRIPTIONAL ACTIVITY OF TRANSFORMING GROWTH FACTOR BETA 1 GENE BE A MARKER FOR EARLY STAGES FOR CORONARY ATHEROSCLEROSIS? 1071
J. Dąbek, M. Bałys, J. Piotrkowicz, J. Głogowska-Ligus, **Z. Gąsior** (Poland)

242 ASSOCIATION OF SERUM CAROTENOID CONCENTRATION WITH SINGLE NUCLEOTIDE POLYMORPHISMS IN *APOE, BCMO1, NPC1L1, CD36, GSTP1, ABCG5, FABP1, FABP2* AND *LIPC* GENES 1072
A. Mazeikiene, D. Karciauskaite, N. Burokiene, Z. Daunoravicius, Z.A. Kucinskiene, V. Kucinskas (Lithuania)

243 A TOOL FOR QUANTITATIVE MEASUREMENT OF PROATHEROGENIC HETEROPLASMIC MUTATIONS OF MITOCHONDRIAL DNA 1073
I. Sobenin, K. Mitrofanov, A. Orekhov (Russia)

Board #

244 CREATION OF CYBRID LINES OF MONOCYTE ORIGIN WITH HIGH HETEROPLASMY LEVEL FOR MITOCHONDRIAL GENOME MUTATION M.1555G>A 1074
M. Sazonova, V. Sinyov, A. Ryzhkova, T. Shkurat, N. Demakova, N. Nikitina, I. Sobenin, **A. Orekhov** (Russia)

245 DETECTION OF THRESHOLD HETEROPLASMY LEVEL OF MTDNA IN LYPOFIBROUS PLAQUES OF HUMAN AORTIC INTIMA 1075
A. Ryzhkova, M. Sazonova, V. Sinyov, E. Galitsyna, V. Barinova, N. Nikitina, I. Sobenin, **A. Orekhov** (Russia)

246 PROATHEROGENIC MUTATIONS OF MITOCHONDRIAL DNA IN PATIENTS WITH METABOLIC SYNDROME 1076
I. Sobenin, M. Sazonova, V. Orekhova, A. Zhelankin, A. Orekhov, A. Postnov (Russia)

247 MITOCHONDRIAL DNA MUTATIONS ASSOCIATED WITH CAROTID ATHEROSCLEROSIS: NGS DATA 1077
I. Sobenin, A. Zhelankin, Z. Khasanova, V. Orekhova, A. Orekhov, A. Postnov (Russia)

248 ROLES OF ORPHAN NUCLEAR RECEPTORS IN CARDIAC HYPERTROPHY 1078
G.H. Eom, D.H. Kwon, S. Shin, Y.U. Lee, E. Kim, N. Choe, Y.S. Nam, H. Kook (Republic of Korea)

249 ROLE OF GENETIC POLYMORPHISMS AT THE ADIPONECTIN GENE IN REGULATION OF ADIPONECTIN GENE EXPRESSION AND CIRCULATING ADIPONECTIN LEVELS 1079
L. Kedenko, W. Patsch, I. Kedenko, S.M. Patsch, S. Coassin, F. Kronenberg, F. Krempler, B. Paulweber, C. Lamina (Austria)

250 LOW LDL-CHOLESTEROL, *PCSK9* AND *HMGCR* GENETIC VARIATION, AND RISK OF NEURODEGENERATIVE DISEASE: A MENDELIAN RANDOMIZATION STUDY 1080
M. Benn, B. Nordestgaard, R. Frikke-Schmidt, A. Tybjærg-Hansen (Denmark)

251 RELATIONSHIP BETWEEN CIRCULATING MICRORNA-30C WITH LIPOPROTEINS, THEIR CIRCULATORY TRAFFICKING AND EFFECT OF STATINS 1081
R. Sodi, J. Eastwood, L. Denby, I. Godber, M. Caslake, C.J. Packard (United Kingdom)

252 HYPERGLYCEMIA INCREASES MICRORNAS IN CIRCULATING HDL FROM ACUTE CORONARY SYNDROME PATIENTS AND MODULATES MIRNA PROCESSING MACHINERY IN HUMAN MACROPHAGES 1082
L.S. Niculescu, N. Simionescu, G.M. Sanda, M.G. Carnuta, C.S. Stancu, A.C. Popescu, R.M. Popescu, A. Vlad, D.R. Dimulescu, M. Simionescu, A.V. Sima (Romania)

Board #

253 IS PLASMA MICRORNA-1909-5P A NEW POTENTIAL BIOMARKER FOR ACUTE MYOCARDIAL INFARCTION 1083
E. Coskunpinar, **H.A. Cakmak**, A.K. Kalkan, N. Ozan Tiryakioglu, T. Araz, Z. Ongen (Turkey)

254 DOES THE GENE EXPRESSION OF NUCLEAR FACTOR KAPPA B IN PATIENTS WITH EARLY STAGES OF CORONARY ATHEROSCLEROSIS DIFFERS FROM HEALTHY INDIVIDUALS 1084
J. Dąbek, M. Bałys, J. Głogowska-Ligus, J. Piotrkowicz, **Z. Gąsior** (Poland)

255 ENDOTOXIN STRESS-INDUCED APOLIPOPROTEIN E GENE DOWNREGULATION IN MACROPHAGES IS REDUCED BY METFORMIN 1085
E.V. Fuior, S. Stavri, V.G. Trusca, I.F. Tudorache, M. Simionescu, D. Kardassis, **A.V. Gafencu** (Romania)

256 DNA METHYLATION AND COPY NUMBER EVENTS IN ATHEROSCLEROTIC LESIONS 1086
M. Nazarenko, A. Markov, A. Sleptcov, I. Lebedev, N. Skryabin, O. Barbarash, V. Puzyrev (Russia)

257 GENE THERAPY: CASE STUDY ON THE FIRST LIPOPROTEIN LIPASE DEFICIENCY PATIENT TREATED WITH ALIPOGENE TIPARVOVEC IN GERMANY 1087
U. Kassner, T. Hollstein, M. Wühle-Demuth, I. Demuth, E. Steinhagen-Thiessen (Germany)

258 MAJOR ADIPOKINES AND -420 C>G RESISTIN GENE POLYMORPHISHM AS PREDICTORS OF ACUTE ISCHEMIC STROKE SEVERITY AND IN-HOSPITAL OUTCOME 1088
S. Bouziana, **K. Tziomalos**, A. Goulas, T.A. Vyzantiadis, A. Panderi, A. Hatzitolios (Greece)

259 PPAR-ALPHA GENE HAPLOTYPES, ARSENIC EXPOSURE AND RISK OF CARDIOVASCULAR DISEASE 1089
F.I. Hsieh, S.H. Lin, C.F. Huang, H.Y. Chiou (Taiwan)

Genetics, Nutrition, Biomarkers: Nutrition

260 ABNORMAL BALGHAM MUNZIQ, A UIGHUR HERBAL MEDICINE FORMULA, HAS BEEN RECENTLY SHOWN TO POSSESS EXTENSIVE CARDIOVASCULAR PHARMACOLOGICAL ACTIVITIES 1090
D. Xilifu, **A. Nurmuhammat**, U. Halmurat (China)

261 EFFECTS OF RAMADAN FASTING ON BIOLOGICAL PARAMETERS IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS 1091
K. Bouzid, W. Hmaidi, Y. Molahedh, H. Ben Ahmed, A. Bartkiz, H. Baccar, J. Abdelmoula (Tunisia)

Board #

262 INCREASING ADHERENCE OF CONSUMERS TO DIET & LIFESTYLE CHANGES TO LOWER (LDL) CHOLESTEROL: THE ACT STUDY 1092
T.E. SIALVERA, P. Farajian, E.A. Trautwein, A. Papadopoulou, S. Efstathiou, G. Goumas, I. Dimakopoulos, K. Papavasiliou, A. Koutsouri, A. Zampelas (Greece)

263 NUTRITIONAL MODULATION OF THE TOXICITY OF ENVIRONMENTAL POLLUTANTS: IMPLICATIONS IN ATHEROSCLEROSIS 1093
B. Hennig, M. Petriello (USA)

264 DIETARY POLYUNSATURATED FATTY ACID AND FRAMINGHAM RISK SCORE : ANALYSIS OF THE KOREA NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (KNHAENS 2013) 1094
N.S. Joo, B. Choi, S.I. Jung (Republic of Korea)

265 VITAMIN D STATUS AND BIOMARKERS OF ENDOTHELIAL ACTIVATION IN OBESE INDIVIDUALS 1095
B. Ilincic, E. Stokic, M. Djeric, N. Eremic, D. Popovic, Z. Stosic (Serbia)

266 EFFECTS OF VITAMIN E OR LIPOIC ACID SUPPLEMENTATION ON FASTING OXYPHYTOSTEROL CONCENTRATIONS IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE OR TYPE II DIABETES 1096
S. Baumgartner, R.P. Mensink, G. Haenen, A. Bast, C. Binder, O. Bekers, C. Husche, D. Lütjohann, J. Plat (Netherlands)

267 EFFECTIVENESS OF A LOW GLYCEMIC INDEX SOLUBLE PLANT POWDER, AS A LOW-CALORIE REPLACEMENT MEAL, IN OVERWEIGHT AND OBESE PATIENTS 1097
R. Volpe, A. Bianco, F. Pacioni, E. Schiavetto (Italy)

268 SUSTAINED NUTRITIONAL COUNSELING IMPROVES DIETARY INTAKE IN PARENTS AND THEIR CHILDREN OVER 5 YEARS: THE PEP FAMILY HEART STUDY 1098
P. Schwandt, E. Liepold, M. Heinzel-Gutenbrunner, T. Bertsch, G.M. Haas (Germany)

269 SPANISH OBESE CHILDREN AND BIOCHEMICAL PARAMETERS : NON-HEALTHY NUTRITIVE PATTERNS 1099
C. Rodriguez-Leal, B. Ruiz-Estevez, E. Segura, I. Tinoco-Racero, N. Caro, C. Perez, I. Garcia-Campanario, A. Perez, M. Quezada-Feijoo, A. Mangas, **R. Toro** (Spain)

270 LONG-TERM MAGNESIUM SUPPLEMENTATION IMPROVES ARTERIAL STIFFNESS IN OVERWEIGHT AND OBESE ADULTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INTERVENTION STUDY 1100
P.J. Joris, J. Plat, S.J.L. Bakker, R.P. Mensink (Netherlands)

271 THIRTEEN YEAR FOLLOWUP OF MANAGING PATIENTS WITH KNOWN CORONARY ARTERY DISEASE USING A LECTIN-LIMITED, HIGH DOSE OLIVE OIL AND POLYPHENOL RICH DIET 1101
S. Gundry, J. Epstein (USA)

Board #

272 SERUM CONTENT OF OLEIC ACID IS ASSOCIATED WITH HIGHER PLATELET-, ENDOTHELIAL- AND LEUKOCYTE-DERIVED CIRCULATING MICROPARTICLES IN NORWEGIAN NORMOLIPIDEMIC ELDERLY PATIENTS AFTER AN ACUTE MYOCARDIAL INFARCTION 1102
G. Chiva-Blanch, V. Bratseth, K. Laake, P. Myhre, H. Arnesen, S. Solheim, E. Berg-Schmidt, L. Badimon, I. Seljeflot (Spain)

273 PLANT STANOL SUPPLEMENTATION LOWERS CETP-MASS, BUT NOT CETP-ACTIVITY, IN HEALTHY SUBJECTS 1103
C. Talbot, J. Plat, A. Ritsch, R. Mensink (Netherlands)

274 PLASMA FAT-SOLUBLE VITAMIN AND CAROTENOID CONCENTRATIONS AFTER PLANT STEROL AND PLANT STANOL ESTER CONSUMPTION – A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 1104
S. Baumgartner, R. Ras, E. Trautwein, R.P. Mensink, J. Plat (Netherlands)

275 HAZELNUT-ENRICHED DIET IMPROVES LIPID PROFILE, FATTY ACID COMPOSITION OF ERYTHROCYTES MEMBRANE AND MARKERS OF OXIDATIVE STRESS IN CHILDREN WITH PRIMARY DYSLIPIDEMIA: A RANDOMIZED CONTROL TRIAL 1105
V. Deon, C. Del Bo', A. Bosusco, S. Vendrame, M. Porrini, P. Simonetti, O. Guardamagna, P. Riso (Italy)

276 PLASMA PLANT STEROLS AND PLANT STEROL INTAKE VARY ACROSS PLANT-BASED DIETARY PATTERNS AMONG ADULTS FROM NORTH AMERICA 1106
D. Luetjohann, K. Jaceldo-Siegl, R. Sirirat, E. Haddad (Germany)

277 LOW-FAT DIETARY TREATMENT ENRICHED WITH SOY PROTEIN IN CHILDREN AFFECTED WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM A RANDOMIZED-CONTROLLED PILOT STUDY 1107
O. Helk, K. Widhalm (Austria)

278 ANGIOGRAPHIC AND ANTIOXIDANT CHANGES AFTER SUPPLEMENTATION WITH *HERACLEUM PERSICUM* EXTRACT: RESULTS OF A RANDOMIZED CONTROLLED TRIAL 1108
A. Sahebkar, **Y. Panahi**, H. Taghipour (Iran)

279 DO DIET AND EXERCISE INFLUENCE IN AN ATHLETIC POPULATION?: NEW CLUES OF THE ENTERO-INSULAR AXIS 1109
C. Rodriguez-Leal, V. Aragon, I. Tinoco-Racero, E. Segura, B. Ruiz-estevez, E. Sanchez-Orellana, C. Perez, M. Monsalvo Hernando, N. Caro, A. Perez, I. Garcia-Campanario, A. Mangas, **R. Toro** (Spain)

280 EVALUATION OF ACTUAL CONSUMPTION OF PULSE REDUCING DRUGS IN PATIENTS AFTER ACUTE CORONARY SYNDROME 1110
T. Chudinovskikh, **E. Tarlovskaya** (Russia)

Board #

281 EFFECTS OF RAMADAN FASTING ON CLINICAL AND BIOCHEMICAL PARAMETERS FOR TYPE 2 DIABETICS 1111
K. Bouzid, Y. Molahedh, W. Hmaidi, N. Mchirgui, A. Bartkiz, E. Talbi, N. Ben Abdallah, A. Bahlous, J. Abdelmoula (Tunisia)

282 COMPARISON OF EFFECTS OF DIABETIC ENTERAL NUTRITION AND STANDARD ENTERAL NUTRITION ON POSTPRANDIAL LEVEL OF GLYCEMIA, FREE FATTY ACIDS AND GLUCAGON-LIKE PEPTIDE-1. 1112
J. Visek, A. Ticha, L. Sobotka, V. Blaha (Czech Republic)

283 REGULATION OF HYPOTHALAMIC GENE EXPRESSION BY DNA METHYLATION IS INFLUENCED BY PARENTAL DIET DURING PREGNANCY AND LINKED TO OFFSPRING'S RISK OF OBESITY 1113
I. Khurana, A. Kaspi, M. Ziemann, **T. Block**, T. Connor, B. Spolding, A. Cooper, P. Zimmet, A. El-Osta, K. Walder (Australia)

284 INORGANIC NITRATE DOES NOT AFFECT GLUCOSE AND INSULIN REGULATION BUT LOWERS OXIDATIVE STRESS IN OBESE ADULTS DURING ACUTE HYPERGLYCAEMIA 1114
A. Ashor (United Kingdom)

285 EFFECT OF DIFFERENT ORAL GLUCOSE LOADS ON THE ANTIOXIDANT, INFLAMMATORY AND PLATELET RESPONSE OF HEALTHY VOLUNTEERS 1115
A. Mikellidi, D. Papadopoulou - Pozatzidou, E. Bachti, C. Xenaki, S. Antonopoulou, C. Demopoulos, T. Nomikos (Greece)

286 INCREASED BILE ACID AND CHOLESTEROL SYNTHESES AND PCSK9 IN MORBID OBESITY ARE RAPIDLY NORMALIZED FOLLOWING ACUTE CALORIC RESTRICTION 1116
S. Straniero, F. Rosqvist, D. Edholm, M. Sundbom, U. Risérus, M. Rudling (Sweden)

287 SUPPRESSION OF DNA DAMAGE BY DIETARY SUPPLEMENT WHICH CONTAINS PLANT EXTRACTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL 1117
L. Gavriil, C. Argyrou, I. Malagaris, E. Fragopoulou (Greece)

288 IMPACT OF OIL AND PROTEINS DERIVED FROM ANTARCTIC KRILL ON ATHEROSCLEROSIS DEVELOPMENT IN APOEKO MICE 1118
C. Parolini, F. Dellera, G.S. Ganzetti, S. Manzini, M. Busnelli, M.S. Ramsvik, B. Bjorndal, I. Bruheim, R.K. Berge, G. Chiesa (Italy)

289 INVESTIGATION OF CHIOS MASTIC GUM EFFECT ON METABOLIC PROFILE IN STREPTOZOTOCIN-INDUCED DIABETIC MICE 1119
A. Tzani, I. Georgiadis, L.M. Korou, P. Konstantopoulos, G. Agrogiannis, I. Vlachos, I. Doulamis, N. Katsilambros, D. Perrea (Greece)

290 ANTI-HYPERLIPIDEMIC POTENTIAL OF *EMBLICA OFFICINALIS* IN HIGH FAT FED RATS: UP-REGULATION OF PPARS 1120
B. Variya, S. Patel, A. Bakrania (India)

Board #

291 ENDOTOXIN AND OMEGA-3 FATTY ACIDS EFFECTS ON ENDOTHELIAL OCCLUDIN EXPRESSION IN RAT HEART 1121
J. Dienova, K. Frimmel, **L. Okruhlicova** (Slovakia)

292 LOW-SALT DIET INDUCES ATHEROSCLEROSIS INDEPENDENT OF LOWERING BLOOD PRESSURE IN HYPERTENSIVE MICE 1122
S. Catanozi, F. Fusco, D. Gomes, K. Bispo, V. Toledo, D. Barbeiro, V. Capelozzi, L. Furukawa, A.P. Velosa, W. Teodoro, J. Heimann, E. Quintao, M. Passarelli, **E. Nakandakare** (Brazil)

293 LIQUID FRUCTOSE SUPPLEMENTATION IN WESTERN DIET-FED C57BL/6N MICE CAUSES LIVER CHOLESTEROL LOADING WITHOUT CHANGING CALORIE INTAKE AND BODY WEIGHT 1123
M. Baena, G. Sangüesa, M. González, M. Alegret, N. Roglans, J.C. Laguna (Spain)

294 THE IMPACT OF DIETARY SUPPLEMENTATION OF *VERNONIA CALVOANA* LEAVES ON SERUM LIPID PROFILE AND HAEMATOLOGICAL INDICES IN ALBINO WISTAR RATS 1124
G. Egbung, I. Atangwho (Nigeria)

295 FERULIC ACID FROM RICE BRAN ENZYMATIC EXTRACT IS RESPONSIBLE FOR ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES 1125
C. Perez Ternero, B. Bermudez Pulgarin, A. Macia, M.J. Motilva, M.D. Herrera, M. Alvarez de Sotomayor (Spain)

296 POTENTIAL PROTECTIVE EFFECTS OF DUNALIELLA SALINA ON DEHP-INDUCED MMP-2 AND MMP-9 EXPRESSION VIA MAPK, ERK1/2, AKT, AND NF-κB PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS 1126
M.F. Shih, **J.Y. Cherng** (Taiwan)

297 RIBOSE-CYSTEINE INCREASES GLUTATHIONE-BASED ANTIOXIDANT STATUS AND REDUCES ATHEROSCLEROSIS IN APOE-DEFICIENT MICE 1127
S. McCormick, T. Kader, C. Porteous, G. Jones, N. Dickerhof (New Zealand)

298 ANTIPLATELET EFFECT OF THE MAIN TRITERPENOIDS OF AN OLIVE LEAF EXTRACT 1128
M. Tsoumani, V. Kontogianni, T. Kellici, T. Mavromoustakos, I. Gerothanassis, A. Tzakos, A. Tselepis (Greece)

Board #

Genetics, Nutrition, Biomarkers: Biomarkers

299 URINARY LIVER-TYPE FATTY ACID-BINDING PROTEIN IS ASSOCIATED WITH AORTIC STIFFNESS IN MALE CORONARY ARTERY DISEASE PATIENTS 1129
K. Paapstel, M. Zilmer, J. Eha, K. Tootsi, A. Piir, J. Kals (Estonia)

300 IMPACT OF ALKALINE PHOSPHATASE ON IN-HOSPITAL MORTALITY AND 1-YEAR CLINICAL OUTCOME IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERWENT PRIMARY PERCUTANEOUS CORONARY INTERVENTION 1130
P.C. Oh, K. Woong Chol, M. Jeonggeun, S. Jon, P. Hyun Woo, J. Ho-Jun, K. Tae-Hoon, P. Sang-Don, K. Sung Woo, S. Soon Yong, L. Kyounghoon, H. Seung Hwan, A. Taehoon, S. Eak Kyun (Republic of Korea)

301 THE GENERATION OF MALONDIALDEHYDE-POSITIVE MICROVESICLES 1131
F. Puhm, T. Afonyushkin, C. Binder (Austria)

302 LEUKOARAIOSIS IS UNRELATED TO CAROTID STENOSIS OR RISK FACTORS FOR ATHEROSCLEROSIS 1132
B. Muinjonov, E. Giyazitdinova (Uzbekistan)

303 VARIABILITY AND TEMPORAL TREND OF VICORDER-ESTIMATED PULSE WAVE VELOCITY 1133
A.K. Mistri, **P. Connell**, T. Robinson (United Kingdom)

304 EVALUATION OF OXIDATIVE STRESS INDEX AND ITS CORRELATION WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS, INFLAMMATION AND CAROTID INTIMA MEDIA THICKNESS IN DIABETES AND HEALTHY SUBJECTS 1134
R. Dalan, **H. Liew**, L.L. Goh, X. Gao, D.E. Chew, B.O. Boehm, M.K.S. Leow (Singapore)

305 PLASMA ARGININE/ADMA RATIO IS A SENSITIVE RISK MARKER FOR ATHEROSCLEROSIS: SHIMANE COHRE STUDY 1135
S. Yano, Y. Notsu, A. Nagai, T. Nabika (Japan)

306 THE ALANINE AMINOTRANSFERASE/ ASPARTATE AMINOTRANSFERASE RATIO PREDICTS FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE AND HOMA INSULIN RESISTANCE 1136
A. Vonbank, C. Saely, P. Rein, D. Zanolin, **A. Leiherer**, H. Drexel (Austria)

307 IMPACT OF AGE ON THE CARDIOVASCULAR EVENT RISK CONFERRED BY HBA1C IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 1137
A. Vonbank, C. Saely, D. Zanolin, P. Rein, **A. Leiherer**, H. Drexel (Austria)

308 PROBNP STRONGLY PREDICTS FUTURE MACROVASCULAR EVENTS IN ANGIOGRAPHIED CORONARY PATIENTS WITH AS WELL AS IN THOSE WITHOUT TYPE 2 DIABETES 1138
P. Rein, C. Saely, A. Vonbank, D. Zanolin, **A. Leiherer**, H. Drexel (Austria)

Board #

309 THE LEVEL OF EOSINOPHIL CATIONIC PROTEIN IS CORRELATE WITH SEVERITY OF CORONARY ATEROSCLEROSIS 1139
F. Byazrova, V. Lopukhova, V. Buza, K. Zykov, Y. Karpov (Russia)

310 SIMPLE MORTALITY PROGNOSTIC RISK CALCULATOR FOR PATIENTS WITH ACUTE CORONARY SYNDROME 1140
N. Zagidullin, E. Travnikova, B. Zagidullin, R. Zulkarneev, S. Zagidullin (Russia)

311 THE INVERSE ASSOCIATION BETWEEN PLASMA ENDOGLIN LEVELS AND THE SEVERITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH STABLE CAD 1141
E. Saita, K. Miura, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami, Y. Kishimoto, K. Kondo, Y. Momiyama (Japan)

312 NITRIC OXIDE-RELATED CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH MAJOR DEPRESSION 1142
A. Meinitzer, S. Zelzer, H. Mangge, **G. Almer**, R. Prassl, O. Amouzadeh-Ghadikolai, C. Robier, A. Baranyi (Austria)

313 BRANCHED-CHAIN AMINO ACID PROFILES INDICATE CARDIO METABOLIC RISK INDEPENDENT OF BODY MASS INDEX 1143
S. Zelzer, A. Meinitzer, D. Enko, G. Almer, R. Prassl, H. Mangge (Austria)

314 STATUS OF NOVEL CARDIOVASCULAR RISK FACTOR AND CARDIOVASCULAR DISEASE RISK IN AN URBAN DELHI POPULATION-A PILOT STUDY 1144
V. Sharma, R. Shahrawat (India)

315 THE ATHEROGENIC PROFILE – PREDOMINANT LIPOPROTEIN PROFILE IN CARDIOVASCULAR DISEASE 1145
S. Prof. Dr. Oravec, K. Dr. Gruber, A. Prof. Dr. Dukat, P. Ass. Prof. Gavornik, L. Ass. Prof. Gaspar, E. Dr. Dostal (Slovakia)

316 IMPACT OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND NEUTROPHIL COUNTS IN THE LUDWIGSHAFEN RISK AND CARDIOVASCULART HEALTH STUDY 1146
R. Woitas, H. Scharnagl, M.E. Kleber, G.E. Delgado, T.B. Grammer, M. Pichler, B.K. Krämer, W. März, **T. Stojakovic** (Austria)

317 INCREASED LEVELS OF YKL-40 ARE ASSOCIATED WITH ALL-CAUSE MORTALITY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 1147
C.T. Herz, M.L. Tscharre, C. Höbaus, G. Pesau, F. Obendorf, R. Koppensteiner, G.H. Schernthaner (Austria)

318 RELATIONSHIP OF INFLAMMATORY BIOMARKERS, PTX3 WITH SEVERITY OF PERIPHERAL ARTERIAL DISEASE 1148
K. Igari (Japan)

Board #

319 GALECTIN 3 AND THE REMODELING OF ARTERIAL WALL IN PATIENTS WITH METABOLIC SYNDROME 1149
V. Ionin, D. Brovin, E. Bazhenova, T. Karonova, E. Polyakova, O. Belyaeva, E. Baranova, E. Shlyachto (Russia)

320 RELATION OF PLASMA COPEPTIN LEVELS AND WAIST CIRCUMFERENCE IN NON-DİABETIC ACUTE ST-SEGMENT ELEVATION MYOCARDİAL INFARCTION PATIENTS 1150
K. Cosansu, A. Turer Cabbar, H.A. Cakmak (Turkey)

321 CORRELATION OF PIGMENT EPITHELIUM-DERIVED FACTOR WITH OXIDATIVE AND INFLAMMATORY MARKERS IN OBESE, NON-DIABETIC PATIENTS 1151
I. Juhász, **I. Seres**, A. Szentpéteri, E.V. Varga, S. Somodi, P. Fülöp, H. Lőrincz, G. Paragh (Hungary)

322 AORTIC VALVE STENOSIS IN ASSOCIATION WITH INFLAMMATORY PROCESS AND BIOCHEMICAL MARKERS. 1152
J. Lūriņš, A. Visocka, V. Mackēvičs, P. Tretjakovs (Latvia)

323 ASSOCIATIONS OF LIPOCALIN 2 WITH MARKERS OF INFLAMMATION AND OXIDANT STATUS IN OBESE NON-DIABETIC PATIENTS 1153
P. Fülöp, H. Lőrincz, S. Somodi, M. Harangi, I. Seres, G. Paragh (Hungary)

324 FIRST TRIMESTER SERUM CONCENTRATIONS OF AFAMIN ARE ASSOCIATED WITH THE DEVELOPMENT OF PREECLAMPSIA AND GESTATIONAL DIABETES MELLITUS IN PREGNANT WOMEN 1154
A. Tramontana, B. Dieplinger, G. Stangl, E. Hafner, H. Dieplinger (Austria)

325 IS RED BLOOD CELL GLUTATHIONE A BETTER MARKER FOR CORONARY ARTERY DISEASE THAN PLASMA GLUTATHIONE? 1155
A. Lima, R. Ferin, E. Santos, A. Fontes, S. Ferreira, C. Almeida, D. Martins, J. Baptista, **M.L. Pavão** (Portugal)

326 CHANGES BRAIN NATRIURETIC PEPTIDE (BNP) LEVELS IMPROVE RISK PREDICTION OF SHORT-TERM MORTALITY FOLLOWING ACUTE MYOCARDIAL INFARCTION COMPARED TO GRACE SCORE: A *BRASILIA HEART STUDY* SUBANALYSIS 1156
L.S. Carvalho, L.A. Bogniotti, O.L. Almeida, J.C. Quinaglia e Silva, L. Trindade, G. Oliveira, A. Sposito (Brazil)

327 GENETIC DETERMINANTS CONTROLLING LIPID DEPOSITS IN DIFFERENT WILD TYPE STRAINS OF ZEBRAFISH (*DANIO RERIO*) 1157
K. Vishnolia, K. Tarhbalouti, P. Ciba, C. Kruse, Z. Aherrahrou, J. Erdmann (Germany)

328 CELL-DERIVED MICROPARTICLES AS MARKERS OF ENDOTHELIAL FUNCTION, INFLAMMATION AND COAGULATION IN PATIENTS WITH SLEEP APNEA-HYPOPNEA SYNDROME: A SYSTEMATIC REVIEW 1158
A.J. Vallejo-Vaz, R. Muñoz-Hernández, J. Villar, P. Stiefel (United Kingdom)

Board #

329 ANTIOXIDANT ENZYMES IN PATIENTS WITH ATHEROSCLEROSIS 1159
J. Bogdanska, D. Labudovic, S. Alabakovska, S. Cekovska, K. Tosheska Trajkovska, S. Jovanova (FYR Macedonia)

330 THE NUMBER OF REQUESTS FOR HIGH SENSITIVE TROPONIN I MEASUREMENT AND THE NUMBER OF PATIENTS DIAGNOSED WITH ACUTE MYOCARDIAL INFARCTION 1160
L. Majnaric, M. Mikic, S. Bekic, S. Guljas (Croatia)

331 CAROTID ATHEROSCLEROSIS IN A VERY ELDERLY POPULATION: ROLE OF AGEING AND OTHER CARDIOVASCULAR RISK FACTORS 1161
F. Spannella, F. Giulietti, G. Cocci, P. Giordano, M. Ricci, E. Espinosa, **R. Sarzani** (Italy)

332 BIOMARKER DISCOVERY BY PLASMA PROTEOMICS IN FAMILIAL *LMNA* DILATED CARDIOMYOPATHY 1162
I. Izquierdo, D. De Gonzalo-Calvo, V. Llorente-Cortes, I. Rosa, R. Brugada, C. Oscar, A. Perez-Serra, J. Broncano, A. Luna, J. Vazquez-Alfageme, J.R. Gonzalez-Juanatey, A. Mangas, A. Garcia, **R. Toro** (Spain)

333 BLOOD PRESSURE FLUCTUATIONS AS A LEADING LINK IN THE DEVELOPMENT OF COMPLICATIONS OF ATHEROSCLEROSIS 1163
A. Kebryakov, P. Bondarenko, M. Ermina, M. Ivanov, N. Koplyarova, A. Yadernaya, A. Mishchenko (Russia)

Genetics, Nutrition, Biomarkers: Guidelines and Miscellaneous

334 ACC/AHA GUIDELINES SUPERIOR TO ESC/EAS GUIDELINES FOR PRIMARY PREVENTION WITH STATINS: THE COPENHAGEN GENERAL POPULATION STUDY 1164
M.B. Mortensen, B.G. Nordestgaard, S. Afzal, E. Falk (Denmark)

335 PREDICTING THE IMPACT OF THE ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS FOR SECONDARY PREVENTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE 1165
A. Merezhanova, **E. Tarlovskaya**, B. Nechaeva, A. Semenkin, S. Malchikova (Russia)

336 APPLICATION OF A MULTILEVEL HIERARCHICAL MODEL TO CORRELATE TOTAL CHOLESTEROL IN EIGHT DIFFERENT SETTINGS 1166
A. Pereira, F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)

337 PROPOSAL OF A NEW APPROACH TO ACCESS CHOLESTEROL RANGES ACCORDING TO DIFFERENT CONDITIONS 1167
A. Pereira, F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)

Board #

338 PREDICTING FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS' QUALITY OF LIFE AND SELF-ASSESSED HEALTH: ILLNESS BELIEFS, BELIEFS ABOUT MEDICATION, AND HEALTH LITERACY 1168
M. Hagger, J. Pang, G.F. Watts (Australia)

339 METABOLIC DISTURBANCES AND RISK OF CANCER IN THE 25 YEARS FOLLOW-UP OF THE "VENTIMIGLIA HEART STUDY" EPIDEMIOLOGICAL PROJECT. 1169
D. Noto, A.B. Cefalù, C.M. Barbagallo, A. Giammanco, F. Fayer, O. Palesano, G.I. Altieri, R. Spina, V. Valenti, M. Pagano, G. Cavera, M.R. Averna (Italy)

340 ESTRADIOL TREATMENTS CHANGE THE LIPID PROFILE IN NATURALLY MENOPAUSAL RATS FROM DIFFERENT AGE GROUPS: A THERAPEUTIC POTENTIAL DRUG FOR ATHEROSCLEROSIS 1170
P. Kumar, N. Baquer (India)

341 HYPONATREMIA : A RISK FACTOR OF OVERT HEPATIC ENCEPHALOPATHY 1171
S. Khedher, A. Maoui, K. Bouzid, S. Lahiani, A. Bartkiz, M. Salem, J. Abdelmoula (Tunisia)

342 HYPONATREMIA, A PREDICTING FACTOR OF MORTALITY IN CIRRHOTIC PATIENT 1172
K. Bouzid, S. Khedher, A. Maoui, S. Lahiani, A. Bartkiz, M. Salem, J. Abdelmoula (Tunisia)

343 ANDROGEN-DEPRIVATION THERAPY-INDUCED ATHEROSCLEROSIS IN PROSTATE CANCER: DIFFERENCES BETWEEN GNRH-AGONIST AND ANTAGONIST 1173
W. Duivenvoorden, S. Hopmans, G. Werstuck, J. Pinthus (Canada)

344 RELIABILITY ASSESSMENT OF DETERMINATION OF PROCALCITONIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS : ABOUT TWO CASES 1174
A. Bartkiz, K. Bouzid, S. Ghezaiel, S. Lahiani, S. Hammami, E. Talbi, A. Zannouri, M. Omrane, S. Barbouche, J. Abdelmoula (Tunisia)

Abstract not Registered

400 WHAT WOULD YOU DO IF YOU WERE WITH AN EMBRYO-LIKE GIANT THROMBUS IN THE LEFT VENTRICLE: CASE REPORT 1175
Z. Aktop, E. Coskun (Turkey)

401 RELATIONSHIP BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND THE WEIGHT GAIN 1176
T. Alexescu, I. Cheta, M. Handru, V. Negrean, L. Ciumarnean, I. Para (Romania)

402 EFFECTS OF OSTEOPATHIC MANIPULATIVE TREATMENT ON VASCULAR AND AUTONOMIC FUNCTIONS IN HEART PATIENTS: A RANDOMIZED, CLINICAL TRIAL 1177
F. Amatuzzi, A. Guervazoni, V. Marães, K. Bousquet, F. Stauffer, M.A. Catai, G. Chiappa, S. Thomaz, C. Nakata, R. Jácomo, M. Lucena, G. Cipriano Jr. (Brazil)

403 APPLANATION TONOMETRY PROPOSE DIFFERENT PHYSIOLOGIC MECHANISMS IN CHAGASIC VERSUS ISCHEMIC HEART FAILURE 1178
A. Lima, J. Vilela-Martin, L. Giollo, A.P. Silva, M.E. Otto, S. Marianne, V. Maldaner, G. Chiappa, G. Cipriano, F. Amatuzzi, G. Cipriano Jr (Brazil)

404 PREVALENCE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND IMPACT ON ACHIEVEMENT OF LIPID TARGETS DURING CARDIAC PREVENTION AND REHABILITATION PROGRAMMES IN ITALY: THE HEREDITY REGISTRY 1179
M. Ambrosetti, **P. Faggiano**, P.L. Temporelli, R. Griffo, R. Pedretti (Italy)

405 PEDIATRIC IMT ASSESSMENT 1180
E. Barabesi, O. Guardamagna, F. Abello (Italy)

406 RISK FACTORS FOR DEVELOPING DRUG-RELATED PROBLEMS IN PATIENTS WITH CARDIOVASCULAR DISEASES ATTENDING GONDAR UNIVERSITY HOSPITAL, ETHIOPIA 1181
A. Bhagavathula, O. Abubeker, A. Elnour, A. Shehab (Ethiopia)

407 CLINICAL UTILITY OF DABIGATRAN IN UNITED ARAB EMIRATES. A PHARMACOVIGILANCE STUDY 1182
A. Shehab, A. Elnour, A. Bhagavathula, S. Al Nuaimi (United Arab Emirates)

408 A MUFA RICH-DIET MAY REDUCE LIVER FAT CONTENT IN TYPE 2 DIABETES PATIENTS THROUGH AN ENHANCED POSTPRANDIAL FAT OXIDATION 1183
L. Bozzetto, G. Costabile, G. Annuzzi, D. Luongo, D. Naviglio, V. Cicala, M. Giorgini, C. Piantadosi, E. Griffo, P. Cipriano, A. Giacco, A. Rivellese (Italy)

409 AN ASSOCIATION STUDY OF EARLY-LIFE ARSENIC EXPOSURE ON THE RISK OF HYPERTENSION, HYPERGLYCEMIA, AND HYPERLIPIDEMIA 1184
H.Y. Chiou, S.Y. Kuo, F.I. Hsieh (Taiwan)

410 NOVEL EFFECTS OF SARCOPENIC OSTEOARTHRITIS ON METABOLIC SYNDROME AND INSULIN RESISTANCE: THE NATIONAL SURVEY 1185
S.M. Chung, M.H. Hyun, H.S. Seo, D.J. Oh, C.G. Park, S.W. Rha, E.J. Kim, H.E. Lim, J.W. Kim, C.U. Choi, J.O. Na, S.K. Lee (Republic of Korea)

411 THE EXPRESSION OF MIR-125A-3P IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH CORONARY HEART DISEASE 1186
H.L. Dai, X.L. Yin, J. Xiao, X.F. Guang (China)

412 ENDOTHELIAL VASCULAR MOTOR FUNCTION IN ARTERIAL HYPERTENSIVE PATIENTS 1187
N. Demikhova, O. Chernatskaya, Y. Smiianova, O. Smiianova, L. Vynnychenko (Ukraine)

413 ROSUVASTATIN COMPARED TO ATORVASTATIN ON LIPID PROFILE AND APOLIPOPROTEIN LEVELS IN DYSLIPIDEMIC PATIENTS WITH ELEVATED LIPOPROTEIN (A) 1188
G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy)

414 RESPONSE TO AN ORAL FAT LOAD WITH A NON DAIRY CHEESE CREAM CONTAINING FERMENTED SOYBEAN EXTRACT SOY COMPARED TO A DAIRY CHEESE IN HEALTHY SUBJECTS 1189
G. Derosa, D. Romano, A. D'Angelo, **P. Maffioli** (Italy)

415 EFFECTS OF A NON DAIRY CHEESE CREAM CONTAINING FERMENTED SOYBEAN EXTRACT ON LIPID PROFILE AND LIPOPROTEINS IN DYSLIPIDEMIC PATIENTS 1190
G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy)

416 EVALUATION OF LIPID-LOWERING THERAPYPREFACINGACUTE CORONARY SYNDROME AND FATSDEPENDING ON CARDIOVASCULARRISK GROUP OF PATIENTS WITH ATRIAL FIBRILLATION 1191
Y. Dorofeeva, **E. Tarlovskaya**, S. Malcnikova (Russia)

417 RENOPREDICT: MULTIPLE BIOMARKER APPROACH TO IMPROVE THE PREDICTION OF MORTALITY IN DIALYSIS PATIENTS 1192
C. Drechsler, W. März, V. Krane, B. Kollerits, F. Kronenberg, C. Wanner (Germany)

418 PROGRANULIN MAY BE A BIOMARKER OF PERIPHERAL ATHEROSCLEROTIC DISEASE 1193
E. El Eter, H. Al Zamil, L. Al Dokhi, M. Al Omran (Egypt)

419 MATERNAL ENDOTHELIUM AND RISKS OF DEVELOPING CARDIOVASCULAR DISORDERS 1194
A. Fatima (Pakistan)

420 RELATIONSHIP BETWEEN THE LOCATION OF LESION AND THE ASSOCIATED ARRHYTHMIAS AND CONDUCTION ABNORMALITIES IN PATIENTS WITH MYOCARDIAL INFARCTION 1195
U. Ganiev, S. Khaitov, M. Kenjaev (Uzbekistan)

421 ASSOCIATION OF IDEAL CARDIOVASCULAR HEALTH WITH SUBCLINICAL VASCULAR STRUCTURE FUNCTION AND ELASTICITY IN THE COMMUNITY. THE PARIS PROSPECTIVE STUDY 3 1196
B. Gaye, P. Boutouyrie, G. Parati, M.C. Perier, F. Thomas, C. Guibout, B. Pannier, X. Jouent, J.P. Empana (France)

422 CARDIOVASCULAR DISEASE RISK ASSESSMENT: TRIGLYCERIDE/ HIGH-DENSITY LIPOPROTEIN VERSUS METABOLIC SYNDROME CRITERIARUNNING TITLE: CVD RISK ASSESSMENT: TG/HDL VERSUS METS 1197
M. Gharipour, M. Sadeghi, P. Nezafati, N. Sarrafzadegan (Iran)

423 CARDIOVASCULAR RISK IN CHILDREN: THE CLINICAL RELEVANCE OF EARLY AND TIMELY STRATIFICATION AND TREATMENT 1198
I. Gomes, B. Cardoso, P. Loureiro, M. Bourbon, F. Pinto (Portugal)

424 THE MOST COMMON CARDIOVASCULAR RISK FACTORS IN ADOLESCENTS SIGNIFICANT FOR DEVELOPMENT OF CARDIOVASCULAR DISEASES IN ADULTHOOD 1199
G. Grujic Ilic (Serbia)

425 CLINICAL OUTCOMES OF MULTI-VESSEL CORONARY ARTERY SPASM ARE COMPARABLE TO SINGLE VESSEL SPASM ON RECOMMENDED OPTIMAL MEDICAL TREATMENTS: KOREA VASOSPASTIC ANGINA REGISTRY DATA ANALYSIS 1200
S.H. Han, O. Pyoung Chun, S. Dong Il, H. Sung Ho, A. Youngkeun, P. Keun Ho, K. Dong Soo, Y. Tae Hyun, C. Dong Ju, S. Jung Won, K. Hyuck Moon, L. Byoung Kwon, G. Hyeon Gheol, R. Seung Woon, J. Sang Ho, B. Sang Hong (Republic of Korea)

426 ABNORMAL METABOLIC CONDITIONS ARE INDEPENDENT RISK FACTORS FOR INCREASED ARTERIAL STIFFNESS INDEPENDENT OF AGE AND BLOOD PRESSURE 1201
S.H. Han, H. Hyo Sang, O. Pyung Chun, K. Kwang Kwon (Republic of Korea)

427 THE RATIO OF SKELETAL MUSCLE MASS TO VISCERAL FAT AREA IS A MAIN DETERMINANT LINKING CIRCULATING IRISIN TO METABOLIC PHENOTYPE 1202
Y.C. Hwang, P. Cheol-Young, Y. Byung-Soo (Republic of Korea)

428 PLATELET RELEASE REACTIONS ARE MODIFIED IN VITAMIN D DEFICIENCY 1203
L. Kasatkina, I. Trikash (Ukraine)

429 RESPIRATORY FUNCTION OF LUNGS AT ISCHEMIC HEART DISEASE PATIENTS CONCOMITANT WITH TYPE 2 DIABETES MELLITUS 1204
S. Murtazaev, A. Mansurov, N. Sharapov, K. Khalikulov (Uzbekistan)

430 FREQUENCY OF STATIN DOWNTITRATION DURING OPEN LABEL EVOLOCUMAB TREATMENT IN THE OSLER-2 STUDIES 1205
M. Koren, Y. Ma, R. Somaratne, M. Bolognese (USA)

431 HIGH LYMPHOCYTES AND LOW MEAN CORPUSCULAR VOLUME ARE ASSOCIATED WITH DIABETES, TRIGLYCERIDE-TO-HIGH-DENSITY-LIPOPROTEIN RATIO AND METABOLIC SYNDROME, IN PATIENTS AT HIGH RISK OF CORONARY ARTERY DISEASE 1206
B. LI, I. Trakarnwijitr, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia)

432 NUMBER OF BLOOD PRESSURE MEASUREMENTS NEEDED TO ESTIMATE LONG TERM VISIT-TO-VISIT SYSTOLIC BLOOD PRESSURE VARIABILITY FOR PREDICTING 10-YEAR CARDIOVASCULAR RISK 1207
H.M. Lim, Y.C. Chia, S.M. Ching (Malaysia)

433 PLASMA TRIMETHYLLYSINE, TRIMETHYLAMINE-*N*-OXIDE, CARNITINE AND INCIDENT MYOCARDIAL INFARCTION IN PATIENTS WITH STABLE ANGINA PECTORIS 1208
K.H. Løland, H. Olset, G.F.T. Svingen, H. Schartum-Hansen, E.K. Pedersen, E. Strand, P.M. Ueland, A. Svardal, Ø. Bleie, J.E. Nordrehaug, O. Nygård (Norway)

434 IMPACT OF INSULIN RESISTANCE ON CARDIAC AND VASCULAR FUNCTION 1209
G. Manno, S. Novo, R. Russo, D. Buccheri, S. Dell'Oglio, P. Morreale, G. Vitale, G. Novo (Italy)

435 ASSOCIATION OF CAROTID ATHEROSCLEROSIS WITH CORONARY ARTERY DISEASE: A RETROSPECTIVE STUDY OF 589 PATIENTS 1210
D. Migliorino, A. Mignano, S. Evola, G. Novo, E. Corrado, S. Novo (Italy)

436 NIGELLA SATIVA AND THYMOQUINONE REDUCE GENE AND PROTEIN EXPRESSION OF INTERLEUKIN-6 VIA NUCLEAR FACTOR KAPPA B PATHWAY 1211
F. Mohtar, **H. Nawawi**, T. Rahman, G.R.A. Froemming (Malaysia)

437 OXIDATIVE-ANTIOXIDATIVE CHANGES OF LDL, CORONARY HEART DISEASE, SOME ATHEROSCLEROSIS RISK FACTORS AND 7-YEAR UNFAVORABLE LONG-TERM RESULTS IN MEN POPULATION OF NOVOSIBIRSK 1212
Y. Ragino, Y. Polonskaja, S. Malyutina, M. Voevoda (Russia)

438 ISCHEMIC HEART DISEASE MORTALITY AND ALCOHOL CONSUMPTION IN THE FORMER SOVIET REPUBLICS: A COMPARATIVE ANALYSIS OF TRENDS 1213
Y. Razvodovsky (Belarus)

439 ALCOHOL AND PREMATURE CARDIOVASCULAR MORTALITY IN BELARUS 1214
Y. Razvodovsky (Belarus)

440 LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE CORRELATES WITH CAROTID FEMORAL PULSE WAVE VELOCITY 1215
S. Rico Martin, J.F. Sánchez Muñoz-Torrero, J.F. Calderón García, J.M. De Nicolás Jiménez (Spain)

441 LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE CORRELATES WITH CORONARY CALCIUM SCORE 1216
J.F. Sanchez Munoz-torrero, **S. Rico Martin**, J.M. De Nicolas Jimenez, J.F. Calderon Garcia (Spain)

442 THE ROLE OF TRACKING OF BCL-2 AND CASPASE-3 ACTIVITY IN PLAQUE EVOLUTION IN ISCHEMIC HEART DISEASE PATIENTS 1217
T. Ristic, V. Djordjevic, V. Cosic (Serbia)

443 ASSOCIATION BETWEEN 677C>T POLYMORPHISM WITHIN METHYLENETETRAHYDROFOLATE REDUCTASE GENE AND POSTSTROKE HEMIPARESIS IN POLISH PEDIATRIC PATIENTS 1218
B. Sarecka-Hujar, I. Kopyta, I. Zak, E. Emich-Widera (Poland)

444 CAROTID INTIMAL-MEDIAL THICKNESS ,PREVALENCE OF DOCUMENTED CORONARY AND CEREBRAL VASCULAR ATHEROSCLEROTIC DISEASES IN PATIENTS WITH ABDOMINAL AORTIC ANEURISM AND AORTO-ILIAC OCCLUSIVE DISEASE 1219
N. Sharashidze, **I. Botchorishvili**, Z. Pagava (Georgia)

445 ENDOTHELIAL FUNCTION ASSESSED BY PERIPHERAL ARTERIAL TONOMETRY IS NOT RELATED TO CARDIOVASCULAR RISK SCORE IN HEALTHY SUBJECTS 1220
Y.R. Sigurðardóttir, B.R. Stefánsdóttir, T. Aspelund, G. Þorgeirsson, V. Guðnason, L.B. Kristinsdóttir, **K. Andersen** (Iceland)

446 ASSESSMENT OF THE RISK OF PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH CORONARY ARTERY DISEASE 1221
K. Sirojiddin, A. Alavi, **M. Kenjaev** (Uzbekistan)

447 EFFECTS OF HIGH-DOSE ATORVASTATIN PRETREATMENT ON MYOCARDIAL STUNNING IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION 1222
K. Sirojiddin, D. Alimov, B. Mukhamedova, M. Kenjaev, R. Rakhimova (Uzbekistan)

448 EFFECT OF LOX1 RECEPTOR GENE EXPRESSION BY ORAL MGSO4 ADMINISTRATION TO CONTROL ATHEROSCLEROSIS IN STZ-INDUCED DIABETIC RAT 1223
N. Soltani, M. Fazali, F. Kharazmi, M. Kamran (Iran)

449 THE LEADING RISK FACTORS FOR DEVELOPMENT OF MYOCARDIAL INFARCTION IN ELDERLY PATIENTS 1224
I. Sukmanova, I. Zheltova (Russia)

450 GENDER-SPECIFIC RISK FACTORS OF MYOCARDIAL INFARCTION 1225
I. Sukmanova, I. Suspitsyna (Russia)

451 THE ROLE OF PSYCHOSOMATIC FACTORS AND HYPODYNAMIA IN THE DEVELOPMENT OF MYOCARDIAL INFARCTION IN MIDDLE AND ELDERLY WOMEN 1226
I. Suspitsyna, I. Sukmanova (Russia)

EAS

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



INDEX OF AUTHORS

www.eas2016.kenes.com



PCSK9 inhibitors: a conversation on selecting the right patients

PROGRAMME

Chair: Alberico Catapano, Italy

Welcome and introduction	Alberico Catapano, Italy
Who is at greatest unmet need?	Michel Farnier, France
Clinical perspective	Panel
How effective are PCSK9 inhibitors in reducing LDL-C?	Erik Stroes, The Netherlands
Clinical perspective	Panel
Which patients find it hardest to achieve recommended LDL-C levels?	
- Familial hypercholesterolaemia	Michel Farnier, France
- Statin intolerance: GAUSS-3 data	Erik Stroes, The Netherlands
Clinical perspective	Panel
Will lowering LDL-C with PCSK9 inhibitors reduce CV risk?	Alberico Catapano, Italy
Closing Q&A and panel discussion	Panel
Chair's summary and close	Alberico Catapano, Italy

Lunch bags will be provided

AMGEN
Cardiovascular

Amgen (Europe) GmbH
Dammstrasse 23
CH-6300 Zug
Switzerland
www.amgen.com

ACKNOWLEDGEMENTS

CORPORATE PARTNERS

GOLD LEVEL CORPORATE PARTNER

AMGEN

SILVER LEVEL CORPORATE PARTNER

SANOFI REGENERON

BRONZE LEVEL CORPORATE PARTNERS

Aegerion Pharmaceuticals
AstraZeneca
Chiesi
People and ideas for innovation in healthcare
Kowa
Lilly
MSD
Pfizer

JOINT BRONZE PARTNERS

BASF
The Chemical Company
RAISIO
Unilever

ACKNOWLEDGEMENTS

The Organising Committee and the EAS Executive Committee would like to express their gratitude and acknowledgement to the following companies for their generous support in the 84th EAS Congress:

PLATINUM SPONSORS

AMGEN

MEDA

MSD

Pfizer Cardiovascular Metabolic

GOLD SPONSORS

ALEXION

REGENERON science to medicine

SANOFI

SILVER SPONSORS

BASF The Chemical Company

Chiesi People and ideas for innovation in healthcare

Mylan Seeing is believing

RAISIO

Unilever

SPONSORS

AstraZeneca

Aegerion Pharmaceuticals

fhscore

Kowa

EXHIBITORS

AKCEA THERAPEUTICS

ALEXION

AMGEN

FH Europe The European FH Patient Network

fhscore

VISUALSONICS FUJIFILM

IBL

kaneka

MEDA

MSD

Mercodia

numares HEALTH

RANDOX BIOSCIENCES Discovery | Drug Development | Diagnostics

REGENERON science to medicine

SANOFI

wisepress.com

INDUSTRY SUPPORTED SESSIONS

SUNDAY, MAY 29, 2016

12:30-13:30 CARL VON ROKITANSKY (BRUSSEL) HALL

MEET THE EXPERTS - THE MEDICAL PUZZLE OF HOFH

Aegerion Pharmaceuticals

Chairperson: **Cesare Sirtori, Italy**

- **Jeanine Roeters Van Lennep**, The Netherlands
- **Claudia Stefanutti**, Italy
- **Marcello Arca**, Italy

16:00-17:30 NIKOLAI N. ANITSCHKOW (TIROL) HALL

MOVING PCSK9 INHIBITION FORWARD: THE FUTURE OF EVIDENCE-BASED CV OUTCOMES IN HIGH-RISK PRIMARY AND SECONDARY PREVENTION PATIENTS

Pfizer Cardiovascular Metabolic

Chairperson: Jean-Claude Tardif, Canada

16:00 - Welcome and Introductions
Jean-Claude Tardif, Canada

16:05 - Case-Based Approach to Identifying High-Risk Primary and Secondary Prevention Patients
Michel Farnier, France

16:25 - Current Guidelines for High-Risk Patients: The Need for Evidence-Based Decision Making to Address Remaining Unmet Need
G Kees Hovingh, The Netherlands

16:45 - Cardiovascular Risk Reduction With PCSK9 Inhibition: Evidence-Based Long-Term CV Outcomes
Jean-Claude Tardif, Canada

17:05 - Panel discussion/Q&A

MONDAY, MAY 30, 2016

13:00-14:30 NIKOLAI N. ANITSCHKOW (TIROL) HALL

PCSK9 INHIBITORS: A CONVERSATION ON SELECTING THE RIGHT PATIENTS

AMGEN Cardiovascular

Chairperson: **Alberico Catapano, Italy**

13:00 - Welcome and introduction
Alberico Catapano, Italy

13:05 - Who is at greatest unmet need?
Michel Farnier, France

13:15 - Clinical perspective
Panel

13:20 - How effective are PCSK9 inhibitors in reducing LDL-C?
Erik Stroes, The Netherlands

13:30 - Clinical perspective
Panel

Which patients find it hardest to achieve recommended LDL-C levels?

13:35 - Familial hypercholesterolaemia
Michel Farnier, France

13:45 - Statin intolerance: GAUSS-3 data
Erik Stroes, The Netherlands

13:55 - Clinical perspective
Panel

14:05 - Will lowering LDL-C with PCSK9 inhibitors reduce CV risk?
Alberico Catapano, Italy

14:15 - Closing Q&A and panel discussion
Panel

14:25 - Chair's summary and close
Alberico Catapano, Italy

13:00-14:30 KARL LANDSTEINER (INNSBRUCK) HALL

LDL-CHOLESTEROL UPDATE 2016

MSD

Chairpersons: **Lale Tokgözoglu, Turkey**
Pepe Zamorano, Spain

13:00 - Welcome and Introduction – What's Hot 2016
Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain

13:10 - The Clinical Reality – Attaining Treatment Targets in 2016
Lale Tokgözoglu, Turkey

13:20 - What Do Recent Combination Studies Teach Us? – The Most Recent Insights
Peter Toth, USA

13:45 - Novel Findings on Genetics and Mendelian Randomization
Heribert Schunkert, Germany

14:00 - The Role of Combination Therapy – Defining Treatment Options for the Individual Patient
Pepe Zamorano, Spain

14:15 - Panel Discussion
Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain

TUESDAY, MAY 30, 2016

13:00-14:30 KARL LANDSTEINER (INNSBRUCK) HALL

PCSK9 THERAPEUTICS – CAN WE REDEFINE THE CLINICAL MANAGEMENT OF HYPERCHOLESTEROLEMIA?

SANOFI REGENERON

Chairperson: **John Chapman, France**

13:00 - Introduction
John Chapman, France

13:05 - PCSK9 therapeutics – the evidence so far
Eli Roth, USA

13:25 - PCSK9 therapeutics – early insights from the correlation between LDL-C and cardiovascular events
Kausik Ray, UK

13:45 - PCSK9 therapeutics - what do we have yet to learn?
Ulrich Laufs, Germany

14:05 - Panel Discussion and Q&A
John Chapman, France
Eli Roth, USA
Kausik Ray, UK
Ulrich Laufs, Germany

14:25 - Closing remarks
John Chapman, France

14:00-14:45 NIKOLAI N. ANITSCHKOW (TIROL) HALL

SPECIAL LECTURE: NOVEL CONCEPT AND CLINICAL PROOF TO ADDRESS UNMET MEDICAL NEEDS FOR THE TREATMENT OF RASIDUAL VASCULAR RISK

Chairpersons: **Yuji Matsuzawa, Japan**
Jean-Charles Fruchart, France

14:00 Welcome and Introduction
Yuji Matsuzawa, Japan
Jean-Charles Fruchart, France

14:05 Novel generation of Peroxisome Proliferator-Activated Receptor alpha (PPARα) agonists: selective PPARα modulator (SPPARMα)
Jean-Charles Fruchart, France

14:25 Clinical proof of concept of SPPARMα developed to be more effective and less harmful
Shun Ishibashi, Japan

14:10-14:55 CARL VON ROKITANSKY (BRUSSEL) HALL

CETP INHIBITION – WHAT'S HOT IN 2016?

Chairperson: Alberico Catapano, Italy

14:10 Opening by the chair
Alberico Catapano, Italy

14:15 The pharmacologic basis: Recent insights into kinetics
Gisette Reyes-Soffer, USA

14:25 Facts, Findings & Expectations
Ulf Landmesser, Germany

14:35 Is there a need for a new small molecule?
Wouter Jukema, The Netherlands

14:45 Round Table, Q&A
Alberico Catapano, Italy

14:05-14:50 WILHELM AUERSWALD (STRASSBURG) HALL

MEET THE EXPERT: INTRODUCING SEBELIPASE ALFA, A NOVEL TREATMENT FOR LAL-D

A case-based meet-the-expert session chaired by Professor Thomas Stulnig

Experts will present cases on Lysosomal Acid Lipase Deficiency including early treatment results with Sebelipase alfa.

EDUCATIONAL GRANT

The following session is supported by an Educational Grant.

MONDAY, MAY 30, 2016

N. ANITSCHKOW HALL 18:40-19:40

KEYNOTE LECTURE

Supported by Amgen, AstraZeneca, MSD, Pfizer, Regenron and Sanofi.

Chair: Alberico Catapano (Italy)
Chair: Wolfgang J. Schneider (Austria)

18:40 How genes control cholesterol
Michael S. Brown (USA)

EXHIBITION INFORMATION

EXHIBITION MAP

EXHIBITORS LIST

Company Name	Booth #
Akcea Therapeutics	22
Alexion Pharma	2
Amgen	18
Denka Seiken	8
European Atherosclerosis Society	10 and 25
European FH Patient Network	5
FH SCORE	23
Fujifilm VisualSonics	12
Immuno-Biological Laboratories	7
Kaneka Pharma Europe	6
Meda Pharma	17
Merck MSD	1
Mercodia	24
Nebion	4
Numares Health	9
Randox	21
Sanofi Regeneron	20
Wisepress Medical Bookshop	26

LIST OF SPONSORS, SUPPORTERS & EXHIBITORS

AEGERION

Aegerion Pharmaceuticals Inc
One Main St, Suite 800
Cambridge
MA 02142
USA
http://www.aegerion.com

Aegerion Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company was founded in 2005 with an initial focus of bringing new therapies to patients with severe lipid disorders and is now focused on research, development, commercialization of orphan drugs for the treatment of debilitating rare diseases.

AKCEA THERAPEUTICS

55 Cambridge Parkway, Suite 100
Cambridge
02142
USA
Booth #: 22
http://www.akceatx.com

Akcea Therapeutics is a development and commercialization company focused on transforming the lives of patients with serious cardiometabolic lipid disorders. Established as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea's portfolio spans multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Akcea's investigational pipeline includes novel drugs designed to reduce several lipid risk factors, including LDL-Cholesterol, apoC-III, triglycerides and Lp(a). Volanesorsen, Akcea's most advanced investigational drug, is in Phase 3 trials for ultra-orphan lipid disorders characterized by extremely high triglycerides and apoC-III, including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL). www.akceatx.com.

ALEXION PHARMA

Giesshübelstrasse 30
Zürich
8045
Switzerland
Booth #: 02
http://www.alexionpharma.eu
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

AMGEN

DAMMSTRASSE 23
ZUG
6300
Switzerland
Booth #: 23
http://www.amgen.com
Amgen's Commitment to Cardiovascular Disease Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address a number of today's important unmet patient needs, such as high cholesterol and heart failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. Amgen has grown to be the world's largest independent biotechnology company, reaching millions of patients around the world.

AMGEN EU HQ

Dammstr. 23
Zug
6301
Switzerland
Booth #: 18
http://www.amgen.com
Amgen's Commitment to Cardiovascular Disease Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address a number of today's important unmet patient needs, such as high cholesterol and heart failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. Amgen has grown to be the world's largest independent biotechnology company, reaching millions of patients around the world.

ASTRAZENECA

SE-43183 Mölndal,
Pepparedsleden 1
Sweden
www.AstraZeneca.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

BASF

Carl-Bosch-Strasse 38
Ludwigshafen,Rhineland-Palatinate
Germany
website: http://www.basf.cm
www.newtrition.com
BASF's Nutrition & Health division develops, produces and markets a comprehensive range of products and services for the human and animal nutrition, pharmaceutical as well as flavor and fragrance industries. The division strives to contribute to a better life through improving the nutrition, health and wellbeing of people across the world. Important human nutrition products are vitamins and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Its feed additives such as vitamins, carotenoids, enzymes and organic acids make Nutrition &Health a worldwide leader for the animal nutrition market. The division provides the pharmaceutical industry with active ingredients such as caffeine and ibuprofen, as well as excipients and custom synthesis services. Furthermore, it produces aroma ingredients such as citral, geraniol and L-menthol for the flavor and fragrance industry.

DENKA SEIKEN CO., LTD

Nihonbashi Mitsui Tower, 2-1-1 Nihonbashi-Muromachi
Tokyo
103-8338
Japan
Booth #: 08
http://denka-seiken.jp
Denka Seiken offers assays directly quantifying (without any sample pretreatment) lipid subfractions, and also latex-enhanced turbidimetric immunoassays for specific protein biomarkers to be run on automated chemistry analyzers. The range of lipid subfraction assays includes small dense LDL, HDL3, Remnant Lipoproteins and Triglycerides in LDL particles. The latex-enhanced turbidimetric immunoassays are available for Adiponectin, Lp(a), Cystatin C, hsCRP, RF, Myoglobin, IgE, Ferritin, etc.

EUROPEAN ATHEROSCLEROSIS SOCIETY

Mässans gata 18/ Box 5243
Gothenburg
40224
Sweden
Booth #: 10
http://www.eas-society.org
Advancing and exchanging knowledge of the causes, natural history, treatments and prevention of atherosclerotic disease.

FH EUROPE

7 North Road
Maidenhead
SL6 1PE
UK
Booth #: 05
http://www.fheurope.net
FH Europe is the European FH Patient Network, consisting of 20 European patient organisations. We actively work to secure early identification and diagnosis of FH patients to prevent early cardiovascular disease. Our vision is to identify all FH patients across Europe and for them to be optimally treated in order they may live a full and healthy life. We were founded in 2015 and have successfully achieved a number of activities, including launching a Call to Action at the European Parliament in Brussels, we contributed to videos and articles about FH, attended health care professional meetings to raise awareness of the network and held a meeting of all countries to share best practice.

FUJIFILM VISUALSONICS

3080 Yonge Street Suite 6100
Toronto
M4N3N1
Canada
Booth #: 12
http://www.visualsonics.com
FUJIFILM VisualSonics, Inc is the undisputed world leader in high-resolution, micro-ultrasound systems designed for cardiovascular research. Our Vevo systems operate at 10-70 MHz, achieving up to 30 µm resolution, 5-10 times higher than any other ultrasound system. Our small animal handling platforms captures key physiological parameters including temperature, respiration, ECG and heart rate. These are integrated in real-time with echo images and data. VisualSonics platforms combine high-resolution, real-time, in vivo imaging at reasonable cost with ease-of-use and quantifiable results.

IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. (IBL)

1091-1 Naka Aza-Higashida,
Fujioka-Shi, Gunma
375-0005
Japan
Booth #: 07
http://www.ibl-japan.co.jp/en/
"LipoSEARCH" is a sophisticated comprehensive lipoprotein profiling service (using HPLC-based system) that can deliver a reliable and promising complete set of data on Cholesterol and Triglyceride profiled in 4 major classes (CM, VLDL, LDL and HDL) and 20 subclasses classified by particle size. In addition, it also can deliver number of the particles that is recognized as an important factor in recent international research of atherosclerosis and dyslipidemia. The proprietary system and service "LipoSEARCH" is operated and provided by Skylight Biotech Inc. who is owned by Immuno-Biological Laboratories Co., Ltd. located in Japan.

KANEKA PHARMA EUROPE N.V.

Frankfurter Straße 80-82
Eschborn
65760
Germany
Booth #: 06
http://www.kanekapharma.com
Kaneka Corporation is touching the lives of people all over the world with infinite possibilities of chemistry. By further enhancing our key of highly innovative technology in producing medical devices and building blocks for active pharmaceutical ingredients (API), macromolecules, fermentation and bioscience, Kaneka is exploring new possibilities beyond the traditional boundaries of chemistry. Kaneka Pharma Europe N.V. (KPE) is the independent subsidiary responsible for the European market. Lipoproteinapheresis (Lp(a), LDL), in which Kaneka is one of the pioneers since 1989, is beside the interventional products one of KPE's main business.

KOWA

6-29, Nishiki 3-chome, Naka-ku, Nagoya, Aichi 460-8625
Nagoya
460-8625
Japan
http://www.kowa.co.jp/eng/
Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Especially, the pharmaceutical field is positioned as the key business segment; prescription (ethical drug), Over-the-Counter (OTC) / Consumer Healthcare / Dietary supplement and Medical equipment. Moreover, the pharmaceutical R&D division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and anti-inflammatory agents. To visit Kowa Company, Ltd.'s website, please visit www.kowa.co.jp/eng

MEDA PHARMA S.P.A.

Via Valosa di Sopra, 9
Monza
20900
Italy
Booth #: 17
http://www.meda.se
Meda is a leading international pharma company with a broad product portfolio. The nutraceuticals developed fall into the same therapeutic categories in which Meda has a wealth of experience. The cardiovascular area of nutraceuticals is represented by Armolipid product line (patented), dietary supplements with natural substances for the control of lipids when integrated in an adequate diet for such purposes. The ingredients of Armolipid line derive from high quality natural extracts with very well documented activity. The production process follows pharmaceutical quality standards, every product is clinically tested and the results of clinical trials published in peer-reviewed international medical journals.

MERCODIA AB

Sylveniusgatan 8A
Uppsala
75450
Sweden
Booth #: 24
http://www.mercodia.com
Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies to large pre-clinical and clinical phase trials. The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world.

MSD

2000 Galloping Hill Road
Kenilworth
07033
USA
Booth #: 01
http://www.msd.com
Today's MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well. For more information, visit www.msd.com

MYLAN

Building 4 Trident Place Mosquito Way
Hatfield
AL10 9UL
UK
http://www.mylan.com/
Mylan is one of the world's leading global pharmaceutical companies. Our medicines include generic and brand name products in a variety of dosage forms and therapeutic categories, such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral therapies. The company has innovative research and development capabilities and is one of the world's largest active pharmaceutical ingredient manufacturers. Mylan applies one global quality standard to all of our medications regardless of where they are produced.
Creating better health for a better world. That's what inspires Mylan in our mission to provide quality healthcare to the world's 7 billion people, one person at a time.

NUMARES AG

Am BioPark 9
Regensburg
93053
Germany
Booth #: 09
http://www.numares.com
numares HEALTH develops innovative, in vitro diagnostic (IVD) tests running exclusively on the AXINON® System. AXINON® relies on numares' proprietary MGS® technology for generating reproducible, quality controlled metabolic information using nuclear magnetic resonance (NMR) spectroscopy. The AXINON® software makes this information based on disease-specific metabolic profiles easily accessible for in vitro diagnostics. The integration of different tests into one system makes AXINON® a highly flexible tool for various diagnostic questions. The new IVD test lipoFIT-S100 (CE) determines clinically proven lipoprotein parameters such as LDL-P and sdLDL in high throughput. Further tests for various indications (e.g. nephrology, oncology) are in development.

RAISIO

P.O. Box 101,
FI-21201 Raisio,
Finland
Website: www.raisio.com
Benecol® - proven to reduce cholesterol
Raisio Group is an expert in plant-based nutrition with strong international and local food brands. Benecol® is the expert brand in cholesterol reduction and a pioneer in the cholesterol lowering functional food category.
Raisio Group produces the unique cholesterol-lowering ingredient, Plant stanol ester, and licenses the Benecol brand worldwide. Benecol products are manufactured and sold by local food companies in 30 countries on five continents.
Over 70 clinical studies support the use of Benecol as an effective, easy and safe dietary tool to lower LDL-cholesterol. The cholesterol-lowering effect of Benecol is additive to those of a healthy diet and statin medication.

RANDOX BIOSCIENCES

55 Diamond Road
Crumlin
BT29 4QY
UK
Booth #: 21
http://www.randoxbiosciences.com/
Randox Biosciences is dedicated to improving health worldwide through scientific discovery, drug development and diagnostics. We offer a range of molecular products that provide diagnostic, prognostic and predictive solutions across a variety of disease areas including cardiology (cardiac risk prediction) and inherited disease. Our Familial Hypercholesterolemia Arrays I & II enable the simultaneous detection of 40 FH-causing mutations within the LDLR, ApoB and PCSK9 genes. Utilising our award winning Biochip Array Technology for multi-analyte screening of biological samples, our assays provide a complete patient profile from a single sample for rapid, accurate diagnosis.

REGENERON

777 Old Saw Mill River Road
Tarrytown, NY
10591
USA
Booth #: 20
http://www.regeneron.com
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

SANOFI

54, av. La Boétie
Paris
75008
France
Booth #: 20
http://en.sanofi.com/
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY)

WISEPRESS MEDICAL BOOKSHOP

wisepress.com

25 High Path
London
SW19 2JL
UK
Booth #: 26
http://www.wisepress.com

Wisepress.com, Europe's leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.

EAS INTERNATIONAL EVENING

The EAS International Evening Networking event in Innsbruck will take place at Congress Park Igls

TUESDAY, MAY 31, 2016 AT 19:30

Tickets are subject to availability and can be purchased at the registration desk.

Transportation
Buses will leave from the front of the Congress Centre at 18:45

WE LOOK FORWARD TO WELCOMING YOU


EAS